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Abstract 
Cancer is undoubtedly one of the main threats to global human health and as a result, 
despite significant advances in the field, new and improved cancer treatments are still in 
great need. Although chemotherapy (in combination with other therapies) is widely 
used to suppress the growth of tumours, many of the current anti-cancer drugs suffer 
from poor selectivity and consequently severe toxicity. In order to conquer these 
limitations, targeted drug delivery systems have been designed and studied with the 
primary aim of improving the accuracy of transporting anti-cancer drugs into cancer 
cells and tissue areas. The overall aim of the work presented in this thesis is to design 
new anti-cancer drug delivery systems using three different strategies.  
In Chapter 2, intelligent stimulus-responsive short elastin-like peptides (ELPs) and 
elastin-based side chain polymers (ESPs) were synthesised. The conformation and 
aggregation properties of these ELPs and ESPs were studied in different aqueous 
buffers (varying pH also) using ultraviolet-visible (UV-Vis) spectroscopy and circular 
dichroism (CD). Of the ELPs investigated, peptide 10 (N-acetylated VPGVG) was 
found to have the lowest transition temperature at pH 7 (i.e. 45
o
C). Amongst all the 
ESPs, PF100-GABA(VPGVG) (29) was proven to have the lowest transition 
temperature (47
o
C) which was most likely due to the fact that it had the highest 
molecular weight. 
In Chapter 3, gold nanoparticles (GNPs) were synthesised and functionalised with 
biomolecules including elastin-like peptides (ELPs), elastin-based side chain polymers 
(ESPs) and the pro-apoptotic peptide D-(KLAKLAK)2 (KLA). The hybrids materials, 
ELP-GNPs and ESP-GNPs were characterized by UV-Vis, CD and transmission 
electron microscopy (TEM). The hybrids showed the same temperature sensitive 
properties as the free ELPs and ESPs previously studied, confirming the successful 
functionalization of GNPs. The KLA-GNPs were found to have increased anti-cancer 
activity against HeLa cells compared to the free KLA. 
In Chapter 4, the pro-apoptotic KLA peptide was conjugated to a series of cell 
penetrating peptoids (CPPos) to prepare peptoid-peptide hybrids (CPPos-KLA). The 
anti-cancer, antimicrobial and cell penetrating properties of these peptoid-peptide 
hybrids were investigated. The results demonstrated an increasing trend in anti-cancer 
ability of CPPos-KLA hybrids (compared to free KLA) and KLA-CPPo6 (57) gave the 
lowest IC50 value (ca.8 μM) against HeLa cells.  
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Chapter 1: Introduction 
1.1 Background  
1.1.1 Cancer cases and global health  
Over the last century cancer has become one of the main threats to global human health. 
According to worldwide cancer statistics, around 14.1 million new cases were recorded 
in 2012 and an estimated 8.2 million people died from cancer. Despite significant 
improvements in cancer treatments, cancer deaths are still predicted to rise from 8.2 
million to 13 million per annum largely due to increasing life expectancies.
1
  
According to the ‘Global Cancer Facts & Figures’, cancer is the second leading cause of 
death worldwide following cardiovascular diseases.
2
 The most common form of cancer 
often varies from country to country and between the male and female populations. As 
shown in Figure 1.1, in a global context among women breast cancer is the most 
common form of the disease, while cases of prostate, lung and throat cancer are the 
highest among men. The specific reasons for geographic differences in cancer 
occurrences are not clear, but they are most probably due to local environmental and/or 
lifestyle differences. If one looks, for example, at the range in China, the most common 
cancers are lung and throat (bronchus & trachea) among both women and men. These 
data provide strong evidence that cancers are caused by factors related to lifestyle 
choices and, for example, in China, which has a large smoking population, the incidence 
rate of lung cancer is relatively high. In addition, air pollution is becoming a major issue 
in China, and this is likely to also contribute significantly to the expected increase in the 
number of lung and throat cancer cases.
3
  
As indicated in some cases, the occurrence of cancer can largely be attributed to 
particular factors. However, cancer is a very complex illness and the aetiology of cancer 
may involve more than one of the following factors: carcinogenic chemicals in 
2 
 
industrial pollution such as tar or soot; tobacco smoke; cancer-causing food; radiation; 
oncogenic virus; genetic disposition; and the ageing process.  
 
Figure 1.1: Overview of the most common forms of cancers worldwide split by sex, 
2012.
2
 
Cancer may arise in any part of the body, and cancer cells can migrate inside the body 
either through the bloodstream or the lymph system. All cancers begin with a change in 
the function of normal healthy cells. Compared to normal cells, cancer cells have 
3 
 
damaged, lost, or multiple copies of some genes. A gene change is called a mutation, 
and more than half a dozen different mutations of a gene turns a normal cell into a 
cancer cell. These mutations will make cells grow and reproduce in an uncontrolled way, 
resulting in unlimited cell division, leading to maligant tumours, vascularisation and 
metastasis.
4
  
1.1.2 Cancer treatment options  
Before the development of modern chemotherapy, traditional methods of cancer 
treatment were mainly surgery and extended radiotherapy. Even today surgery is still a 
viable option for many types of cancer where solid tumours can be removed by an 
experienced surgeon without significant damage to the surrounding tissues or organs. 
Surgery is most often followed by radiotherapy, which is used to kill any surviving 
cancer cells missed by surgery. However, where surgery and radiotherapy can often 
eradicate localised or primary malignant tumours, they are less useful when a cancer has 
metastasised to different parts of the body. In this case cancer treatment relies heavily 
on chemotherapy or a combination of treatments depending on the type of cancer. 
Chemotherapy combined with traditional therapies (surgery or radiotherapy) is 
commonly called adjuvant therapy.
5
 In the following section, we will review these three 
major treatments briefly.  
1.1.2.1 Surgical resection 
The first recorded surgery for cancer goes as far back as around 1500 BC. The Ebers 
Papyrus, a written knowledge of ancient Egyptian medical treatise, contains chapters on 
surgical treatment of identified tumours.
6
 Hippocrates, a famous Greek physician, was 
the first to identify the cause of cancer as an excess of black bile and described the 
tumours by the term carcinoma or sarcoma. Hippocrates’ discovery and study of cancer 
was continued by another Greek physician, Galen, who recorded the appearance of 
some cancers as characteristically crab-like and classified cancer as a systemic disease.
7
 
Galen was also the first to observe that breast cancer was found to frequently occur 
among women. He wrote about successful surgical treatments for breast cancer but only 
in cases where the tumour was at an early stage and was of a notable size. However, it 
should also be noted that in the time of Galen surgery was still very primitive and 
patients often died due to complications such as extensive blood loss. 
6,8
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It was not until the nineteenth century, that standard surgical resection technique was 
established and the successful surgical treatment of cancer became possible. With the 
improvement of anaesthetic techniques in 1846, surgery started to play a very important 
role in the treatment of malignant diseases like cancer. A new speciality was developed, 
known as surgical oncology. Generally, a surgical oncologist is a fully qualified surgeon 
who has undertaken additional training in areas such as pathology, radiology, 
epidemiology and even clinical psychology.
9
 The creation of a multidisciplinary skill 
set is required to enable a more advanced approach to the diagnosis, treatment and 
rehabilitation of cancer patients.  
In order to describe how much cancer is in the body and where it is located, the staging 
system was developed. The first classification of malignant tumours (TNM) system was 
reported by Pierre Denoix in the mid-1940s.
10
 The T represents the primary tumour size, 
N stands for the regional lymph node involvement and the M is for metastasis. The 
TNM system has proved to be a very effective method for recording the malignant 
tumour status and for enabling suitable cancer therapy to be tailored to individual 
patients. Based on the cancer stage, a suitable surgery will be operated and as much as 
possible of the tumour-related area will be removed. Surgical resection is now a highly 
established and mature technique for treatment of primary stage cancers, but as 
previously highlighted even when 99.99999 % of the tumour has been removed, without 
combination therapy the chance of a new tumour developing is still high.
8
  
1.1.2.2 Radiotherapy 
In 1895, Wilhelm Conrad Roentgen, a German physicist, first detected an unknown 
electromagnetic radiation (wavelength from 0.01 to 10 nanometers) and named it X-rays. 
This exciting discovery brought Roentgen the first Nobel Prize in physics in 1901.
6
 It 
did not take long for researchers to establish that X-ray radiation had destructive effects 
on healthy cells and could cause carcinogenicity and mutagenicity.
9
 However, beyond 
the negative and harmful effects the discovery of X-ray radiation also opened up new 
opportunities for cancer diagnosis and therapy. 
When high energy X-rays pass through an atom, the atom will absorb the energy 
resulting in excitation (an electron moves to a higher orbital level) or ionization (remove 
one electron from an atom). In the human body, bones contain calcium ions that are 
more likely to absorb X-rays compared with soft tissues (smaller atoms).
11
 The 
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difference between the absorption of X-rays provides doctors with an image (radiograph) 
which shows the internal structure of the body. The dense materials show up as white 
areas on a radiograph, while the soft materials are present as varying shadows. A routine 
X-ray scan has been broadly used for detection of cancerous tumours especially located 
in the bone, lung and breast. A more powerful detection technique, called X-ray 
Computed Tomography (CT), has also been used widely since the 1970s. CT scans take 
many X-ray images from 360
o
 to produce a cross-sectional image and give more 
detailed information about a tumour, such as the location, size and shape.
12
  
Radiation therapy is a therapy using ionizing radiation to shrink tumours and kill cancer 
cells by damaging DNA directly or indirectly. Compared to surgery, radiotherapy is 
designed to have several rounds of treatments and only a portion of cancer cells are 
affected within one cycle. To understand how radiation works, it is also very important 
to have an understanding of the normal life cycle of a cell. As shown in Figure 1.2, the 
cell cycle has four stages: G1 (Gap 1) phase during which the proteins and RNA are 
made and cell size increases; S (Synthesis) phase when the DNA is synthesised; G2 
(Gap 2) phase during which apparatus for mitosis is built; M (Mitosis) phase when the 
cell divides into two daughter cells. This process is precisely controlled by proteins 
called cyclins and cyclin-dependent kinases (CDKs).
8
 They are associated with each 
other and control various stages of the cell cycle. For example, there is a distinct 
restriction point during Gap 1 (Figure 1.2), before which extracellular signals are 
required and after which the cell is committed to preparing for DNA duplication.  
The relative sensitivity of cells, tissues or organs to the harmful effect of ionizing 
radiation is called radiosensitivity.
13
 The most effective radiation happens during the 
dividing phase (M phase) of the cell cycle, then the G2 phase, then the G1 phase and S 
phase. Cancer cells divide more quickly than normal cells, meaning that normal cells 
that divide slowly are more likely to survive after radiotherapy. However, some normal 
cells can divide quite quickly (e.g. skin or bone marrow cells) and these can be damaged 
by radiotherapy. One possibility to improve therapeutic radiosensitivity is to modulate 
the cell cycle of cancer cells making them even more different to healthy normal cells.  
6 
 
      
Figure 1.2: A cell life cycle.
8
 
1.1.2.3 Chemotherapy  
Attempts to treat cancer with chemical entities date back as far as 1800 BC when 
preparations of plant and herbal medicines were used. Over the years it has been 
repeatedly shown that natural products isolated from a range of sources can have very 
potent anti-tumour activities.
14
 However, the concept of chemotherapy was first clearly 
outlined by Paul Ehrlich, a German physician and scientist. Ehrlich pioneered the use of 
dyes for histological studies and bacterial diagnostics, and this work led him to identify 
agents which could bind to specific cellular components.
9
 In 1908, he was awarded the 
Nobel Prize in Physiology and Medicine because of his theory of the immune system 
and discovery of antibodies behaving in a highly specific manners in response to 
infection.
15
 Based on his immune system hypothesis, Ehrlich developed the idea of 
‘magic bullet’ treatment which would go straight to the specific disease-causing 
organisms to which they targeted.
16
 To try and prove his theory, hundreds of chemicals 
were tested and finally he discovered the arsenic-containing drug, known as Salvarsan, 
which was developed as the first selective anti-syphilitic drug.
17
 Since then, Ehrlich’s 
receptor theory/‘magic bullet’ treatment hypothesis have been applied and become the 
main foundations for the design of new selective cancer-targeted medicines.  
The first successful systemic anti-cancer drugs were initially developed as chemical 
weapons. In 1917 the Germans fired shells containing mustard gas (sulfur mustard 1) 
into the trenches where soldiers slept overnight, and the next morning they found 
7 
 
themselves with burning eyes and skin.
8
 The specific biological effects and 
subsequently the anti-cancer therapeutic application of mustard gas did not become 
known until Gilman and Philips published a review in 1946.
18
 They synthesised 
nitrogen mustard analogues (Figure 1.3) based on the structure of 1 and studied their 
cytotoxic actions on cancer tumours. In this study they discovered that the sulfur 
mustards eliminate a chloride ion and form a cyclic sulfonium ion which reacts with the 
guanine nucleotides in DNA leading to permanent alkylation and subsequent 
programmed cell death.
19
  
For anti-tumour clinical trials, sulfur mustard itself was found to be too toxic for 
systemic use, so the less reactive and less toxic nitrogen mustards (N-mustard, see 
Figure 1.3) were further developed. The nitrogen mustards’ anti-tumour effects were 
examined by injecting them into lymphomas-bearing mice and almost immediate 
regression of cancer tumours was seen. Subsequently, clinical trials of mechlorethamine 
(Mustine 3) were undertaken on more than 150 patients who suffered from Hodgkin’s 
lymphoma, and positive results were demonstrated by remission of some patients who 
went on to live up to three years.
8
 Nowadays, 3 is still used as an effective anti-cancer 
drug. Based on the original structure of 3, many more nitrogen mustards drugs have 
been developed and used in the treatment of a range of cancers, such as 
cyclophosphamide 5, one of the most successful alkylating drugs. The cyclic 
phosphoramide provides a non-toxic effect as a prodrug, and it needs to be broken down 
by enzymes in the liver before the active mustard can be revealed. Anti-cancer activity 
of 5 lasts 1-2 days which is much longer than 3 which only lasts a few minutes.
8
  
 
8 
 
 
Figure 1.3: Structures of mustard gas and several nitrogen mustards. 
Not long after the discovery of the DNA alkylating agents, another successful class of 
anti-cancer drugs known as the anti-metabolite agents were developed. Generally, the 
anti-metabolites have a similar structure to naturally occurring metabolites (such as folic 
acid 6 shown in Figure 1.4) and as such they compete for enzyme and receptor binding 
sites, disrupting natural cellular processes. There are three main types of anti-metabolite: 
anti-folate, anti-purine and anti-pyrimidine. The first known anti-folate drug is 
aminopterin 7, which was investigated with its effects in leukemic children by Sidney 
Farber in 1947.
20
 Remissions occurred among most of the children and this positive 
effect inspired a search for more efficient and less toxic antagonists to folic acid. 
Methotrexate 8 was synthesised and proven to be the best anti-folate type drug so far.
21
 
In 1956, methotrexate was found to be a successful cure for a rare cancer called 
choriocarcinoma.
22
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Figure 1.4: The structure of folic acid, aminopterin and methotrexate.  
Over the years, many new anti-cancer drugs have been discovered. Due to the 
development of a variety of anti-cancer drugs, chemotherapy as a cancer treatment, has 
become the most promising form of treatment against malignant tumours with high 
dividing rates. In summary, surgery, radiotherapy and chemotherapy are all effective 
treatments in cancer therapy. A combination of surgical resection and radiotherapy has 
enormously improved the first stage of cancer remission, but as mentioned before once 
the tumour has reoccurred or metastasized, chemotherapy is the only viable option.  
1.2 Chemotherapy: Advantages and disadvantages  
One of the main aims in the development of new chemotherapies is to be selective for 
proliferating tumour cells over non-proliferating normal healthy cells. Many commonly 
used anti-cancer drugs are more targeted and effective against tissue with a higher 
portion of dividing cells, the proportion which is often called ‘growth fraction’. As 
discussed in Section 1.1.2.2, growth fraction is calculated by the fraction of the active 
cells in the life cycle (G1, S, G2, M) divided by total viable cell population (G0, G1, S, 
G2, M). Since it is the dividing cells that are targeted by chemotherapeutic drugs, it has 
been observed that cancer cells and normal tissues with high growth fractions are more 
susceptible to be affected by anti-cancer drugs. Also, the growth fraction is inversely 
proportional to the mass doubling times for tumours. It follows that tumours with 
shorter doubling time are more curable with chemotherapy.  
However, when the cancer cells are killed largely by a good and efficient chemotherapy, 
normal tissues with a high growth fraction, such as bone marrow, hair follicles and 
10 
 
gastrointestinal mucosa, are also damaged by anti-cancer drugs, leading to significant 
adverse effects. For example, damage of bone marrow, bleeding and infection are some 
examples of complications of cancer treatment. Thus, the aim of chemotherapy is to 
enhance the toxicity specifically targeted to cancer cells, at the same time as reducing 
the side effects on normal cells.  
With advances in the development of cancer treatments, more anti-cancer agents have 
been introduced into chemotherapy, such as proteins, oligo-peptides, antibodies, 
hormones, nucleic acids, growth factors and so forth. The major problem with 
chemotherapy in the treatment of cancer is its lack of selectivity when destroying cancer 
or normal cells. The efficacy of cancer chemotherapy is limited by their poor uptake by 
cancer cells and high toxicity to normal cells. In addition, most anti-cancer drugs are not 
water-soluble and thus have poor cellular uptake. 
In such circumstances, the development of new anti-cancer drugs aims at addressing the 
following issues: 1) be safe and non-toxic until within the tumour map; 2) can 
effectively target the tumour site; 3) can kill cancer cells without affecting normal cells 
and tissues; 4) achieve good permeability in tumour tissue; 5) maintain long lasting in 
vivo stability and metabolism in blood; 6) capture and kill free cancer cells, restraining 
recurrence. Therefore, the development of novel anti-cancer drug delivery systems that 
specifically target cancer cells is urgently required. 
1.3 Anti-cancer drug delivery systems 
For therapeutic applications, advanced drug delivery systems have been designed and 
studied to improve the efficacy and accuracy of transporting anti-cancer drugs into the 
cancer area. Different delivery systems have been developed in order to improve the 
specific targeting ability, such as loading drugs into liposomes, degradable polymers 
and novel nanoparticles. In the following section, several common drug delivery 
systems will be summarized and their applications in the field of cancer therapy 
discussed.  
1.3.1 Polymers 
The well-studied field of polymer chemistry provides a solid foundation for discovering 
new approaches by which anti-cancer drugs can be conjugated to polymers or captured 
within polymeric micelles.
23
 Polymeric materials have great advantages in the 
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application of drug delivery systems due to their biocompatibility and stable mechanical 
properties. During the past 40 years, polymers have played a significant role as inert 
carriers to which therapeutic agents can be covalently linked. Examples include 
polymer-protein conjugates, polymer-drug conjugates, polymer-DNA complexes and 
polymeric micelles as shown in Figure 1.5.
24
 These approaches have developed into a 
new area of research which is known as polymer therapeutics. Many studies on 
polymer-drug conjugates have demonstrated clear improvements in pharmacokinetic 
and pharmacodynamic properties. For example, longer plasma half-life, increased 
stability of proteins, enhanced solubility of lipophilic drugs, decreased immunogenicity 
response and the potential for target delivery.
23-25
 The majority of these polymer 
conjugates are designed for anti-cancer chemotherapy, although they can be also 
designed for other diseases, such as diabetes, arthritis and ischemia.
26,27
 
 
Figure 1.5: Schematic representations of polymer therapeutics: (a) polymer-protein 
conjugate; (b) polyplex: polymer-DNA conjugate; (c) polymer-drug conjugate; (d) 
polymer micelle. Reproduced from 
24
 with permission from Nature Publishing Group, 
copyright © 2003. 
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1.3.1.1 Polymer-drug conjugates 
Polymer therapeutics have been studied for over four decades and one of the most 
studied approaches for polymer therapies is polymer-drug conjugates. The pioneering 
work carried out by Ringsdorf in 1975 on water soluble polymers demonstrated that 
they were an efficient platform for the delivery of low molecular weight drugs.
28
 Further 
pioneering work by Duncan et al. focused on the design of a series of HPMA 
(N-(2-hydroxypropyl) methacrylamide) copolymer-anticancer drug conjugates.
29,30
 It 
has been proven that polymer-drug conjugates have several advantages compared with 
using anti-cancer drugs alone in chemotherapy such as fewer side effects, enhanced 
uptake efficiency, longer circulation time, improved patient compliance and easier 
passive targeting to the tumour site via the enhanced permeation and retention (EPR) 
effect.
31
  
This EPR effect was first found by Matsumura and Maeda when they were studying  
macromolecular systems (polymer conjugates, nanoparticles and liposomes) and they 
observed that such systems tend to be selective and accumulate in tumour tissues rather 
than normal healthy tissues.
32
 Tumour vessels, which are normally used as cancer cells’ 
blood and oxygen supplies, are abnormal in formation with a lack of smooth muscle. In 
addition, tumour tissues have imperfect lymphatic drainage. These defective 
characteristics of tumour vessels make it easier to retain macromolecular systems in the 
interstitium, leading to effective tumour targeting.
33
 In addition, the high molecular 
weight of the polymer carriers slows the clearance of conjugates and allows the drug to 
have a longer systemic circulation time. Furthermore, because of the EPR effect, the 
polymer-drug conjugate accumulates more in the tumour area leading to a maximised 
anti-cancer activity.
34
   
In general, the rational design of polymer-drug conjugates is composed of three parts: a 
water soluble polymeric carrier, a small molecule anti-cancer agent and a biodegradable 
linker between them which is usually a peptidyl or ester linkage.
33
 The first reported 
synthetic polymer-anti-cancer drug complexes were HPMA copolymer-doxorubicin 
conjugates named PK1.
35
 The linkage between the drug and the polymer is a 
tetrapeptide chain with a sequence of Gly-Phe-Leu-Gly which can be broken by the 
action of lysosomal enzymes to release the drug. The pharmacokinetic behaviour of 
PK1 was significantly enhanced compared to free DOX, with a longer half-life of 2.7 h 
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(0.13 h of DOX) and an elimination half-life of 49 h (85 h for DOX). In addition, the 
tumour targeting ability increased over 10-100 fold compared to free doxorubicin, 
depending on the tumour size, and this suggested that the complex was a potent 
anti-cancer agent.
36,37
 Another example of a polymer-drug conjugate is the HPMA 
copolymer-camptothecin complex. Camptothecins (CPTs) are a family of synthetic 
anti-cancer agents that inhibit topoisomerase I activity. The water-insolubility and 
instability of CPTs limit their therapeutic efficacies in patients. Conjugation of 
CPT-HPMA has improved the drug solubility and stability of the lactone ring.
31,38
  
Since the first example of a HPMA copolymer conjugated with DOX was applied as a 
polymer therapy in cancer treatment, more than twelve polymer-drug conjugates have 
entered early clinical trials as shown in Table 1.1.
23,25
   
Table 1.1: Polymer-drug conjugates summary.
23
  
Compound  Name Clinical 
trial status 
Target  
Polyglutamate-pacliatxel CT02103; Xyotax Phase III Non-small-cell lung 
cancer; ovarian cancer  
Polyglutamate-camptothecin CT-2106 Phase I Various cancers 
HPMA-doxorubicin PK1; FCE28068 Phase II Lund and breast 
cancers 
HPMA-doxorubicin-galactosamine PK1; FCE28069 Phase I/II Hepatocelular 
carcinoma 
HPMA-paxlitaxel PNU166945 Phase I Various cancers 
HPMA-camptothecin MAG-CPT Phase I Various cancers 
HPMA-carboplatin platinate AP5280 Phase I/II Various cancers 
HPMA-DACH-platinate AP5346; ProLindac Phase I/II Various cancers 
Dextran-doxorubicin AD-70, DOX-OXD Phase I Various cancers 
Modified dextran-camptothecin DE-310 Phase I Various cancers 
PEG-camptothecin Prothecan Phase II Various cancers 
DACH: diaminocyclohexane; HPMA: N-(2-hydroxypropyl)methacrylamide; PEG: 
poly(ethyleneglycol).  
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1.3.1.2 Polymer micelles 
Polymer micelles are macromolecular assemblies that are formed from AB type or ABA 
type amphiphilic block polymers. They have many advantages to support their 
biological applications, such as being biodegradable, non-toxic, biocompatible and 
non-immunogenic. Generally, polymer micelles are spherical nanostructures and they 
consist of a hydrophobic inner core and a hydrophilic outer shell. The sizes of these 
polymer micelles are on average 10-200 nm in diameter, which also categorise them as 
nanoparticle delivery systems. Water-insoluble drugs can be encapsulated inside the 
hydrophobic core physically via self-assembly or chemically linked through covalent 
bonds. Due to the hydrophilicity of the outer shell and biodegradability of the polymer 
micelle, this drug delivery system can maximize tissue compatibility, increase the 
half-life in plasma and minimizing the cytotoxicity of the hydrophobic drug.
39
   
The major contribution of polymer micelles as drug carriers is to stabilize the drug in 
the body with a longer circulation time. The large molecular weight of polymer micelles 
above a threshold molecular weight (42000-5000 Da) means that they can escape 
glomerular filtration. In addition, the polymer micelle with good biocompatibility can 
avoid being recognized by the reticuloendothelial system (RES) which is located in the 
spleen, liver and lung, and thus escape elimination from blood circulation.
40
 In order to 
obtain good biocompatibility, the structure of polymers should have high flexibility, a 
high degree of hydration and display low immunogenicity. Poly(ethylene oxide) (PEO) 
is a commonly used hydrophilic polymer of amphiphilic block polymers that has been 
approved by the FDA.
41
 The hydrophobic core of the copolymers can be poly(propylene 
oxide) (PPO), poly(D,L-lactic acid) (PDLLA), poly(ɛ-caprolactone) (PCL) or 
poly(β-benzyl-L-aspartate) (PBLA). Thus, the polymer micelles can be prepared from 
copolymers PEO-PPO-PEO, PEO-PDLLA or PEO-PBLA and so on.
42
 The micelle 
formation process is affected by many factors, such as the chain ratio of hydrophobic 
and hydrophilic domains, concentration, temperature and solvents. When the 
hydrophilic domain volume fraction of the copolymer is more than 45%, polymeric 
micelle morphologies are formed from self-assembly.
43
 The minimum concentration of 
the self-association of copolymers is known as the critical micelle concentration (CMC). 
Below the CMC, the amphiphilic copolymer cannot form polymer micelles. The lowest 
temperature and the highest temperature that polymer micelles can exist in the solution 
are both named the critical micellization temperature (CMT).
44
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The encapsulation of a hydrophobic drug by copolymers can be carried out using either 
the dialysis method or the oil/water emulsion method.
45
 In the dialysis method, the drug 
and polymers are first dissolved in an organic solvent and then dialysed against another 
solvent, most commonly distilled water. The polymer micelles are formed during the 
dialysis process with the hydrophobic drug being incorporated into the hydrophobic 
core at the same time. In the other method, the drug is first dissolved in an organic 
solvent with a low volatile point and then added dropwise to the polymer micelle 
solution in water to form the oil/water emulsion. The emulsion is kept overnight in an 
open atmosphere to allow evaporation of the organic solvent with the drug entrapped 
inside the hydrophobic core. The free drug can be removed by ultrafiltration. For 
example, doxorubicin is loaded inside the PEO-PBLA polymer micelles with a highest 
incorporation ratio of 22% (w/w).
46
 Drug loading and release have been investigated 
through many polymer micelles examples. 47,48 The loading efficacy of polymeric 
micelles is increased when the hydrophobic chain length is increased. In addition, the 
rate of drug release from polymeric micelles is related to the hydrophobicity of the inner 
core, the less hydrophobic the faster the drug release due to the weaker interaction 
between the inner core and the drug. Therefore, it can be concluded that the drug 
loading and release is dependent on the chemical structure of the amphiphilic polymer 
micelles.
49
  
During the last decade, many types of copolymer micelles have been formed and 
investigated. Polyion complex micelles (PIC) are formed via electrostatic interactions 
between two oppositely charged copolymers. For example, when the negatively charged 
poly(ethylene glycol)-poly(aspartic acid) PEG-P(Asp) and the positively charged 
poly(ethylene glycol)-poly(L-Lysine) PEG-P(Lys) are mixed in stoichiometric charged 
ratios in aqueous solution they form narrowly distributed PIC micelles with sizes in the 
range of 30-50 nm.
50
 Furthermore, polymer micelles can be designed to have 
environmental responses, such as to pH, temperature and light. Thus, the drug can be 
released from the polymeric micelles by physical stimuli which can enhance the specific 
targeting ability.  
1.3.1.3 Polymer-protein Conjugate 
The development of recombinant DNA (rDNA), monoclonal antibody (mAb) and solid 
phase peptide synthesis techniques has introduced new classes of anti-cancer drugs that 
16 
 
are protein, peptide and antibody-based drugs.
51
 Over the past decade, more than 350 
protein-based drugs have been entered into clinical trials.
52
 However, the short 
half-lives and low enzymatic stabilities of protein and peptide drugs limit their 
therapeutic applications. In order to achieve the desired effects in a relatively low dose, 
hydrophilic polymers have been used to modify protein drugs. The polymer-protein 
conjugates improve the in vivo stability thus increasing the biological half-life and also 
in many cases offer an EPR effect.
24
 
Davis et al. conjugated a water-soluble polymer polyethylene glycol (PEG) to bovine 
serum albumin (BSA).
53
 This strategy of covalent combination between the selected 
drug and PEG has now become widely used and is known as PEGylation.
54
 PEG is a 
polymer formed from the repeating ethylene glycol units and the structure of PEG can 
be chosen as linear or branched with certain molecular masses. Each unit of PEG is 
tightly bound to two or three water molecules and this becomes much larger in water. 
This is confirmed by size-exclusion chromatography and gel electrophoresis.
55
 The 
binding water property of PEG can protect the drug from enzyme degradation, slow 
renal clearance and decrease the immunological effects of the protein drugs. In order to 
maximize the stability of the PEGylated protein drug, stable chemical bonds between 
the protein drug and the PEG polymer are needed. Modification of PEG with a variety 
of functional groups to prepare a more active PEG derivative is the most common 
method and these include PEG carbonate, PEG ester or PEG aldehyde. Generally, the 
PEG derivatives are reacted with the amino groups of lysine or N-terminal amino 
groups.
56
  
In 1990, PEG-adenosine deaminase (Adagen
®
) was approved by the FDA in the 
treatment of severe combined immunodeficiency disease (SCID) as the first PEGylated 
protein drug. Subsequently, more PEGylated protein drugs have been designed, and 
evaluated in clinical trials with some progressing to the market. For example, 
PEGylated L-asparaginase (Oncaspar
®
, approved by the FDA in1994) has been used as 
a chemotherapeutic agent in the treatment of acute lymphocytic leukaemia. This enzyme 
drug breaks down L-asparagine to aspartic acid and ammonia, which deprives the 
leukemic cells of asparagine, leading to cell death. PEG-L-asparaginase has been shown 
to increase the plasma half-life and most importantly decrease hypersensitivity 
reactions.
57
 Although there are many improvements obtained from PEGylation, there 
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are still some problems left to solve. For example, the size, structure and the active 
functional groups of PEG need to be carefully designed and controlled. Even small 
changes can affect the biological activity of the PEGylated protein drugs.  
In summary, the polymer therapeutic approach has made some great achievements in 
delivering potent anti-cancer drugs. Nowadays, four polymers including HPMA 
copolymer, poly-L-glutamic acid, PEG and Dextran have been conjugated with 
anti-cancer drugs (DOX, paclitaxel, camptothecin and cis-platin) and tested in clinical 
trials. The key point of successful medical application is to optimize polymer structures 
based on the multi-disciplinary knowledge of biology, cancer pathophysiology and 
clinical rules. More polymers with specified structures, responsivenesses and biological 
activities have been designed and synthesised, the combinations between newly 
designed polymers and drugs will also be explored. It is believed that polymer therapies 
have potential for providing improved treatments in the future.  
1.3.2 Nanoparticles  
Generally, nanoparticle drug delivery systems can transport pharmaceutically active 
agents into cells/tissues via conjugation to nanometeric carriers. The nanometeric carrier 
typically consists of sub-particles within the size range of 2-1000 nm and they can have 
various morphologies, including nanospheres, nanoliposomes and nanocapsules (Figure 
1.6).
58,59
  
Nanoparticles, due to their relatively small size, can enhance cargo retention time in the 
bloodstream. For anti-cancer drug delivery, using nanoparticles as a method of 
transportation enhances the ability of targeting cancer cells in a passive or an active 
manner.  
There are many advantages of nanoparticle based drug delivery systems. 1) Due to the 
small size of the nanoparticle, usually smaller than a tissue cell, drugs can be 
administered in a flow form, such as injection into a vein. Nanoscale carriers can enter 
the blood capillary tubes through the free flow of blood in the circulatory system and 
are taken up through the cells via endocytosis, which improves the absorption and 
bioavailability of drugs. 2) Nanoparticle can pass through natural biological barriers in 
the body, such as the cell membrane barrier, blood-brain barrier to reach the cancer site. 
3) The large surface area of nanoparticles can increase the solubility of poor 
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water-soluble drugs, which means that they can overcome conventional formulation 
problems of low utilization. 4) The nanoparticles may also be designed as a targeting 
system, more precisely for a particular tissue, organ or cells. 5) Nanocarrier systems can 
achieve active targeting effects by introducing a specific targeting ligand to seek tumour 
cells.  
When nano-drug carriers enter into the blood by intravenous injection, they can be 
excreted from the body before they reach their target tissue. The major challenge 
therefore is to extend the circulation time of nanocarriers in the blood, which can be 
affected by the anti-cancer drug, the materials of nanoparticles and modification method 
of the nanoparticles.  
 
Figure 1.6: Different type of nanoparticle-based carriers. 
1.3.2.1 Polymeric nanoparticles  
Polymeric nanoparticles are made from biodegradable polymers and they form solid 
colloidal carriers with sizes smaller than 1 µm. These polymeric nanoparticles can target 
cancer cells through surface functionalization, and can enhance the therapeutic 
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efficiency of anti-cancer agents by increasing the systemic circulation half-life.
60
 For 
example, polyethylene glycol (PEG) has been used to functionalize the surfaces of 
polymeric nanoparticles to increase their stability.
60
  
Compared with other solid colloidal carriers, polymeric nanoparticles have been 
considered as highly promising materials for cancer treatments, because of their 
biocompatibility, stability and efficacy of high loading. Natural and synthetic polymers 
are both good candidates. Examples of natural polymers have been investigated to form 
nanoparticles including gelation, alginate, and chitosan.
61-63
 For synthetic polymers, 
poly(lactic-co-glycolic acid) (PLGA) is one of the most widely studied copolymers for 
delivery due to its great biodegradability.
64
 PLGA undergoes hydrolysis in the body and 
the products are lactic acid and glycolic acid which are non-toxic. Some other polymers 
like PEG, PLGA, poly (glycolic acid) (PGA), PCL can also degrade inside the body via 
normal metabolic pathways and have been approved by the FDA.
65
  
By varying the preparation method, nanospheres with a dense matrix or nanocapsules 
with a liquid core can be obtained. There are two classes of polymeric nanoparticle 
preparation methods. One is based on the polymerization of monomers carried out by 
emulsion or interfacial polymerization. The other is a polymer dispersion method, 
including particle precipitation and double emulsification methods.
66
 For the 
preparation of drug loaded nanoparticles, higher entrapment efficiency can be obtained 
when the drug is incorporated during the polymerization of monomers rather than 
absorbed on prepared polymeric nanoparticles.
67
   
The polymeric nanoparticles prepared from amphiphilic block copolymers can be 
considered as core/shell structures, but they are different from polymeric micelles. First, 
preformulated nanoparticles is controlled kinetically while micelles is controlled 
thermodynamically. The formation of nanoparticles is controlled by several factors 
including pH level, temperature and solvents, etc. The formation of micelles is based on 
the self-assembly of the block polymer unit above CMC. Second, the inner core of 
nanoparticles is presented in a ‘frozen’ state due to the entanglement of the hydrophobic 
domain. Once formed, the polymeric nanoparticles can be stabilized in the solvent by 
steric or electrostatic repulsion.
68
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Both hydrophobic and hydrophilic drugs can be delivered by polymeric nanoparticles. 
In addition, by functionalization of the nanoparticles with specific targeting domains, 
the polymeric nanoparticle drug delivery system can then release the drug only in the 
cancer site. For example, biodegradable PLGA-b-PEG copolymer encapsulated 
hydrophilic anti-cancer drug docetaxel was used to form polymeric nanoparticles via the 
nanoprecipitation method. Then, the surface of the formed nanoparticles were 
functionalized with A10 aptamers which has preloaded DOX via intercalation.
69
 The 
targeted bioconjugate carrier of polymeric nanoparticle and aptamer can release both 
drugs only in cancer cells that have specific membrane antigens which aptamers bind to. 
This novel targeted drug delivery system may allow co-delivery in future cancer 
treatments.  
1.3.2.2 Gold nanoparticles (GNPs)  
Gold nanoparticles (GNPs) have a long history of being used in biomedical research. 
The interest in studying GNPs has been stimulated by their ability to be easily 
functionalized with a wide range of molecules, low levels of cytotoxicity and their size 
related optical properties. Functionalization of GNPs with different biological 
molecules has many applications in biomedical imaging, clinical diagnosis and therapy. 
GNPs are good candidates for medical processes such as labelling, sensing and imaging, 
drug delivery, and cancer therapeutics due to their unique optical and photothermal 
properties.
70-72
 
One of the early examples of how the optical aspects of spheroidal GNPs can be 
usefully applied was demonstrated by Mirkin et al. in 1996. They showed that 
DNA-capped gold nanoparticles can assemble into controlled aggregates through DNA 
hybridization, leading to a distinct shift in surface plasmon properties which can be 
detected by the naked eye.
73,74
 This concept can be useful in the detection of nucleic 
acids and pathogen nuclear materials in clinical samples. Nanosphere Inc. has 
developed a concept which uses gold nanoparticles conjugated with oligonucleotides 
(DNA or RNA) combined with multiplex array analysis and microfluidics for diagnostic 
tests to detect nucleic acids. Conjugates of functionalized GNP-DNA have also been 
applied in therapeutics that are reliant upon efficient delivery. For example, remotely 
controlled GNPs with near-infrared illumination have shown their potential application 
as optical switches for gene delivery with gene-interfering DNA oligonucleotides.
75
 UV 
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light can be used as a means for illumination as well, activating the release of an 
inhibiting group from a GNP-peptide conjugate and thus permitting the nanocomplex to 
bind to a cell.
76,77
  
GNP-DNA conjugates can also be used for gene silencing. Gene silencing is well 
known for its ability to specifically abolish a molecular pathway and in vivo delivery 
could make a considerable impact on genetic diseases such as cancer. GNP-DNA 
conjugates have been tested as vehicles for gene silencing DNA or RNA transcripts.
78,79
 
Although this technology has not been demonstrated in vivo, it clearly showed that 
designed GNPs are favourable candidates for biomedical applications. Other interesting 
uses of GNPs include molecular sensing based on Raman spectroscopy and the 
enhancement of Raman signatures by surface plasmons. Raman imaging holds 
significant potential as a strategy for biomedical imaging of living subjects. The Raman 
images of methylene blue molecules that adsorbed on gold nanospheres have been 
studied.
80
 Dye molecules attached to the GNPs and localized in the hotspots, leading to 
the enhancement of their vibrational state. In this report, Raman imaging was tested in 
cells but not within living organisms.
81
 Recently, this spectroscopic method of detection 
has been applied for in vivo sensing.
82
  
In recent years, GNPs have been widely used in biomedical applications, such as 
targeting probes or drug carriers due to their small size, biocompatibility and ease of 
synthesis and modification. Chan et al.
83
 studied the uptake of GNPs in HeLa cells and 
found that particles with diameters between 20-60 nm have the highest cellular uptakes. 
Functionalization of GNPs with cell penetrating peptides can be carried out to help 
improve the efficiency of living cell uptake. In 2008, Sun et al.
84
 utilised CALNN and 
its derivative CALNNGGRRRRRRRR (CALNNR8) to functionalize GNPs to prepare 
nanomaterials that could target intracellular components. In this study, GNPs of 
different sizes (13nm, 30nm, 60nm) were synthesised by using the Frens-Turkevich
 
method.
85,86
 Then, peptide-capped GNPs were prepared by a one-step gold-thiol 
reaction. The ratio of the CALNNR8 to CALNN on the surface of the GNPs was 1:9 
respectively. After incubation with HeLa cells, it was found that the peptide-GNPs had 
translocated into the cell nucleus. 
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1.3.3 Cell penetrating peptides 
Recently, therapeutic peptides have been found to be useful in drug delivery due to their 
biocompatibility, biodegradability and non-immunogenicity. Among polypeptides, cell 
penetrating peptides (CPPs) are promising drug delivery systems that are capable of 
transferring molecules into, cytosol and even to reach intracellular targets.
87
 During the 
last decade, cell penetrating peptides (CPPs) have been developed extensively and 
applied to CPP-based drug delivery strategies. Firstly, Frankel and Pabo
88
 discovered 
that the purified Tat protein which is derived from the human immunodeficiency virus 1 
(HIV-1) can be taken up by cells and localized into the nucleus. Later, Derossi et al.
89
 
found that a 16 amino acid peptide (pAntp or penetratin) derived from the third helix of 
the homeodomain protein
90
 is also capable of internalizing into nuclei through plasma 
membranes. Based on the discovery of these two types of CPPs, additional examples 
have been identified that are generally rich in basic cationic residues (Lys, Arg). This is 
due to the interaction between the polycations and the negatively charged molecules on 
the cell surface. It is now known that CPPs are normally made of short polycationic 
peptide sequences, in the range of 10-30 amino acids. There are three subgroups of 
CPPs as defined by their origin or sequence characteristics: protein derived, chimeric 
and synthetic as listed in Table 1.2.
91
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Table 1.2: Categories of cell-penetrating peptides with a few examples.
91
  
Category  Name and sequence  Origin 
Protein derived 
CPP 
Penetratin  
RQIKIWFQNRRMKWKK-NH2 
Drosophila homeoprotein 
Antennapedia 
Tat (48-60) 
GRKKRRQRRRPPQ 
Human immunodeficiency 
virus type 1 (HIV-1) Tat 
Chimeric CPP MPG 
GALFLGFLGAAGSTMGA-cya* 
A hydrophobic domain 
from the fusion sequence of 
HIV gp41 and NLS of 
SV40 T-antigen 
Pep-1 
KETWWETWWTEWSQPKKKRKV-cya* 
NLS from Simian Virus 40 
large antigen T and 
reverse transcriptase of 
HIV 
Synthetic CPP MAP 
KLALKLALKALKAALKLA 
Amphipathic model peptide 
Octa / Nona-Arginine 
RRRRRRRR/R 
Positively charged sequence 
* -cya : N-terminal cysteamide 
 
CPPs have been shown to improve the intracellular delivery of a variety of 
biomolecules, including DNA and short interfering RNA (siRNA).
92
 In the field of 
cancer drug delivery research, CPPs have been used to increase the therapeutic 
efficiency of commonly used cancer drugs, such as doxorubicin and methotrexate.
93,94
 
For example, the Tat-Doxorubicin conjugates have demonstrated an increased killing 
ability on drug resistant tumour MCF-7cells (MCF-7/ADR). Although combining 
anti-cancer agents with CPPs has improved cellular uptake, CPPs suffer like all peptides 
from poor stability in vivo and have no intracellular specificity.
95
 In response to this 
tumour specificity problem, adding a home targeting domain to the sequence of CPPs to 
containing both tumour targeting properties and cell penetrating ability has been carried 
out. For example, a folate acid receptor as a homing domain has been conjugated to a 
CPP-modified liposomal nanocarrier which demonstrated an enhanced cellular uptake 
in folate receptor-responsive cell lines.
96
 It has been discovered that folate receptors are 
highly expressed in cervical, breast, lung and brain tumours.
97
 Another example of 
modulated CPP delivery is RGD. The internalizing RGD (iRGD) has demonstrated the 
ability to target many types of tumour in vivo and can be detected throughout the 
24 
 
tumour substance, not limited to the tumour vasculature.
98
 Liu et al. designed a 
multifunctional peptide R8-RGD, a modified RGD peptide conjugated to a cell 
penetrating peptide R8, which increased the cellular uptake of liposomes in C6 glioma 
cells by nearly 30-fold.
99
 Moreover, this modified CPP-conjugated liposome efficiently 
delivered the anti-cancer drug paclitaxel to specific tumour areas.  
1.4 Stimuli responsive drug delivery  
Compared to normal tissues, tumour areas have a high temperature (about 39-42°C) and 
a low pH (pH = 6.5-7.2).
100
 In cancer treatment studies, attempts are often made to 
exploit these properties to design target treatments. Intelligent stimulus-responsive 
materials, especially temperature and pH-responsive materials are widely used in 
biomedical research due to their spontaneous changeable properties under variable 
conditions. 
It is well known that biopolymers such as proteins or nucleic acids can react sensitively 
to changes in the environment. Using chemistry to create mimics of biopolymers and 
biological systems is a significant area of research. During the past decades, 
stimuli-responsive novel materials have proved to be effective for targeted drug 
delivery. 
The nature of the environmental stimulus can be classified into three categories: 
physical, chemical, and biomedical (Table 1.3).
101
 Stimuli-responsive delivery systems 
can be made of polymers, liposomes or nanoparticles. Here, we will mainly focus on the 
discussion of stimuli-responsive polymers (SPRs) applied in drug delivery areas. SPRs 
are known as smart polymers or environmentally responsive polymers and can respond 
to a variety of signals that include temperature, ionic strength, environmental pH and 
chemical agents including ligands and enzymes. 
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Table 1.3: Environmental stimuli categories. 
Physical             Chemical               Biomedical 
Temperature           pH                    Enzyme substrate 
Ionic strength          Specific ions             Affinity ligands 
Solvents              Chemical agents          other biochemical agents  
Electromagnetic radiation  
(UV, light) 
Electric fields 
Mechanical stress, strain 
Sonic radiation 
Magnetic fields 
 
Physical stimuli have an effect on the interaction between the polymer molecules 
themselves or between the polymer chains and the solvent molecules as well as 
chemical and biomedical stimuli. Physical stimuli, such as temperature, can change 
molecular interactions at a certain point which creates a phase transition. These changes, 
which can be observed by microscopy, can explain the smart behaviour.  
With respect to possible applications in biomedicine or biotechnology, the main focus is 
based on smart polymers with transitions triggered by temperature, pH and light. Many 
materials have been widely studied in drug targeting delivery and controlled release, 
such as poly(N-isopropylacrylamide) (PNIPAAm).
102
 In the following section, aspects 
of temperature, pH and light responsiveness will be introduced.  
1.4.1 Temperature sensitive targeting  
Temperature responsive polymers undergo inverse temperature phase transitions. Below 
their transition temperature (Tt) thermally-responsive SRPs are soluble in aqueous 
solution, but upon raising their temperature above the Tt, SRPs become insoluble and 
aggregate in solution. In this case, the transition temperature is called a lower critical 
solution temperature (LCST). Otherwise, if aggregation is observed below a critical 
temperature the polymer shows an upper critical solution temperature (UCST) or higher 
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critical solution temperature (HCST) behaviour. However, most research is conducted 
on polymers with LCST behaviour. 
The most studied synthetic responsive polymer (SNP) is PNIPAAm. It undergoes a 
transition temperature in water at 32-34 °C, changing from a hydrophilic state below 
this temperature to a hydrophobic state above it.
103
 The sharp phase transition of 
PNIPAAm is attributed to the balance between hydrophilic and hydrophobic 
interactions. The phase change of an aqueous PNIPAAm solution is from coil to globule 
when raising the temperature. The phase transition, as shown in Figure 1.7, arises 
because the water molecules bonded to the side-chain isopropyl moieties are released 
into the aqueous phase when temperature exceeds the critical point.
104
 The balance 
between segment-segment interactions and segment-solvent intermolecular interactions 
can be shifted by temperature changes. The phase separation can also be explained 
thermodynamically in terms of the change of the free energy (ΔG). The free energy of 
polymer systems can be described as: ΔG = ΔH-TΔS with the ΔH representing enthalpic 
energy and ΔS standing for entropy change. Below the LCST, the polymer and the 
solvent molecules form a homogeneous mixture supported by hydrogen-bonding to the 
polymer chain and this has a favourable free energy (ΔG<0). When the temperature is 
raised above LCST, the occurrence of phase separation is due to the enthalpic 
contribution that overcomes the entropic part resulting in an unfavourable free energy of 
the system (ΔG>0).105   
 
Figure 1.7: Schematic of ‘smart’ polymer conformation change with temperature. 
Reproduced from 
104
 with permission from Royal Society of Chemistry, copyright © 
2005. 
According to the theory above, the LCST of a given polymer can be adjusted by 
changing the hydrophilic or hydrophobic moieties in the polymer chain. Raising the 
hydrophobicity will cause a decrease in LCST. On the other hand, more hydrophilic 
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domains will increase the LCST. This temperature shift can be affected by many 
possibilities. PNIPAAm contains a hydrophobic isopropyl group and a hydrophilic 
amide group. The balance mainly depends on the N-substituent. Many PNIPAAm-based 
materials that have the LCST close to body temperature (37°C) have been reported for 
biomedical applications.
106-108
 Except for PNIPAAm, there are some other important 
temperature sensitive polymers. They are poly(N,N-diethylacrylamide) (PDEAAm), 
poly(N-vinyl caprolactam) (PVCL), poly(ethylene glycol) (PEG), poly(propylene oxide) 
(PPO) and poly(VPGVG) as shown in Figure 1.8.
104
 
 
Figure 1.8: Structures of commonly used responsive polymer systems. 
PDEAAm has a lower enthalpy value of phase transition than PNIPPAm which means 
its LCST is 32°C.
109
 PVCL is water soluble at room temperature gradually becoming 
insoluble from 32-40°C.
110,111
 PEG polymers in pure water have a high LCST of 96°C, 
while in aqueous salt solution, the critical temperature decreases.
112
 Copolymerization is 
the most common way of adjusting the LCST. For example, PPO itself is hydrophobic, 
but PPO-PEG copolymers can lead to a wide range of hydrophilic-lipophilic properties 
when the composition is varied.
113
 A number of PEO-PPO-PEO block polymers have 
been shown to aggregate in the form of micelles or even in the form of gels at high 
concentrations with increasing temperature.
114
 As is well known, PEO and PPO block 
copolymers like Poloxamers and Pluronics are commercially available and exhibit 
phase transition varying from 20°C to 85°C.
115
 All the materials currently mentioned 
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can be also classified as multiple-responsive polymers because they are not only 
temperature sensitive but also respond to pH, salts or electromagnetic radiation.
112,116
 
1.4.2 pH targeting  
Polymers containing ionizable functional groups that respond to pH variations are called 
pH-sensitive polymers. Their structure and solubility change in response to pH change. 
This is a common feature of biopolymers. For example, the conformation of peptides 
mainly depends on intramolecular or intermolecular interactions such as hydrogen 
bonds or charge attractions.
117
 As the environmental pH varies, the transition point 
within this equilibrium of accepting and donating protons at a specific pH is the 
so-called pKa value. If the solution has a pH value close to the pKa, the degree of 
ionization will be changed dramatically. When the polymers’ pendant groups become 
charged in aqueous solution, they become polyelectrolytes and the conformation is 
expanded. But when the pH changes, the polymer turns into an uncharged 
macromolecule and has a transition from an expanded state to a collapsed state. This is 
explained by the osmotic pressure applied by mobile counter ions neutralizing the 
network charges.
118
 There are two types of pH-responsive polyelectrolytes: weak 
polyacids and weak polybases. 
Polyacids 
The presence of carboxylic groups in polymers is the most common feature of 
pH-responsive polyacids (Figure 1.9). The pKa values of the carboxylic groups are 
usually between 5 and 6. At a higher pH, the pendant carboxylic group is deprotonated 
forming polyelectrolytes. On the other hand, the carboxylic groups accept protons 
forming an uncharged and hydrophobic molecule at a lower pH. 
 
Figure 1.9: Structures of pH-responsive polyacids: (a) poly(acrylic acid) (PAAc); (b) 
poly(methacrylic acid) (PMAAc); (c) poly(2-ethyl acrylic acid) (PEAAc); (d) 
poly(2-propyl acrylic acid) (PPAAc).
119
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Poly(acrylic acid) (PAAc) and poly(methacrylic acid) (PMAAc) are typical examples of 
pH-sensitive polyacids.
119-122
 According to the theory above, PAAc and PMAAc are 
polyelectrolytes at high pH because of electrostatic repulsion forces between the 
molecular chains. Their carboxylic groups accept protons at low pH and release them at 
high pH. PMAAc has an additional hydrophobic methyl group than PAAc which means 
it shows a more compact conformation and an abrupt phase transition compared with 
the relatively continuous phase transition of PAAc. This compact conformation of 
uncharged PMAAc is sometimes referred as a ‘hypercoiled’ conformation. Following 
this trend, adding a more hydrophobic moiety can offer a more compact conformation 
and a sharper phase transition. Therefore, poly(2-ethyl acrylic acid) (PEAAc) and 
poly(2-propyl acrylic acid) contain more hydrophobic moieties and provide more 
hypercoiling behaviour at low pH.
118,123
 This behaviour of polymers, changing from a 
charged extended chain to an uncharged coil structure, can act as a simple switch 
between ‘on’ and ‘off’ state which can be applied in pharmaceutical areas.118  
Polybases 
Figure 1.10 shows some representatives of weak polybases. The amine groups of these 
polymers accept protons at low pH values forming polyelectrolytes, while releasing 
protons at higher pH resulting in uncharged macromolecules. Poly(N,N-dimethyl 
aminoethyl methacrylate) (PDMAEMA) and poly(N,N-diethyl aminoethyl methacrylate) 
(PDEAEMA) are the most frequently investigated pH-responsive polybases. As for the 
theory of polyacids, a polymer that has a longer hydrophobic group at the end of the 
pendant group causes stronger hydrophobic interactions at high pH. PDEAEMA has a 
more compact structure at high pH than PDMAEMA, therefore also leading to a 
‘hypercoiled’ conformation. When the pH is 7.5, PDEAEMA shows an abrupt 
precipitation due to the deprotonation of amino groups.
124
 PDMAEMA was reported to 
have similar sensitive properties as PNIPAAm that has not only pH sensitivity but also 
temperature sensitivity.
125
 Poly(4 or 2-vinylpyridine) (P4VP or P2VP) have aromatic 
amines and offer a critical pH at 5 due to the process of deprotonation of pyridine 
groups.
126,127
 Poly(vinyl imidazole) (PVI) is another pH-sensitive polybase that has the 
imidazole group.  
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Figure 1.10: Structures of pH-responsive polyabases: (a) poly(N,N-dimethyl aminoethyl 
methacrylate) (PDMAEMA); (b) poly(N,N-diethyl aminoethyl methacrylate) 
(PDEAEMA); (c) poly(4 or 2-vinylpyridine) (P4VP or P2VP); (d) poly(vinyl imidazole) 
(PVI).
128
 
For different applications, sometimes it is required to adjust the critical pH of certain 
polymers, at which phase transitions happen as well as conformation changes. This 
usually can be modified by copolymerization with hydrophilic or hydrophobic 
co-monomers.
123,129
  
1.4.3 Light activation 
Light as an easily controlled stimulus is very important and attractive. It has been used 
broadly in smart materials as it offers a wide range of adjustable parameters such as 
wavelength, intensity and duration.
129,130
 Azobenzene and spyrobenzopyran moieties in 
macromolecules can lead to photoresponsive polymers that undergo an efficient and 
reversible photo-isomerization reaction upon irradiation with UV-Vis light.
131
 For 
example, Nalluri and co-workers reported a light-responsive interaction of vesicles that 
are composed of amphiphilic with bifunctional guest molecules containing azobenzene 
groups. Only the trans-azobenzene can bind to the cyclodextrins, the cis-azobenzene 
adopts a conformation that prevents it from acting as a guest. When UV light (350 nm) 
irradiation was used excite molecules, the trans-azobenzene induces rapid aggregation 
and adhesion of vesicles. This photoresponsive supramolecular system is highly 
selective and fully reversible.
132
  
1.5 Summary and project aims 
The overall aim of this thesis is to combine different components to develop three 
delivery systems that have potential applications in drug delivery and specifically 
cancer therapy.  
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The first aim of the work is to design and synthesise stimuli-responsive polymers based 
on the structure of natural elastin-like polypeptide (ELP). Solid-phase peptide synthesis 
and reversible addition-fragmentation chain-transfer (RAFT) polymerisation techniques 
will be used to prepare novel elastin-based side chain polymers (ESPs).  
The second aim of the work is to focus on preparing peptide-functionalized GNPs 
including thermo-responsive polymers and anti-cancer peptide (D-KLA). GNPs can 
improve the stability of peptides and permeability in cancer cells, and their fluorescence 
properties can be used as in vivo tracking molecules. Here we are looking to develop a 
novel system which can deliver the anti-cancer peptide D-KLA into cancer cells for 
application in cancer diagnosis and therapy. Under normal physiological conditions, the 
nanoparticles will be coated with polymers that will ‘hide’ the peptide prior to it 
reaching the tumour tissue. The elastin-like polymers (ESPs) can protect the 
nanoparticle constructs from degradation in vivo (so-called ‘stealth’ behaviour). While 
in the extra-cellular space of tumour tissue (higher temperature 42
o
C), the ESPs’ 
aggregation behaviours will lead to the exposure of anti-cancer KLA peptide. The 
surface of GNPs will be modified with temperature-sensitive ESPs and anti-cancer KLA 
peptide via thiol-gold linkages. Temperature-responsiveness of ESP functionalized 
GNPs will be studied using UV-Vis spectroscopy and circular dichroism measurements. 
KLA peptide conjugated GNPs will be synthesised and their cytotoxicities and cellular 
uptake abilities will be studied. Then, GNPs nanocomposites functionalized by both 
ESPs and KLA peptide will be synthesised and temperature related cytotoxicities will 
be tested.  
Finally we will study delivery of mitochondrial pro-apoptotic peptide (D-KLA) into cell 
with organelle specificity using cell penetrating peptoids (CPPos). CPPos are very 
promising candidates, as they not only have the same penetrating ability of cell 
penetrating peptides (CPP), but also highly resistant to proteolysis. Based on this, we 
will conjugate anti-cancer peptide D-KLA to a series of cell penetrating peptoids (CPPos) 
to obtain better D-KLA delivery systems. KLA-peptoid hybrids cytotoxicity will be 
tested in HeLa cervical cancer cells.  
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Chapter 2: Synthesis of elastin-like peptide and elastin-based 
side chain polymers  
2.1 Introduction 
Elastin is a protein, which helps provide structural integrity to tissues and organs, such 
as the lungs, the dermis and larger blood vessels.
1
 This highly crosslinked insoluble 
protein is a main component of the extracellular matrix and it is an essential element of 
elastic fibres, which provide elasticity to tissues within the human body.
2
 One of the 
most interesting properties of elastin (and tropoelastin, the precursor protein of elastin) 
is its ability to self-assemble and form a coacervate phase when the temperature is 
increased above their transition temperature (Tt).
3
 This thermodynamic inverse phase 
transition is completely reversible. This particular property has led to the development 
of a new family of synthetic proteinaceous polymers, the elastin-like polypeptides 
(ELPs). 
2.1.1 Properties of elastin-like polypeptides  
Elastin-like polypeptides (ELPs) are artificial biopolymers, derived from hydrophobic 
domains of tropoelastin. ELPs are composed of repeating pentapeptide sequences 
Val-Pro-Gly-Xaa-Gly (VPGXG), where the guest residue Xaa can be any amino acid 
except proline.  
Usually, ELPs are described using the notation ELP [XiYjZk-n], as this can distinguish 
between two different ELP constructs. The bracketed capital letters indicate the single 
letter amino acid code specifying the guest residues in the pentapeptide sequence 
VPGXG, the subscripts designate the ratio of the Xaa replacement residue and n 
represents the total length of the ELP in number of pentapeptides.
4
 For example, ELP 
[V1A3G4-160] represents an ELP of 160 unit pentapeptides which has a repeat sequence 
composed of 8 pentapeptides with the guest residues Val, Ala and Gly in a 1:3:4 ratio. If 
n is not given, the notation only shows the sequence of a given ELP without a specific 
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chain length. The most common structure of studied ELPs is poly(VPGVG) or 
alternatively poly(GVGVP). The structure of poly(VPGVG) is shown in Figure 2.1. 
 
Figure 2.1: Chemical structure of poly(Val-Pro-Gly-Val-Gly). 
Urry and co-workers
5-7
 were the first to synthesise a large number of ELPs, and they 
looked at both oligomers and also elastin-like polymers. They studied the biophysical 
properties of the ELPs in solution and they investigated their potential medical 
applications as cross-linked elastomeric materials. Urry also found that ELPs have a 
distinctive property which is known as inverse phase transition behaviour.
5
 At low 
temperatures, ELPs are soluble in solution, but when the solution temperature is 
increased, they become insoluble and aggregate. Aggregation occurs at a critical 
temperature, termed the inverse transition temperature (Tt). The coacervation of solution 
is due to the conformational change of the ELPs, including loss of water from 
hydrophobic domains and the thermodynamic driving force provided by the increased 
temperature. Above the Tt, the ELP forms an ordered structure and the entropy of the 
ELPs is decreased, but the loss of entropy is compensated by the released water from 
the hydrophobic hydration.
8
 This coacervation process is typically reversible; when the 
temperature is cooled down to below the Tt, the ELPs become soluble again. For 
example, high molecular weight poly(VPGVG), which has a series of β-turns as shown 
in Figure 2.2a, is soluble in water below 25°C. When the temperature is increased 
above the Tt, the chain undergoes a conformational change to a β-spiral (Figure 2.2b) 
causing a phase transition and macroscopic aggregation.
6
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Figure 2.2: (a) Recurring β-turn found in poly(VPGVG); (b) β-spiral structure of 
poly(VPGVG) when the temperature is above the transition temperature (Tt). Reproduced 
from 
6
 with permission from Elsevier, copyright © 1992.  
Urry discovered that the Tt has a quantitative relationship with the primary amino acid 
sequence, the hydrophobicity of the guest residue (Xaa) and the overall peptide chain 
length.
9
 Subsequently, a more accurate and complete description of the ELP transition 
behaviour was given by Meyer and Chikoti.
10
 They demonstrated that the transition 
temperature can be modulated by the ELP sequence, concentration, peptide chain length 
and nature of the guest residue. For example, Tt was found to have an approximately 
linear relationship with the natural log of molecular weight in the range of 1,000 Da to 
100,000 Da, where a reduction in molecular weight (MW) causes an increase in Tt.  
Within the ELP sequence, the main parameter that can modulate the Tt is the 
hydrophobicity of the fourth ‘guest’ residue. The hydrophobicity scales for amino acid 
residues in proteins is presented as: Phe > Leu ≈Ile > Val > Ala > Gly. If the guest 
residue is Val which is more hydrophobic than Gly, the Tt will be lower. The inverse 
phase transition can be also influenced by peptide concentration, the addition of NaCl, 
and pH.
11, 12
 Although the effects of many of the parameters that effect Tt have been 
evaluated, it is still very challenging to rationally design an ELP which has an accurate 
targeted transition temperature.  
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2.1.2 Synthesis of elastin-like polypeptides  
ELPs can be produced by either biosynthesis or chemical synthesis. Short elastin-like 
polypeptides can easily be prepared via chemical synthesis, usually using solid phase 
peptide synthesis (SPPS). However, the SPPS approach can only produce polypeptides 
with limited chain lengths of up to 50 amino acids. Given this, the biosynthetic 
approach is more suitable to access longer ELPs when a defined polymer length is 
required.   
2.1.2.1 Elastin biosynthesis 
Protein engineering methods have been used for the design and modification of proteins 
for many years, enabling the preparation of long polypeptides with a defined chain 
length. Figure 2.3 outlines the basic approach for producing polypeptides via protein 
engineering.
13
  
 
Figure 2.3: Overview of the protein engineering methodology. Adapted from Ref 
13
. 
As elastin is characterized by a repetitive amino acid sequence; it is easier to make a 
smaller oligonucleotide sequences to prepare an artificial gene which codes for high 
molecular weight elastin. After constructing the artificial gene library, each gene is 
incorporated into plasmid DNA, which can be applied to transform a bacterial host. The 
plasmids are replicated through the bacterial cells. After verifying the sequence of the 
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selected artificial gene, it is cloned into a second plasmid which allows protein 
expression. The expression plasmid is re-introduced into the host, and the host cells are 
cultured to grow to high density. After expression, the target protein needs to be 
separated from other proteins to obtain the pure product.  
Elastin based materials have been made by protein engineering, which is ideally suited 
for the synthesis of higher molecular weight elastin-like polypeptides. Conticello et al.
14
 
have used this approach to prepare ELP block copolymers which comprise hydrophilic 
and hydrophobic blocks. Protein engineering can completely control the sequence, 
composition and chain length of the blocks. Therefore, carefully designed elastin-like 
biopolymers which may be good candidates for drug delivery or tissue engineering can 
be produced. There are several other examples where ELPs were expressed in 
Escherichia coli or yeast.
15-17
 ELPs can be readily purified from other proteins in cell 
lysates by exploiting their inverse temperature phase transition without the need to use 
chromatography.
18
  
2.1.2.2 Solid phase peptide synthesis (SPPS)  
In 1902, Emil Fisher first introduced peptide chemistry by synthesizing a 
glycine-glycine dipeptide. Then, another milestone was achieved by Merrifield who 
won the 1984 Nobel Prize in chemistry for his development of methodology for 
chemical synthesis on a solid matrix.
19
 Since then, most peptides are synthesised by 
applying the SPPS developed by Merrifield. 
As shown in Figure 2.4, the basic principle of SPPS is to couple the C-terminus of the 
first amino acid to an insoluble support and then to build up the polymer chain by 
coupling the C-terminus of another amino acid continuously. After each coupling, the 
peptide chain is washed by solvents which can release byproducts. Finally, the designed 
peptide is cleaved from the polymeric support using a cleavage cocktail. Compared to 
traditional solution-phase methods, the solid phase approach is simpler and more 
efficient. Now automated synthesisers based on the Merrifield synthesis are available, 
which can assemble sequences of more than 50 amino acids in around two days.
20, 21
 
However, the reactivity between the amino acid and the resin is the main disadvantage 
of solid phase peptide synthesis. Even though the yield of each coupling step is very 
high, almost close to 99%, at the end of the whole sequence the yield could become 
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only 60% if there are 50 amino acids in the chain. The longer the polypeptide chain, the 
lower the yield.
22
  
 
Figure 2.4: The solid-phase peptide synthesis (SPPS) principle. 
2.1.3 Applications of elastin-like polypeptides (ELPs) 
ELPs have shown considerable potential as drug delivery vehicles in cancer therapy. 
Soluble polymeric ELP carriers can help to improve drug pharmacokinetics for systemic 
tumour therapy.
23
 ELP carriers have been shown to display enhanced permeability and 
retention (EPR) effects leading to increased tumour accumulation over the free drug.
24
 
ELP polymeric carriers can also be used for hyperthermia treatment due to their LCST 
behaviour. Hyperthermia can synergistically enhance cytotoxicity when applied in solid 
tumour therapy.
25
 Moreover, hyperthermia can further enhance the drug delivery to 
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tumour infected areas due to the increased permeability of the tumour vasculature.
26
 
Finally, ELPs with defined chain lengths and sequences can adopt complicated 
secondary structures through self-assembly and they can be used to encapsulate drugs 
by forming micelles and vesicles.
27, 28
  
One example of a targeting strategy is to design an ELP that has a transition temperature 
between body temperature and clinical hyperthermia temperature (42
o
C). Chilkoti and 
co-workers
29, 30
 synthesised two ELPs by protein engineering to make a comparison. 
One had a guest residues ratio of Val, Gly and Ala of 5:3:2, while the other had a ratio 
of 1:7:8. ELP[V5G3A2-150] has a Tt of 41
o
C and the control ELP[V1G7A8-160] has a Tt of 
67
o
C, which is considerably above the hyperthermia temperature. These two 
biopolymers were studied by in vivo fluorescence microscopy in nude mice with 
implanted human tumours. The accumulation of these two ELPs in tumours was 
quantified by analysis of fluorescence intensity across a broad spectral window. The 
results showed that the accumulation of ELP[V5G3A2-150] was about two-fold greater 
than ELP[V1G7A8-160] in the tumour area when heated to 42
o
C. It is important to note 
that thermally responsive ELPs can lead to an increase in tumour localization compared 
to the control ELP without hyperthermia. In addition, the uptake of the thermally 
responsive ELP was studied to confirm the results which showed a similar 2-fold 
enhancement in the uptake of the ELP by heated cancer cells compared with unheated 
cells.
31
  
Chilkoti et al. also exploited thermally responsive ELPs to deliver the conventional 
anti-cancer drug, doxorubicin (DOX), to tumours.
32
 They synthesised ELP-DOX 
conjugates, which can self-assemble to form nanoparticles of about 40 nm diameter, in 
the treatment of solid tumours in mice. The structure of ELP-DOX consists of two parts, 
a hydrophilic ELP and a short repeated segment attached to doxorubicin via a pH-labile 
linker as shown in Figure 2.5. It was found that the concentration of ELP-DOX 
conjugates had a 14-fold higher efficacy than the free drug at pH 5.0, and tumour 
regression showed after a single dose which led to a substantial increase in cell survival.  
The properties of ELPs enable them to be used as drug delivery vehicles in different 
ways (Figure 2.6). The first one, known as ‘passive targeting’ is the simplest. 
Hydrophobic drugs are attached to a hydrophilic ELP, which has a Tt much higher than 
body temperature (Tb), to trigger the self-assembly of micelles. These micelles 
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accumulate in the tumour area by passive targeting due to the EPR effect (Figure 2.6 
(a)).
33
 The second one is a ‘thermal targeting’ strategy which builds on the first 
approach. ELPs are designed to exhibit a Tt between 37
o
C and 42
o
C. Then ELP-drug 
conjugates can be applied to a heated tumour area by using mild hyperthermia to trigger 
micro-sized aggregates of ELP that adhere to the tumour vasculature. During the return 
to normothermia, the aggregates dissolve, leading to a large concentration gradient that 
drives the ELP to dissolve from the aggregates into the tumour (Figure 2.6 (b)).
29
 This 
approach can increase the tumour accumulation compared to an ELP control that does 
not have phase transition between 37
o
C and 42
o
C. Third, ELP block copolymers form 
micelles in response to hyperthermia, and present multivalent ligands on the micelle 
corona (Figure 2.6 (c)).
27
 In this approach, the block copolymers were also triggered by 
hyperthermia in the tumour area, resulting in a multivalent display of ligands on a 
self-assembled drug delivery vehicle. The last strategy is to use ELPs as vehicles for 
local delivery of drugs by injection (Figure 2.6 (d)). In this method, ELPs that are 
soluble and injectable at room temperature, but which aggregate at body temperature, 
are required. An ELP with Tt below body temperature can be injected directly into a 
tumour area to form an in situ ELP depot, which extends the length of exposure of the 
tumour to conjugated radiotherapeutics. This approach is supposed to delay the tumour 
growth significantly.
34
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Figure 2.5: ELP–DOX structure: (a) high molecular weight ELPs were conjugated to 
DOX at cysteine residues via a heterobifunctional linker; (b) the hydrophobic drug block 
triggers self-assembly of chimeric polypeptide nanoparticles with a drug core surrounded 
by a hydrophilic polypeptide corona. Reproduced from 
32 
with permission from Nature, 
copyright © 2009.  
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Figure 2.6: ELP–drug delivery strategies: (a) passive targeting (Tt>>Tb); (b) thermal 
targeting (Tt between 37-42
o
C); (c) ELP block copolymers form nanoparticle micelles; (d) 
ELP vehicles (Tt is physiological temperature). Reproduced from 
34
 with permission 
from Elsevier, copyright © 2010.  
2.1.4 Chapter aims  
In this chapter, we aimed to synthesise stimuli-responsive elastin-like peptides and 
elastin-based side chain polymers. Firstly, the synthesis of short repeated sequences of 
elastin-like peptides and a study of their properties were carried out. Secondly, the 
design and synthesis of novel thermo-responsive elastin-based side chain polymers 
(ESP) were undertaken.  
The short elastin-like peptides (ELPs) with different end groups were prepared via the 
SPPS approach, then the transition temperature of the short ELPs in aqueous buffer 
solution were examined using ultraviolet-visible (UV-Vis) spectroscopy. In addition, 
the secondary structure of the ELPs was studied by circular dichroism (CD). The 
elastin-based side chain polymers (ESP) were prepared by the reversible addition 
fragmentation chain transfer (RAFT) technique. ESPs with different chain lengths were 
synthesised and characterized. The influence of the length of chain length, side chain 
length and buffer concentration on the LCST behaviour was discussed.  
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2.2 Synthesis of short elastin-like peptides 
In order to examine the thermodynamic behaviour of a single unit of VPGVG sequence, 
peptide 9 was chosen to be synthesised first; Rink Amide resin was used to provide an 
amide at the C-terminus. Peptide 10 was synthesised to prove how N-acetylation affects 
the conformation transition property at various pH values. Peptide 11 was designed for 
conjugation to GNPs. These short elastin-like peptides were synthesised via Fmoc-SPPS, 
and their sequences are shown in Table 2.1.  
Table 2.1: Sequences and chemical structures of synthesised short elastin-like short 
peptides. 
Sequence Structure 
 H-VPGVG-NH2 (9) 
 
 
Ac-VPGVG-NH2 (10) 
 
 
HS-VPGVG-NH2 (11) 
 
 
2.2.1 Synthesis of peptide H-VPGVG-NH2 (9) 
The synthesis of 9 is shown in Figure 2.7. In solid phase peptide synthesis, the 
sequence of amino acids added on the resin starts from right to left.  
For peptide 9, Fmoc-Gly-OH was first added with PyBOP and NMM to the Rink Amide 
resin (loading 0.74 mmol g
-1
). In order to achieve a high coupling efficiency, each 
amino acid reaction was repeated to ensure complete functionalization. For cleavage of 
the peptide from the Rink Amide resin, a TFA solution in the presence of water and 
triisopropylsilane (TIPS) in a 1:1 ratio was employed. The cleavage cocktail was 
reduced by rotary evaporation and the condensed solution was added into cold diethyl 
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ether to obtain the crude peptide. Then the crude peptide was dissolved in deionised 
water and lyophilised. 
For purification process, 10 mg of crude peptide was dissolved in H2O (containing 0.1% 
TFA) and purified by semi-preparative reverse phase HPLC. The peptide 9 was the 
main peak at RT= 16.5-20.2 min, which has an asterisk on it in the chromatogram 
illustrated in Figure 2.8. A small sample of purified 9 was dissolved in water and 
analyzed by LC-MS. The obtained spectrum is shown in Figure 2.9. The peak at 1.5 
min is the main product. The mass is 427.2 which represents [M+H]
+
. The small peaks 
that appear at 0.5 min and 2.8 min are solvent peaks which also appear in a blank 
sample. Analytical HPLC analysis of 9 was carried out and the trace is shown in Figure 
2.10. 
 
         Figure 2.7: Solid phase peptide synthesis of peptide 9. 
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Figure 2.8: Semi-preparative HPLC chromatogram for peptide 9. 45 min from 0-100% B, 
retention time range from 16.5-20.2 min. 
 
 
Figure 2.9: LC-MS spectrum of purified peptide 9 (VPGVG-NH2). 
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Figure 2.10: Analytical HPLC trace of purified peptide 9 (VPGVG). This pentapeptide 
was synthesised on a solid resin. HPLC was carried out on an analytical column (C18, 4.6 
x 100 mm, 3.5 m particle size). Peptides were eluted in H2O/MeCN + 0.05 % 
trifluoroacetic acid. Retention time = 7.8 min.  
2.2.2 Synthesis of acetylated peptide Ac-VPGVG-NH2 (10) 
The same synthetic strategy was used to prepare peptide 10. In order to cap the 
N-terminus, acetic anhydride in DMF (20% v/v acetic anhydride in DMF) was used as 
the capping reagent. When the capping reaction was completed, the peptide was cleaved 
from the resin.  
A sample of the crude peptide 10 was purified by semi-perparative reverse phase HPLC. 
The peptide 10 was the main peak at RT=19.8-23.2 min, which has an asterisk on it. 
The HPLC chromatogram is shown in Figure 2.11. A small sample of purified peptide 
10 was dissolved in water and analyzed by LC-MS. The obtained spectrum is shown in 
Figure 2.12. The peak at 2.0 min is the main product. The mass is 469.2 which 
represents [M+H]
+
. The small peak that appears at 2.7 min is a solvent peak which also 
appears in the blank sample. Analysis by analytical HPLC was carried out to confirm 
peptide purity (Figure 2.13). 
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Figure 2.11: Semi-preparative HPLC chromatogram for peptide 10. 45 min from 0-100% 
B, retention time range from 19.8-23.2 min.  
 
Figure 2.12: LC-MS spectrum of acetylated peptide 10. 
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Figure 2.13: Analytical HPLC trace of peptide 10. HPLC was carried out on an analytical 
column (C18, 4.6 x 100 mm, 3.5 m particle size). Peptides were eluted in H2O / MeCN + 
0.05 % trifluoroacetic acid. Retention time = 10.3 min.  
2.2.3 Synthesis of thiol-functionalised peptide HS-VPGVG-NH2 (11) 
In order to thiol-functionalize the N-terminus, 3-tritylsulfanyl-propionic acid was used. 
This reagent rather than 3-mercaptopropionic acid was chosen to avoid the disulfide 
reaction between free thiol groups. In 3-tritylsulfanyl-propionic acid, the trityl group 
can protect the thiol and also can be easily cleaved by TFA. After synthesizing the 
sequence VPGVG, the exposed amino acid valine was coupled by adding a mixture of 
3-tritylsulfanyl-propionic acid with PyBOP and NMM in DMF. At first, two equivalents 
were used but the yield was poor. Thus, the amounts of the reagents and 
3-tritylsulfanyl-propionic acid were increased to five equivalents which helped to obtain 
a higher yield. The cleavage cocktail was the same as used for peptide 9. 
The product was purified by semi-preparative HPLC. A sample of the peptide was 
dissolved in water and analysed using a gradient of 0-100% solvent B in 55 min. The 
peptide was the main peak at RT=29.90 min, which has an asterisk on it in the 
chromatogram given in Figure 2.14.  
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Figure 2.14: Semi-preparative HPLC chromatogram of crude product of peptide 11. The 
peak with an asterisk represents the target peptide peak. 
After purification, a small sample of the peptide was dissolved in water and analyzed by 
LC-MS. The obtained trace is shown in Figure 2.15. The peak at 2.0 min is the main 
product. The mass is 515.1 which represents [M+H]
+
. The other peaks that appear at 2.7 
min and 4.5 min are solvent peaks which also appear in the blank sample. Analysis by 
analytical HPLC was carried out to confirm the purity of peptide 11 (Figure 2.16). 
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Figure 2.15: LC-MS spectrum of purified thiol-peptide 11. 
 
Figure 2.16: Analytical HPLC trace of peptide 11. HPLC was carried out on an analytical 
column (C18, 4.6 x 100 mm, 3.5 m particle size). Peptides were eluted in H2O / MeCN + 
0.05 % trifluoroacetic acid. Retention time = 11.7 min.  
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2.3 Lower critical solution temperature (LCST) and circular dichroism 
(CD) studies of short elastin-like peptides  
2.3.1 LCST behaviour of short elastin-like peptides 
Normally, the LCST value of a polymer depends greatly on its hydrophobicity or 
hydrophilicity. In other words, the hydrophilic and hydrophobic interactions between 
the polymer chains play a vital role in influencing the LCST value. These interactions 
are related to the hydrophobic interaction among polymers and hydrophilic interaction 
(hydrogen bonding) between hydrophilic groups of the polymer and water. The 
conformation and solubility of ELP changes in response to a pH change. The 
conformation of peptides mainly depends on intra- and intermolecular interactions, such 
as hydrogen bonds or electrostatic interactions.
35
 As the environmental pH changes, the 
hydrophobic or hydrophilic nature of peptides also changes and thus affects the LCST 
value. The more hydrophilic the peptide, the higher will be the LCST value.  
2.3.1.1 LCST behaviour at different concentrations 
Figure 2.17 a) shows typical turbidimetry plots obtained for peptide 9 solutions with 
different concentrations in phosphate buffered saline (PBS) at pH=9. There is an 
increase in light absorption as the solution is heated. The values of LCST of the peptide 
9 were evaluated in the concentration range of 0.5-2 mg mL
-1
, which was the lower 
limit of sensitivity of the equipment used. At the lowest concentration (0.5 mg mL
-1
), 
the LCST of the solution arrived at 42
o
C; while at the highest concentration (2 mg mL
-1
), 
the LCST decreased to 39
o
C. This shows that the concentration can affect the LCST to 
some extent: decreasing the concentration gave an increase in the observed LCST. 
However, the transition temperature of the peptide 9 solution (1 mg mL
-1
) is 44
o
C, 
which is higher than the transition temperature with a lower concentration (0.5 mg 
mL
-1
).  
LCST behaviour of acetylated peptide 10 solutions with different concentrations at 
pH=7 was also detected. The curves in Figure 2.17 b) show that the LCST of acetylated 
peptide 10 in the concentration range of 0.5-2 mg mL
-1 
are all 45
o
C, which means the 
concentration does not affect the transition temperature. These data illustrate that 
concentration has a very little influence on LCST in the range of 0.5-2 mg mL
-1
.  
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Figure 2.17: (a) The LCST behaviours of peptide 9 solutions with different 
concentrations at pH=9 as observed by UV-Vis absorbance at 300 nm; (b) the LCST 
behaviour of peptide 10 solutions with different concentrations at pH=7 as observed by 
UV-Vis absorbance at 300 nm. 
2.3.1.2 LCST behaviour at different pH  
Peptide 9 in neutral solutions showed no LCST behaviour, which is the same at a lower 
pH. This was anticipated since peptide 9 bears a free amine (pKaH ~ 9.2) at the 
N-terminus, which was expected to be protonated when pH is 7 or lower than 7. At high 
pH, such as at pH=9, the end-group free amine is not protonated, giving the peptide 9 
more hydrophobic character as shown in Figure 2.18 a).  
We also studied the LCST behaviour of peptide 10 at various pH conditions as shown in 
Figure 2.18 b). The concentration of all the solutions was 1 mg mL
-1
. Compared to 
peptide 9, peptide 10 has a hydrophobic end group which allowed LCST behaviour to 
be observed under neutral solutions. At pH=7 it exhibits a transition temperature of 
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45
o
C, where at pH=9 the transition temperature decreases to 39
o
C. This is because the 
pKaH of the amine group is around 9, therefore peptide 10 becomes a less charged 
molecule, which has more hydrophobic character, at pH=9. At pH=3, there is no LCST. 
This may be due to the hydrolysis of the C-terminalus amide. This experiment was 
repeated three times and still no LCST was observed.  
 
Figure 2.18: (a) The LCST behaviours of peptide 9 solutions (1 mg mL
-1
) at various pH 
values as observed by UV-Vis absorbance at 300 nm; (b) the LCST behaviours of peptide 
10 solutions (1 mg mL
-1
) at various pH values as observed by UV-Vis absorbance at 300 
nm. 
2.3.1.3 Summary of LCST behaviours of Rink Amide peptides  
Neutral solutions of peptide 9 (VPGVG) showed no LCST behaviour, also at a lower 
pH. At a higher pH, such as at pH=9, the free amino end group was not protonated, 
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giving peptide 9 a more hydrophobic character. At pH=9, a clear phase transition at 
44
o
C was observed as shown in Figure 2.19.  
The LCST behaviours of peptide 10 solutions at various pH values are shown in Figure 
2.19 as well. Compared to peptide 9, the N-acetylated peptide 10 has a hydrophobic end 
group, therefore it showed LCST behaviour in neutral solution. The LCST of peptide 10 
at pH=7 is 45
o
C, while at pH=9, the transition temperature decreases to 39
o
C. This is 
because the pKaH of the amine group is around 9, peptide 10 becomes more hydrophobic 
at pH=9. At pH=6, the transition temperature increased to 50
o
C. When pH decreased to 
pH=3, it shows that there is no LCST. This may because of hydrolysis of the amide.  
 
Figure 2.19: The LCST behaviours of peptide 9 and peptide 10 solutions (1 mg mL
-1
) at 
different pH values, absorbance at 300 nm. 
From the above turbidimetry data in Figure 2.19, only peptide 10 shows a transition 
temperature which is close to ideal (38-42
o
C) at pH 7. Peptide 10 has a similar structure 
to thiol-functionalized peptide 11 as shown in Figure 2.20. This means that peptide 11 
should have a similar LCST behavior as peptide 10. As peptide 11 will be conjugated to 
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GNPs to endow the LCST property to the ELP-GNP conjugates, it is important for 
peptide 11 to have a transition temperature close to 42
o
C. 
 
Figure 2.20: Structure of peptide 10 and thiol-functionalized peptide 11. 
2.3.2 CD of short elastin-like peptides  
The temperature dependence of the secondary structure of peptide 10 in dilute solution 
(0.2 mg mL
-1
) was evaluated using CD spectroscopy. The CD spectra obtained in PBS 
buffer (pH 7.4) at different temperatures are shown in Figure 2.21. 
At low temperature (4
o
C), the CD spectrum obtained had a large negative peak at 
approximately 197 nm, which is characteristic of a random coil.
36
 With increasing 
temperature, the mean residue ellipticity (MRE) at 197 nm decreased in magnitude 
which supports increasing β-turn content.37 In addition with increasing temperature, a 
small increase in magnitude in the [θ] value at 222 nm was observed. This peak is 
associated with type I/III β-turn.38  These are indications of transforming from random 
coil to a more stable conformation. The most convincing change is the decreased 
intensity of the negative peak at 197 nm, which is the same trend for long chain 
elastin-like peptides when temperature is increased.
7
 The conformational transition from 
random coil towards β-turn occurred gradually over a wide temperature range from 4oC 
to 60
o
C. The [θ] value change at 200 and 222 nm are plotted respectively in Figure 2.22 
and 2.23, which both show the same trends when temperature increases.  
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Figure 2.21: Temperature dependence circular dichroism (CD) spectra of peptide 10 (0.2 
mg mL
-1
) in PBS buffer at pH 7.4 between 4
o
C and 60
o
C. 
 
 
Figure 2.22: Temperature profile of [θ]200 values for peptide 10 (0.2 mg mL
-1
) in PBS 
buffer at pH 7.4 between 4
o
C and 60
o
C. 
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Figure 2.23: Temperature profile of [θ]222 values for peptide 10 (0.2 mg mL
-1
) in PBS 
buffer at pH 7.4 between 4
o
C and 60
o
C. 
As discussed in Section 2.3.1.3, the structure of thiol-end peptide 11 is similar to the 
structure of peptide 10. The temperature dependence of the secondary structure of 
purified peptide 11 in dilute solution (0.2 mg mL
-1
) was also evaluated using CD 
spectroscopy. The spectra obtained in a PBS buffer (pH 7.4) from 10
o
C to 70
o
C are 
shown in Figure 2.24. 
The CD spectra was found to exhibited an obvious increase in MRE at 195 nm to 200 
nm and a very small increase at 206 nm to 212 nm, which are signatures of β-turn 
formation. At the lowest temperature (10
o
C), the spectrum yielded a large negative peak 
at approximately 195 nm, which is characteristic of a random coil. With increasing 
temperature, there exists a small decrease in MRE at 222 nm. This peak is associated 
with a type I/III β-turn. The spectra are characterized by a high proportion of random 
coils and a low proportion of β-turn at low temperature. This distribution is gradually 
inverted with increasing temperature. With increasing temperature, the random coil 
signal becomes less pronounced at 195 nm to 200 nm, while the β-turn increases at 222 
nm.  
The trends at 200 nm and 222 nm discussed above are both indications of a transition 
from a less-ordered state toward a more ordered secondary structure. The 
conformational transition from random coil to β-turn occurred gradually over a wide 
temperature range from 10
o
C to 70
o
C. This shows that the peptide has a more stable 
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status at higher temperature. When the temperature is increased, the thiol-peptides 
became more hydrophobic and had a structure change from random coil to β-turn.   
Figure 2.24: Temperature dependence CD spectra of thiol-peptide 11 (0.2 mg mL
-1
) in 
PBS buffer at pH 7.4 between 10
o
C and 70
o
C. 
The changes in MRE at 200 and 222 nm when the temperature was increased are plotted 
respectively in Figure 2.25 and 2.26, which both show the same trend. In Figure 2.25, 
the MRE increased slowly with increasing temperature at 200 nm. In Figure 2.26, the 
MRE decreased smoothly with increasing temperature at 222 nm. In Figure 2.27, the 
temperature of the CD spectrometer was changed from 10
o
C to 50
o
C in 3 cycles and the 
CD signal of thiol-peptide 11 at 200 nm was measured. When the temperature was 
lowered to 10
o
C, the MRE decreased, which indicates aggregate dissociation. Multiple 
cooling and heating cycles were executed and showed little effect on the particles’ 
properties. The data showed the reversibility of thiol-peptide 11 under thermal 
conditions.  
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Figure 2.25: Temperature profile of [θ]200 values for thiol-peptide 11 (0.2 mg mL
-1
) in 
PBS buffer at pH 7.4 between 10
o
C and 70
o
C. 
 
Figure 2.26: Temperature profile of [θ]222 values for thiol-peptide 11 (0.2 mg mL
-1
) in 
PBS buffer at pH 7.4 between 10
o
C and 70
o
C. 
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Figure 2.27: The CD signal at 200 nm of thiol-peptide 11 (0.2 mg mL
-1
) in PBS buffer at 
pH 7.4 when alternating the temperature 3 times between 10
o
C and 50
o
C. 
2.4 Synthesis of elastin-based side chain polymers  
2.4.1 Synthesis of pentafluorophenyl acrylate (14) monomer 
In order to modify the transition temperature of short elastin-like peptides to the ideal 
range, elastin-based side chain polymers have been introduced in this study. Here, 
reversible addition fragmentation chain transfer (RAFT) polymerization was used to 
polymerize monomer pentafluorophenyl acrylate (PFPA). RAFT is an important 
technique for tailoring well-defined macromolecular architectures. In addition, 
monomer PFPA is an activated ester with fewer cytotoxic effects which has been widely 
applied in the synthesis of biologically active polymers.
39, 40
 
The reaction of the monomer was performed in a two-necked round bottomed flask 
under a nitrogen atmosphere. In the first step, the ratio of the triethylamine (TEA) to 
pentafluorophenol (PFP) (12) was 1.2:1 in order to give full conversion to the 
pentafluorophenolate anion. Acryloyl chloride (13) was then added drop-wise in the 
presence of TEA and PFP as shown in Figure 2.28.  
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Figure 2.28: Synthesis of pentafluorophenyl acrylate (PFPA) (14). 
Purified 14 was characterized by 
1
H NMR, 
13
C-NMR and 
19
F NMR spectroscpies which 
are shown in Figures 2.29 to 2.31. In the 
1
H-NMR spectrum (Figure 2.29), the set of 
signals at 6.70 ppm, 6.35 ppm and 6.16 ppm are respectively correlated to protons c, a 
and b. In the 
13
C-NMR spectrum (Figure 2.30), the signals at 125.34, 135.42 and 
161.65 respectively represent C-H, CH2 and –C=O. In the 
19
F NMR spectrum (Figure 
2.31), there are three signals at -162 ppm, -158 ppm and -153 ppm which are due to 
three types of aromatic fluorine environment. 
 
Figure 2.29: 
1
H-NMR spectrum of monomer PFPA in CDCl3. 
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Figure 2.30: 
13
C-NMR spectrum of monomer PFPA in CDCl3. 
 
Figure 2.31: 
19
F-NMR spectrum of monomer PFPA in CDCl3. 
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2.4.2 Synthesis of poly(pentafluorophenyl acrylate) polymers  
RAFT polymerization is one of the most convenient and versatile polymerization 
methods. The RAFT mechanism provides a controlled living radical polymerization that 
gives well defined polymers with a narrow molecular weight distribution.
41
 
In our work, pentafluorophenyl acrylate (14) was polymerized in the presence of benzyl 
2-hydroxyethyl carbonotrithioate (15) as a RAFT agent in benzene at 70
o
C. 
Pentafluorophenyl acrylate (14) has been discovered to be a good candidate for RAFT 
polymerization.
41
 One of the advantages of poly(pentafluorophenyl acrylate) (PPFPA) 
is its excellent solubility in common organic solvents and high reactivity compared to 
conventional activated esters. Furthermore, by using 
19
F NMR spectroscopy, it is easy 
to monitor the reaction of the PFP ester groups. We used benzyl 2-hydroxyethyl 
carbonotrithioate (15) as a RAFT agent and it resulted in a trithiocarbonate end group 
on the polymer. This end group can be converted to a thiol through a reductive 
aminolysis, which has advantageous properties for attachment to gold nanoparticle 
surfaces. The reaction scheme is shown in Figure 2.32. 
 
Figure 2.32: Synthesis of poly(pentafluorophenyl acrylate) poly (PFPA) (16-19). 
We synthesised different molecular weights of P(PFPA), from P(PFPA)-25 to 
P(PFPA)-100 (16-19). The data of all the polymers synthesised are summarized in 
Table 2.2. For the lower molecular weight reaction, the ratio of [RAFT]/[I] was 1:0.2; 
while for P(PFPA)-100 reaction, the best ratio of [RAFT]/[I] was 1:0.5. 
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Table 2.2: Summary of all the polymerization reactions. 
       Runs [M]/[
RAF
T]/[I] 
Mn,theor 
g.mol
-1
 
Mn,GPC 
g.mol
-1
 
ƉM 
 
Mn,NMR 
g.mol
-1
 
Yield % 
P(PFPA)-25 (16) 25/1/0.2 6,194 8,200 1.26 6,200 65 
P(PFPA)-50 (17) 50/1/0.2 12,144 15,700 1.27 10,700 60 
P(PFPA)-75 (18) 75/1/0.2 18,094 16,300 1.26 14,500 70 
P(PFPA)-100 (19) 100/1/0.5 24,044 23,500 1.19 19,500 69 
 
Here, we discuss the experimental results of P(PFPA)-100 (19) as an example. The 
conversion of this RAFT polymerization is quite high (83%) which proves that it 
worked very well. The calculation is based on the comparision of the integral (I) of 
monomer peak and polymer peak by 
1
H NMR spectroscopy as shown in Figure 2.33 
and the equation can be found in Section 6.3.3. Then 19 was purified and was analyzed 
by THF GPC, 
1
H NMR and 
19
F NMR spectroscopies (Figure 2.34) in CD2Cl2.  
              
Figure 2.33: 
1
H NMR spectrum of P(PFPA)-100 (19) in CDCl3. 
The molecular weight obtained by THF GPC (23,500 g.mol
-1
) is in very good accord 
with the theoretical molecular weight (24,044 g.mol
-1
) as shown in Table 2.2. The GPC 
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also indicated monomodal distributions with low dispersity (ƉM =1.19). The 
1
H NMR 
spectrum of purified P(PFPA)-100 (19) showed characteristic signals from backbone 
protons (peak b and c) around 2.0 and 3.0 ppm as shown in Figure 2.34. The aromatic 
ring signal (peak a), which is at 7.2 ppm, verified the presence of the RAFT agent (15). 
By comparing the phenyl protons (5H, 7.2 ppm) and backbone proton (1H, 3.0 ppm) 
integrals, the degree of polymerization (DP) can be determined. From the 
1
H NMR 
spectrum, we calculate a DP of 81 and the molecular weight of P(PFPA)-100 (19) is 
19,300 g.mol
-1. 
The
 19
F NMR analysis confirmed the expected structure with three 
signals at -153, -158 and -162 ppm attributed to the pentafluorophenyl group. 
Complementary FT-IR showed a carbonyl absorption peak of pentafluorophenyl ester at 
1782 cm
-1 
and a C=C bond of aromatic band absorption peak at 1516 cm
-1 
as shown in 
Figure 2.35. 
For 16, 17 and 18, the same method was used and the experimental 
1
H NMR and 
19
F 
NMR results can be found in Appendices 2.1, 2.2 and 2.3. The DPs calculated from 
1
H 
NMR spectroscopies were 25, 44 and 60 respectively.  
 
Figure 2.34: 
1
H NMR spectrum of purified P(PFPA)-100 (19) in CD2Cl2. 
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Figure 2.35: ATR-FTIR spectrum of P(PFPA)-100 (19). 
2.4.3 Synthesis of elastin-like peptides for coupling to P(PFPA) 
As for the synthesis of side chain peptides (9, 20-21), solid-phase peptide synthesis with 
a Fmoc-protecting group strategy and Rink Amide resin was employed in the 
preparation of peptides 9, 20 and 21 (Table 2.3).  
Table 2.3: Summary of all the peptides synthesised.   
Sequence  Structure 
H-VPGVG-NH2 (9) 
 
 
H-GVPGVG-NH2 (20) 
 
GABA-VPGVG-NH2 (21) 
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As for peptide 9 (VPGVG), the same preparation method was used and the discussion 
can be found in Section 2.2.1. The same method was applied to 20 and 21. Crude 
products were purified by semi-preparative HPLC (Appendix 2.4) using the same 
conditions as discussed in Section 2.2.3. After purification, 53% of pure peptide 20 
(GVPGVG) was obtained. 
 
After purification, a small sample of peptide 20 was dissolved in water and analyzed by 
LC-MS. The obtained spectrum is shown in Figure 2.36. The peak eluting at 2 min is 
the main product. The mass is 484.0 which represents [M+H]
+
. The other peaks that 
appear at 3.0 min and 4.5 min are solvent peaks which also appear in the blank sample. 
Analysis by analytical HPLC was carried out to confirm the purity of peptide 20 
(Figure 2.37).   
 
Figure 2.36: LC-MS spectrum of purified peptide 20. 
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Figure 2.37: Analytical HPLC trace of purified 20. HPLC was carried out on an 
analytical column (C18, 4.6 x 100 mm, 3.5 m particle size). Peptides were eluted in H2O 
/ MeCN + 0.05 % trifluoroacetic acid.Retention time = 8.3 min. 
 
For peptide 21, the same HPLC purification method was used as that for peptide 20 
(Appendix 2.5). After purification, 55% of purified 21 was obtained. The LC-MS 
spectrum of 21 is shown in Figure 2.38. The peak that elutes at 1.7 min is the main 
product. The mass is 511.9, which represents [M+H]
+
. The other peaks that appear at 
2.7 min and 4.5 min are solvent peaks which also appear in the blank sample. The 
analytical HPLC trace of 21 was carried out and the spectrum is shown in Figure 2.39. 
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Figure 2.38: LC-MS spectrum of purified peptide 21. 
 
Figure 2.39: Analytical HPLC trace of purified 21. HPLC was carried out on an 
analytical column (C18, 4.6 x 100 mm, 3.5 m particle size). Peptides were eluted in H2O 
/ MeCN + 0.05 % trifluoroacetic acid.Retention time = 9.1 min. 
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2.4.4 Synthesis of elastin-based side chain polymers  
P(PFPA) was modified by reaction with the amine end of the short elastin-like peptide 
(ELPs). P(PFPA) was dissolved in N,N-dimethyl formamide (DMF) and the solution of 
peptide dissolved in dimethyl sulfoxide (DMSO) in the presence of 1.5 equivalents of 
trimethylamine, which was added slowly. Here, we chose DMSO as the solvent rather 
than water to avoid precipitation of the polymer. The ratio of [NH2-peptide]/[PPFPA] 
was chosen as 1.4:1 to ensure a full conversion of activated ester. The larger ratio will 
not have a significant impact on the yield.
40
 To ensure the total consumption of 
pentafluorophenyl ester, the reaction was carried out overnight at 30
o
C. When the 
reaction was finished, the solution was dialyzed against water for 3 days using a 
membrane with a cut-off of 3500 Daltons. The purpose of dialysis was to remove any 
unreacted peptides. As proof of a successful reaction, the solubility of the polymer was 
transformed from hydrophobic P(PFPA) to hydrophilic elastin-based side chain polymer 
(ESP). After freeze drying, a white fluffy powder was obtained. The reaction scheme is 
shown in Figure 2.40. Table 2.4 shows the characterisation data for all the ESP 22-29.   
 Figure 2.40: Chemical modification of PFPA in the presence of peptide. 
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Table 2.4: Characterisation date for peptide-polymer hybrids 22-29.  
Runs [Polymer]/[
Peptide]/[T
EA] 
Mn,theor 
g.mol
-1
 
Mn,GPC 
g.mol
-1
 
ƉM 
 
Yield 
% 
PF25-VPGVG (22) 1/1.4/1.4 12,125 5,600 1.31 71 
PF50-VPGVG (23) 1/1.4/1.4 21,245 6,400 1.46 87 
PF75-VPGVG (24) 1/1.4/1.4 28,925 10,100 1.30 83 
PF75-G(VPGVG) (25) 1/1.4/1.4 32,345 10,600 1.22 81 
PF75-GABA(VPGVG) (26) 1/1.4/1.4 34,025 11,300 1.23 79 
PF100-VPGVG (27) 1/1.4/1.4 39,005 11,500 1.26 80 
PF100-G(VPGVG) (28) 1/1.4/1.4 43,622 13,000 1.25 80 
PF100-GABA(VPGVG) (29) 1/1.4/1.4 45,890 13,400 1.27 76 
The elastin-based side chain polymers were analysed by 
1
H NMR and 
19
F NMR in 
d6-DMSO and FT-IR spectroscopies. The 
19
F NMR spectrum can be used to easily 
determine whether the pentafluorophenyl ester has fully reacted or not. For low 
molecular weight PF25-VPGVG (22) and PF50-VPGVG (23), the 
19
F NMR spectrum 
showed no signals at -153, -158 and -162 ppm from pentafluorophenyl group, as shown 
in Appendix 2.6 and 2.7. However, for the larger molecular weight PF75-VPGVG (24) 
and PF100-VPGVG (27), the reactions were not complete because the 
19
F NMR 
spectrum showed a very small peak in this area as shown in Appendix 2.8 and 2.9. In 
support, ATR-FTIR spectra of 24 and 27 both showed a small carbonyl absorption peak 
at 1782 cm
-1
 while no such peaks were seen in ATR-FTIR spectra of 22 and 23. The 
comparison ATR-FTIR data can be found in Appendix 2.10. 
These results showed that longer the polymer, the more difficult the reaction. Also 
because of the structure of peptide VPGVG, the amine of amino acid valine is quite 
hindered and slow to react with pentafluorophenyl ester. Therefore, we synthesised 
peptide 20 and peptide 21 which had a short linker glycine and longer linker 
4-aminobutanoic acid to react with P(PFPA)-75 (18) and P(PFPA)-100 (19).  
An example of the 
1
H NMR and 
19
F NMR spectra (in d6-DMSO) of the 
PF75-GVPGVG (25) is given in Figure 2.41. The absence of the backbone proton 
signal at 3.0 ppm indicates an efficient modification of pentafluorophenyl ester. 
Moreover, the signal at 0.85 ppm attributed to the protons which belong to methyl 
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group from amino acid valine confirms a successful modification. The presence of the 
RAFT agent can be found by the signal at 7.2 ppm attributed to the aromatic ring. From 
the 
19
F NMR spectrum, it is easy to tell that the reaction of the ester groups is highly 
efficient from the absence of any signals. In Figure 2.42, ATR-FTIR shows a carbonyl 
absorption shift from 1782 cm
-1
 to 1654 cm
-1
 corresponding to a change of the carbonyl 
functionality from being adjacent to pentafluorophenyl to carbonyl in an amide bond. 
The absence of a band at 1715 cm
-1 
confirms the absence of any free carboxylic acid 
group due to the prior hydrolysis of the pentafluorophenyl group. DMF GPC result 
showed only one peak and the dispersity ƉM is reasonable (1.26). The molecular weight 
obtained from GPC measurement was based on PEO standards and it is not accurate. 
Since the 
19
F NMR as well as the ATR-FTIR spectrum supported the full 
functionalisation of pentafluorophenyl ester, we used the same DP for PF75-GVPGVG 
(25) as for P(PFPA)-75 (18).  
For 26, 28 and 29, the same method was used and the experimental results of 
1
H NMR 
and 
19
F NMR spectroscopy can be found in Appendix 2.11, 2.12 and 2.13.  
 
Figure 2.41: 
1
H NMR and 
19
F NMR spectra of PF75-GVPGVG (25) in d6-DMSO. 
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Figure 2.42: ATR-FTIR spectra of P(PFPA) (16) and PF(75,100)-GVPGVG (25,28) and 
PF(75,100)-GABA(VPGVG) (26,29). 
2.5 LCST and CD experiments of elastin-based side chain polymers 
2.5.1 LCST behaviour of elastin-based side chain polymers (ESPs) 
In the following part, we will describe our investigations of the influence of the length 
of the side chain, polymer weight and NaCl concentration on the LCST behaviour of the 
elastin-based side chain polymers. 
2.5.1.1 Chain length and molecular weight  
It has been shown that, as the molecular weight of linear poly(VPGVG) is increased, the 
transition temperature is decreased.
7, 10
 To investigate whether elastin-based side chain 
polymers (ESP) were also affected in the same way, four different chain length 
polymers were synthesised and studied as shown in Table 2.5. The degree of 
polymerization was determined by 
1
H NMR spectroscopy of the poly(PFPA).  
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Each polymer was dissolved in pH=7.4 phosphate buffer at a concentration of 1mg mL
-1
. 
When the number of VPGVG units (DPn) in the polymer is increased from 25 to 80, we 
see a change in LCST from higher than 100
o
C to 42
o
C. However, as was discussed in 
Section 2.4.4, the reactions of PF75-VPGVG (24) and PF100-VPGVG (27) were not 
complete because the 
19
F NMR spectra showed small peaks in the range of -150 to -165 
ppm. Therefore, 24 and 27 were not 100 % pure with VPGVG side chains, which means 
the LCST of pure 24 and 27 should be higher than what was observed. As the reaction 
temperature, time and ratios of reagents as well as polymer synthesis were the same, we 
assume that the purities of 24 and 27 were similar. Here, we only use the data to discuss 
the effect of chain length on transition temperature as a qualitative analysis.  
For 22 and 23, the absorbance value increased when temperature increased (15
o
C-95
o
C) 
in a liner relationship. The transition temperature of the 22 and 23 could not be detected 
because it is above the highest temperature that could be measured. For 24 and 27, the 
transition temperature was 49
o
C and 42
o
C as shown in Figure 2.43. The turbidity 
measurements clearly showed a decrease in the transition temperature as the chain 
length was increased. It has been proven by Fernandez-Trillo et al.
42 
that transition 
temperature is decreased when the chain length of elastin-based side chain polymers 
(ESPs) is increased. This is because longer chain lengths increase overall molecular 
weights, which will reduce phase transition temperatures.  
Table 2.5: Molecular weight data and transition temperatures for elastin-based side chain 
polymers.  
Polymer DPn Mn,theor kg.mol
-1
 Transition temperature (
o
C) 
PF25-VPGVG (22) 25 12.1 / 
PF50-VPGVG (23) 44 21.2 / 
PF75-VPGVG (24) 60 28.9 49 
PF100-VPGVG (27) 81 39.0 42 
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Figure 2.43: Turbidity measurements of different polymers (1 mg mL
-1
) as observed by 
UV-Vis absorbance at 300 nm: (a) PF75-VPGVG (24) and (b) PF100-VPGVG (27). 
We also investigated whether the peptide sequence affected the transition temperature. 
Four polymers with different peptide side chains were synthesised and studied as shown 
in Table 2.6. The polymers were dissolved in a phosphate buffer of pH 7.4 and at a 
concentration of 1 mg mL
-1
. The first two polymers have the same chain length (60), but 
the side chain is different. The transition temperatures of the first two polymers were 
76
o
C and 68
o
C as shown in Table 2.6. And the last two polymers have longer chain 
length (81), and the transition temperatures were 49
o
C and 47
o
C, which are much lower 
than the first two polymers. The molecular weight was different proving that the larger 
the molecular weight, the lower the transition temperature. Comparing the peptide 
G(VPGVG) 20 and GABA(VPGVG) 21, the longer linker produces a lower transition 
temperature. This is because the longer linker distances the peptides from the polymer.  
Table 2.6: Molecular weight data and transition temperature for elastin-based side chain 
polymers.  
Polymer DPn 
 
Mn,theor 
kg.mol
-1
 
Transition 
temperature (
o
C) 
PF75-GVPGVG (25) 60 32.3 76 
PF75-GABA(VPGVG) (26) 60 34.0 68 
PF100-GVPGVG (28) 81 43.6 49 
PF100-GABA(VPGVG) (29) 81 45.9 47 
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2.5.1.2 Effect of concentration on polymer 28 and 29 
The second physical parameter of interest is the concentration of the polymer solution. 
It has been shown that as the concentration is increased, the transition temperature 
decreases.
10
 To investigate the effect of concentrations on polymer PF100-GVPGVG 
(28) and PF100-GABA(VPGVG) (29), three different concentrations in PBS solution 
were prepared and their transition temperatures measured.  
As shown in Figure 2.44, the turbidity measurements clearly confirmed that as the 
concentration increases, the transition temperature decreases which is the same trend 
that is observed for linear VPGVG. For linear VPGVG, Urry et al.
3,43
 discussed that this 
concentration effect is caused by the fact that the transition of the secondary structure is 
a cooperative process. This means that when concentration is increased, this cooperative 
effect increased as well, and the transition temperature decreased. This explanation 
could also apply to the elastin-based side chain polymers. For polymer 
PF100-GVPGVG (28), when the concentration increased from 0.5 mg mL
-1 
to 2 mg 
mL
-1
, the transition temperature changed from 52
o
C to 47
o
C. For the polymer 
PF100-GABA(VPGVG) 29, the transition temperature decreased from 48
o
C to 46
o
C 
when the concentration was increased.  
 
Figure 2.44: Turbidity measurements of different concentrations of polymer: (a) 
PF100-G(VPGVG) (28) and (b) PF100-GABA(VPGVG) (29) as observed by UV-Vis 
absorbance at 300 nm. 
2.5.1.3 Effect of added sodium chloride on 25 and 26 
The third physical parameter investigated is the concentration of NaCl in the polymer 
solution. It has been shown that as the concentration of NaCl is increased, the transition 
temperature decreases.
44
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To investigate the effect of NaCl concentration on polymer PF75-GVPGVG (25) and 
PF75-GABA(VPGVG) (26), four different polymer solutions which had different 
concentrations of NaCl were prepared and their transition temperatures measured. As 
shown in Figure 2.45, the turbidity measurements clearly confirmed that as the NaCl 
concentration increases, the transition temperature decreases which is the same trend 
that was observed for linear VPGVG. It has been suggested that anions weaken the 
hydrogen bonding of water to the carbonyl moiety of the amide backbone.
44
 This 
explanation could also apply to the elastin-based side chain polymers.  
For polymer PF75-GVPGVG (25), when the NaCl concentration increased from 0 to 
0.3 M, the transition temperature decreased from 76
o
C to 65
o
C. As for polymer 
PF75-GABA(VPGVG) (26), when the NaCl concentration increased, the transition 
temperature decreased from 68
o
C to 57
o
C.  
Figure 2.45: Turbidity measurements of different NaCl concentrations in PBS solutions 
of polymer as observed by UV-Vis absorbance at 300 nm: (a) PF75-G(VPGVG) (25) and 
(b) PF75-GABA(VPGVG) (26). 
2.5.1.4 Summary of LCST behaviour of ESPs 
In summary, we found that the transition temperature of elastin-based side chain 
polymers was mainly modulated by the change of chain length and molecular weight of 
the polymers. PF25-VPGVG (22) and PF50-VPGVG (23) showed no transition 
behaviour when the temperature increased in the range 20-100
o
C. PF75-GVPGVG (25) 
and PF75-GABA(VPGVG) (26) were designed and synthesised because they provided 
linkers between the backbone and side-chains which enable possible occurrence of 
polymer behaviour. The LCSTs of PF75-GVPGVG (25) and PF75-GABA(VPGVG) 
(26) are generally above 60
o
C even when the salt effect has been considered. In order to 
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obtain a lower transition temperature, PF100-GVPGVG (28) and 
PF100-GABA(VPGVG) (29) were synthesised and their transition temperatures were 
measured as 49
o
C and 47
o
C. The polymers were dissolved in a phosphate buffer of pH 
7.4 and at a concentration of 1 mg mL
-1
. Due to its higher molecular weight, 
PF100-GABA(VPGVG) (29) has been shown to have the lowest LCST as shown in 
Figure 2.46. The turbidity change of its solution in a small vial when the temperature 
increased and decreased can be seen visually. Upon heating to 40
o
C, the solution of 
PF100-GABA(VPGVG) (29) exhibited coacervation as the colour changed from 
transparent to cloudy white. This coacervation process is reversible, when the 
temperature is cooled down to below the Tt, it become soluble again.  
 
Figure 2.46: Turbidity measurements of PF100-GABA(VPGVG) (29) (1 mg mL
-1
) in 
PBS solution at pH 7.4 as observed by UV-Vis absorbance at 300 nm. Visual turbidity 
change of 29 when temperature changes.  
2.5.2 CD analysis of elastin-based side chain polymers  
As discussed in Section 2.5.1.4, PF100-GABA(VPGVG) (29) has the lowest transition 
temperature (47
o
C) among the elastin-based side chain polymers prepared. Here, we 
will discuss a secondary structure study of 29. In Figure 2.47, the temperature 
dependence CD spectra of 29 in PBS buffer with a concentration of 0.2 mg mL
-1 
were 
demonstrated. The spectra were obtained from 10
o
C to 50
o
C. Compared to the spectra 
of short elastin like peptide, the trend of MRE at 198 nm, 208 and 222 nm is almost the 
same.  
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Also at the lowest temperature (10
o
C), the spectra had a much smaller negative peak at 
198 nm compared to peptide 10 and 11, which means ESP 29 had a much less random 
coil structure at 10
o
C. With increasing temperature, the spectra exhibited a more 
obvious increase in MRE at 198 nm and 208 nm, which are signatures of β-turn 
formation.
45
 The conformational change from random coil to β-turn occurred smoothly 
over a temperature range of 10
o
C to 50
o
C. Also there is a decreasing signal at 222 nm 
when the temperature was increased, which represents type I/III β-turn of polypeptides. 
The trends discussed above are indications of a structure change from a less-ordered 
state toward a β-turn ordered secondary structure. In Figure 2.48, the MRE increased 
slowly with increasing temperature at 198 nm. In Figure 2.49, the temperature of the 
CD spectrometer was changed from 20
o
C to 50
o
C in 3 cycles and the CD signal of 29 at 
198 nm was measured. The data showed the reversibility of 29 under thermal 
conditions.  
 
Figure 2.47: Temperature dependence CD spectra of 29 (0.2 mg mL
-1
) in PBS buffer at 
pH 7.4 between 10
o
C and 50
o
C. 
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Figure 2.48: Temperature profile of [θ]198 values for 29 (0.2 mg mL
-1
) in PBS buffer at 
pH 7.4 between 10
o
C and 50
o
C. 
 
Figure 2.49: The CD spectra and the CD signal at 198 nm of 29 (0.2 mg mL
-1
) in PBS 
buffer at pH 7.4 when alternating the temperatures 3 times between 20
o
C and 50
o
C.   
2.6 Conclusions   
We synthesised and studied short elastin-like peptides with different end groups. A solid 
phase peptide synthesis approach was applied and Rink Amide resin was used. Under 
normal physiological conditions, the short ELPs prepared are soluble in aqueous 
solution, but as the solution temperature is raised, they become insoluble and aggregate 
at a critical temperature, termed the transition temperature (Tt). The turbidimetry data of 
all the short elastin-like peptides showed that only peptide 10 (N-acetylated VPGVG) 
has a transition temperature (45
o
C) close to the ideal one (38-42
o
C) at pH=7. 
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In addition, the secondary structure of peptide 10 was found to change from random coil 
to a mixture of α-helix and β-turn structures when the temperature was gradually 
increased. The same trend was also observed with peptide 11 which has a thiol end. 
According to the experimental results, these stimuli-responsive short ELPs have the 
same properties as regular ELPs, while providing a simple and rapid synthesis method.  
We used the reversible addition fragmentation chain transfer (RAFT) technique to 
polymerize pentafluorophenyl acrylate (PFPA) in the presence of benzyl 
2-hydroxyethyl carbonotrithioate as a RAFT agent. We synthesised four polymers with 
different chain lengths. Different molecular weights of polyPFPA (16-19) were 
precipitated in methanol to be purified and then be characterized by THF GPC, NMR 
and FT-IR. Poly(PFPA)s were subsequently modified by attachment of short elastin-like 
peptides (9, 20-21) and conversion of the terminal trithiocarbonate moiety into a thiol. 
We described the influence of the length of the side chain and salt concentration on 
LCST behaviour. Among all the elastin-based side chain polymers, ESP 29 has been 
proven to have the lowest transition temperature (47
o
C) due to the highest molecular 
weight. 
Furthermore, both short elastin-like peptide and ESPs are suitable for sequence 
modification and derivatisation. In the next chapter, short peptide 11 and elastin-based 
polymer 29 will be applied as capping ligands to make hybrid systems with metal and 
anti-cancer drugs which can be used in cancer therapy. 
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Chapter 3: Peptide-functionalised Gold Nanoparticles  
3.1 Introduction  
Colloidal gold solutions have been known and used, since ancient times, for staining 
glass and colouring ceramics, and in the 20
th
 century, gold nanoparticles (GNPs) have 
been extensively studied due to their size dependent electronic and optical properties.
1, 2
 
GNPs can be easily functionalized with biomolecules which contain thiols, amines, or 
even phosphine moieties.
3, 4
 The most common approach is to functionalize the GNPs 
with thiol containing molecules. Using this method it has been possible to synthesise 
novel hybrid materials consisting of combinations of GNPs and proteins (or peptides). 
The peptides and proteins utilised in these systems can fulfil different roles, acting as 
drug carriers, anti-cancer drugs and even cellular-targeting moieties.
5, 6
  
In the last decade, a variety of peptide functionalized GNPs has been synthesised and 
applied in bio-detection, targeted drug delivery, cellular uptake studies, etc.
7-10
 Adding 
peptides to citrate-capped GNPs, sometimes can produce highly stable peptide-capped 
nanoparticles even in an aqueous buffer, and sometimes these can result in the 
formation of aggregates. The ability to assemble/disassemble GNPs can be modulated 
by changing the peptide sequence. For example, pH-responsive peptides can change 
conformation in response to changes in their local environment and this can lead to 
aggregation of GNPs which will itself gives rise to a visual colour change. 
11
  
3.1.1 Gold nanoparticles (GNPs) 
Colloidal gold is a suspension of nanometer-sized particles of gold in a continuous 
phase, usually water. The optical property of colloidal gold was not truly evaluated until 
Michael Faraday’s work in the 1850s. In 1857 Faraday prepared the first sample of 
colloidal gold by using phosphorus to reduce a solution of gold chloride, which he 
called ‘activated gold’. He investigated the relations of thin films prepared from dried 
colloidal solutions to light and observed reversible colour changes of the films upon 
pressurizing.
12
 In the 20
th 
century, various methods for the preparation of gold colloids 
were studied and reported.
13, 14
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GNPs are among the most stable metal nanoparticles, and they have shown fascinating 
properties such as size-related electronic, magnetic and optical properties. Therefore, 
they have been extensively investigated and applied in catalysis and biology.
15, 16
  
In the early 1950s Turkevich developed an approach for the synthesis of GNPs.
17
 This 
approach involved the reduction of hydrogen tetrachloroaurate (III) HauCl4 in water by 
a reducing agent/stabilising ligand, such as sodium citrate.
13
 Using this process, GNPs 
with a size ca. 20nm can be prepared. Later, in 1973 Frens improved this method and  
obtained GNPs with a more controlled diameter (between 16 and 147 nm).
14
 In this 
approach the trisodium citrate to gold ratio controls the size of the GNPs. The higher the 
ratio, the smaller the particle size. However, the aforementioned method is not good at 
controlling polydispersity, which also tends to increase with particle size.  
3.1.2 Preparation of peptide functionalised GNPs 
Generally, a colloidal gold solution is produced by the aforementioned Turkevich-Frens 
approach as it is the simplest one to produce citrate capped nanoparticles.
17,14 
The 
citrate-GNPs can be further functionalized with different peptides to improve stability. 
There are three main approaches to preparing peptide-functionalized GNPs: (1) ligand 
exchange, (2) chemical reduction, and (3) chemical conjugation.  
3.1.2.1 Ligand exchange method  
The ligand exchange method is the most common approach used to prepare 
peptide-GNPs. This method essentially involves displacement of one ligand for 
another
18, 19
 and it was first explored by Hostetler et al.
18
 who attempted to replace 
simple thiol ligands on GNPs with more complex thiols. The ligand exchange method 
has been successfully used to synthesise a range of GNPs capped with 
cysteine-terminated peptides. For example, tetra-chloroaurate ions (AuCl4
-
)
 
are firstly 
reduced by sodium citrate and citric acid to give citrate-stabilized GNPs. In the presence 
of Cys-terminal peptides the citrate-stabilized GNPs undergo ligand exchange to give 
peptide functionalized GNPs.
20,21
 This reaction proceeds due to the fact that the cysteine 
containing peptides have a stronger interaction with GNPs compared to the citrate ions. 
The sulfur-gold bond has a strength of approximately 210 kJ mol
-1
.
22
 This ligand 
exchange method is very useful when the desired thiol ligand is valuable or not 
compatible with the reductive environment. A single thiol group can be already quite 
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strong as a binding ligand to a gold surface, however in some complex systems, 
multiple thiols may be desired if higher chemical stability is required. For example, Lin 
et al.
23
 reported a two-step method to attach neutral and positively charged thiols onto 
the gold surface. The scheme is shown in Figure 3.1. The first step is to reduce 
tetrachloroauric acid by sodium citrate and then replace the citrate and chloride by 
thioctic acid (TA). The second step is to replace TA by thiols containing the functional 
groups. Through the two-step approach, stable GNPs can be functionalized by 
positively charged thiols.  
 
Figure 3.1: Illustration of the two-step method to attach thiols to the surface of GNPs. 
Reproduced from
23
 with permission from American Chemical Society, copyright © 2004. 
3.1.2.2 Chemical reduction 
In 2005, Bhattacharjee et al.
24
 reported an approach to prepare colloidal 
GNP-tripeptides through an in situ tyrosine reduction technique. The designed tripeptide 
sequence was H2N-Leu-Aib-Tyr-Ome, and tyrosine acts as an electron-transfer agent.
25
 
The tyrosine at the C-terminus can reduce AuCl4
- 
to Au
0
, and the free amine at the 
N-terminus of the tripeptide can attach to the gold surface resulting in a colloid 
suspension. The size of the tripeptide-GNPs prepared via this approach was relatively 
small, around 8.7 nm. However, when excess tri-peptides were added to a gold salt 
solution, the resultant tripeptide-GNPs aggregated due to H-bonding between the 
terminal NH2 group and side chains of amino acid residues. Other tyrosine containing 
peptides have also been used to synthesise peptide-GNPs. For example, the peptide 
AG4(NPSSLFRYLPSD) was used to reduce gold ions to GNPs and subsequently form 
organic-inorganic hybrid spheres.
26
 The size of the particles produced was affected by 
temperature, and higher temperatures were found to decrease the size of the spheres.  
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3.1.2.3 Chemical conjugation method  
Generally, GNPs are formed in aqueous solution and capped by water-soluble 
stabilizers, such as thiolated derivatives of PEG, glutathione or mercaptosuccinic acid. 
These stabilizers often have active sites that can be used to bind peptides and other 
biomolecules. This method of combining peptides to GNPs is known as the chemical 
conjugation method.  
In 2009, Xie et al.
27
 showed that nuclear localization signal (NLS) peptide 
functionalized-GNPs can be used as a nuclear targeting nanoprobe. As shown in Figure 
3.2, the nanoparticles were first modified by 11-mercaptoundecanoic acid (11-MUA), 
the NLS peptide was then connected to the modified GNPs by carbodiimide-mediated 
coupling. Later in 2011, Bartczak and co-workers
28
 developed a one-pot synthesis 
method using EDC/sulfo-NHS (N-hydroxy sulfosuccinimide) coupling. Using this 
approach the peptide KPQPRPLS was conjugated to carboxy-terminated oligoethylene 
glycol gold nanoparticles (OEG NPs) via EDC/sulfo-NHS coupling. The degree of 
peptide coupling was affected by experimental parameters, such as reaction time, 
concentration of reagent and the morphology of the nanocrystal.  
 
Figure 3.2: Preparation of the nuclear targeting nanoprobe. Reproduced from
27
 with 
permission from American Chemical Society, copyright © 2009. 
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3.1.3 Applications of peptide functionalised GNPs 
3.1.3.1 Plasmonic biosensors 
As discussed peptide-functionalized GNPs have unique optical and electrical properties 
and their assembly can be triggered by changes in their local environment. Increasingly 
studies have been performed to apply these properties in the detection of metal ions, 
enzymes and antibodies. 
For example the application of functionalised GNPs in the detection of heavy metal ions, 
several studies have appeared in the literature since 2007. Si et al.
29
 developed the first 
peptide-functionalized GNPs to detect Hg
2+
 ions in solution. In this work the 
peptide-GNPs were synthesised by using the tripeptide H2N-Leu-Aib-Tyr-Ome to 
reduce tetra-chloroaurate ions (AuCl4
-
). The UV-Vis spectrum of the peptide-GNPs 
solution showed an absorbance peak at 527 nm, but after adding Hg
2+
 ions, the surface 
plasmon resonance (SPR) showed another peak at wavelength ca. 670 nm. As shown in 
Figure 3.3, the colour of the solution also changed from red to purple. When the 
alkaline EDTA solution was added, the purple colour turned back to red. This method 
can detect Hg
2+
 ions in solution at above 4 ppm, either by the naked eye or UV-Vis 
spectroscopy.  
 
Figure 3.3: The colour change of peptide-GNPs solution in response to Hg
2+
 ions.  
Reprinted from 
29
 with permission from American Chemical Society, copyright © 2007. 
In 2012, Saxena et al.
30
 discovered a novel approach to detect bluetongue virus (BTV) 
specific antibodies based on multiple antigenic peptide (MAP) functionalized-GNPs. In 
this work, the antigenic BTV peptide was designed based on the region of VP7 protein 
which has specific cross reaction with BTV strains. VP7 protein of the BTV was chosen 
as the antigen because the protein shows high sequence homology among the serotypes. 
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The GNPs were decorated with antigenic BTV peptides in a format with a cystine core 
and four BTV arms linked through Di-Fmoc-Lys, to amplify the sensitivity. When 
GNPs labeled with MAP met the specific BTV antibodies, they became aggregated 
resulting in a colour change from pink to violet. This novel approch using MAP 
fuctionalized GNPs has the advantage of minimizing the risk of infectious organisms 
and highly specific targeting to BTV antibodies at the same time.   
In 2014, Chandrawati et al.
31
 demonstrated a label-free detection for blood coagulation 
factor XIII activity based on the optical and electronic properties of GNPs. Factor XIII 
is active in the presence of thrombin and Ca
2+
 and it catalyses the formation of a 
covalent amide bond between the side chains of the amino acid residues Gln and Lys. 
GNPs were functionalized separately with two different peptides, 
Cys-Ala-Leu-Asn-Asn-Gly-Gln-Gly (CALNNGQG) and 
Cys-Ala-Leu-Asn-Asn-Gly-Lys-Gly (CALNNGKG). If factor XIII is present the 
Gln-Lys bond forms an intermolecular crosslinking between the two types of GNPs and 
aggregation occurs. A red shift of the surface plasmon resonance (SPR) absorption band 
confirmed the aggregation and a solution colour change from red to blue was observed 
(Figure 3.4). The concentration of Factor XIII produced a linear relationship with the 
difference of the maximum absorbance peak (∆λmax) and the concentration limit was 
down to 0.01U mL
-1
.This provides a label-free and very sensitive approach to detect the 
activity of Factor XIII.  
 
Figure 3.4:  Schematic illustration of label-free detection of blood coagulation Factor 
XIII activity based on controlled assembly of peptide-functionalized GNPs. Reproduced 
from 
31
 with permission from Royal Society of Chemistry, copyright © 2014. 
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3.1.3.2 Targeted drug delivery and cellular uptake  
In recent years, peptides have been used in biomedical applications, such as targeting 
probes, drug carriers and vaccines etc., because of their small size, biocompatibility, 
cell-penetrating ability and easy chemical synthesis and modification.
5, 6
 Chan et al.
32
 
studied the uptake of GNPs in HeLa cells and found that particles with diameters 
between 20-60 nm have the highest cellular uptake. Also, scientists found that some 
peptides known as CPPs can be even specifically uptaken by certain cellular organelles. 
In addition, CPPs can be conjugated to an anti-cancer drug and used as a drug carrier. 
Functionalization of GNPs with CPPs has been developed with the aim of improving 
the efficiency of live cell uptake.  
In 2005, Fuente and Berry
33
 attached the cell pepetrating peptide Tat to GNPs in order 
to develop a system that was able to target the cell nucleus. The GNPs were firstly 
synthesised by reduction of AuCl4
-
 solution in the presence of tiopronin which has a 
thiol end group. Secondly, Au@tiopronin acid groups and Tat peptide 
(GRKKRRQRRR) amine groups were conjugated via EDC/NHS coupling to give 
Au@Tat nanoparticles (Figuer 3.5). This strategy has also been used to develop 
water-soluble and biocompatible fluorescent quantum dots which can translocate to the 
nucleus.
34
 Human fibroblast cells (HTERT-BJ1) were used to test the biocompatibility 
of Au@tiopronin and Au@Tat and cell uptake was investigated by TEM. These results 
indicate that this Tat peptide can transfer the nanoparticles into the cell nucleus. Without 
peptide functionalization, Au@tiopronin nanoparticles could not penetrate the cell 
membrane and target the cell nucleus, proving the cell-penetrating ability of Tat peptide. 
This work has many potential applications in cancer therapy, however, the ratio of 
Tat/tiopronin on the surface is about 1:50 which is low and makes it hard to quantify 
Tat loading.  
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Figure 3.5: Preparation of Au@Tat nanoparticles. Reproduced from 
33
 with permission 
from American Chemical Society, copyright © 2005. 
Later in 2008, Shukla et al.
35
 reported the development of a GNP system for targeting 
tumour vasculature. Arg-Gly-Asp (RGD) peptide-functionalized dendrimer-entrapped 
GNPs which can be taken up by αVβ3 integrin-expressing cell lines were prepared. The 
αVβ3 integrin is an important marker of the neovasculature and is normally found during 
tumour angiogenesis; without it tumours cannot grow beyond 1-2 mm in size.
36
 Au 
DENPs with a  mean diameter of 3.0 nm were synthesised.
37
 Human dermal 
microvessel endothelial cells (HDMEC) and human vascular endothelial cells (HUVEC) 
were used to examine the binding ability of Au DENPs and confocal microscope results 
confirmed the internalization of gold in the integrin-expressing cells. Given that the 
RGD peptide has a high affinity to αVβ3 integrin, RGD-functionalized GNPs can be 
used as a drug carrier system to deliver anti-cancer drugs or pro-apoptotic peptides.
38
 
However, the interaction between linear RGD peptides and αVβ3 integrin is often weak 
and the utility of individual ligands is limited for efficient tumour targeting. Arosio et 
al.
39
 improved this approach by using cyclic peptide cRGD to functionalise GNPs. A 
short poly (ethylene glycol) (PEG) linker was used as a spacer to combine the cRGD 
and the GNPs, and to enhance the stability of the nanoparticle system. Experimental 
results with PC-3 prostate cancer cells showed that cRGD-conjugated GNPs had an 
enhanced affinity for αVβ3 integrin compared with the unconjugated system.  
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Ghosh et al.
40
 synthesised GNPs coated with a short peptide that can promote 
intracellular delivery of the protein β-galactosidase (β-gal). The β-gal protein is known 
as a membrane impermeable protein with a high molecular weight (465 kDa). This 
system studied the effect of peptide structure on protein delivery. Here, the design of the 
peptide functionalized GNPs contained two parts: the alkyl chains and tetraethyl glycol 
(TEG) which can stabilize the particle and prevent interaction, the exterior peptide 
sequence His-Lys-Arg-Lys which can facilitate cargo translocation into membrane as 
shown in Figure 3.6. Fluorescein isothiocyanate-labelled β-galactosidase (FITC-β-gal) 
was used to monitor the cellular delivery of the β-gal protein. The HeLa cells were 
incubated with GNP-Pep/FITC-β-gal (2:1) complexes for 3 h and green fluorescence 
was found while when the cells were incubated with FITC-β-gal alone, no green 
fluorescence was found. Then confocal laser scanning microscope (CLSM) experiments 
confirmed that the green fluorescence was from inside the cells rather than on the 
surface of cells. This is a new and efficient strategy for delivering anionic proteins.  
 
Figure 3.6: (a) Schematic representation of intracellular delivery of functional protein 
using gold nanoparticles; (b) Structure of the nanoparticle, the protein cargo and the 
ligand on the particle. Reprinted from 
40
 with permission from American Chemical 
Society, copyright © 2010.  
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3.1.3.3 Anti-cancer applications 
A large number of antimicrobial peptides, peptide antibiotics and peptide hormones 
have been isolated from nature. In vitro experiments showed that some peptides have 
the ability to kill cancer cells and inhibit tumour growth. These anti-cancer peptides can 
be used as new cancer killing drugs and potential delivery systems have been studied. 
Functionalization of GNPs with a targeting peptide has been used to deliver the 
anti-cancer peptide into the specific tumour area. 
In 2010, Chanda et al.
41
 conjugated analogues of the peptide bombesin (BBN) to GNPs. 
Bombesin is a gastrin-releasing peptide (GRP) and it can specifically target cancer cell 
receptor sites. It is known that BBN peptides have a high affinity to GRP receptors 
which are overexpressed in breast, prostate and lung carcinoma. Human prostate tumour 
PC-3 cells were used to evaluate the GRP receptor binding affinity of 
BBN-functionalized GNPs. The experimental data of IC50 values showed that the higher 
the degree of BBN peptide on the GNP surface, the higher was the cell binding affinity.  
A multi-functionalized GNPs system that contains both a targeting peptide and a 
therapeutic peptide has also been developed.
42
 The RAF peptide can inhibit the protein 
and signalling kinase Rb-Raf-1 in vivo and thus it prevents cell proliferation. GNPs of 
20 nm diameter were synthesised by the sodium citrate reduction method,
14
 and these 
were then conjugated with targeting peptide (BBN) and the anti-cancer peptide RAF. 
The multi-functionalized GNPs were found to penetrate into HeLa cells which 
overexpress GPRr, while they were not taken up by SHSH-5Y cells which do not 
overexpress the same receptor (Figure 3.7). The mechanism of the selectivity and 
internalization into HeLa cells is still under investigated.  
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Figure 3.7: Multifunctionalization of GNPs with a targeting peptide (BBN) and an 
antitumoral Peptide (RAF). Reproduced from 
42
 with permission from American 
Chemical Society, copyright © 2010. 
In 2012, Kumar et al.
43
 developed novel small GNPs (2 nm) functionalized with both a 
therapeutic peptide (p12) and a targeting peptide (CRGDK). The targeting peptide is 
known to bind selectively to Nrp-1 receptors which are overexpressed in many tumour 
cells. Through receptor-mediated internalization, targeting peptide-functionalized GNPs 
can translocate into the cell and the nucleus. At the same time, the therapeutic peptide 
p12 binds to MDM2 and MDMX proteins leading to the expression of tumour 
suppressive protein p53, which limits the expression of tumour gene thus causing cell 
apoptosis.
44
 The same GNP synthesis method as is shown in Figure 3.8 was used, 
giving small Au@tiopronin to which were added peptide p12, CRGDK and both 
peptides together. The targeting peptide was shown to advance the cellular uptake of the 
GNPs with the therapeutic peptide preload, and the system could be applied in drug 
delivery for cancer therapy.  
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Figure 3.8: Interaction between receptor and targeting ligand enhances intracellular entry 
and increases response to intracellular release of the therapeutic peptide. Reproduced 
from
43
 with permission from Elsevier, copyright © 2011.  
3.1.4 Aim of this chapter  
The aim of the work described in this chapter is to synthesise peptide functionalised 
GNPs which have potential applications in drug delivery and cancer therapy. 
Elastin-like polypeptides (ELPs) undergo a transition from a hydrophilic random coil to 
a hydrophobic β-spiral when the temperature is increased.45 This LCST behaviour is not 
only displayed by poly(VPGXG), but also was found in a single ELP pentapeptide 
unit.
46, 47
 This behaviour suggests that ELPs are suited for single-molecule and 
nanoscale applications. 
The short pentapaptide VPGVG and elastin-based side chain polymers are both good 
candidates and have been used to functionalize gold surfaces which endow GNPs with 
stimuli sensitivities. The transition temperatures of the ELPs in aqueous buffer solution 
were examined using ultraviolet-visible (UV-Vis) spectroscopy. In addition, the 
secondary structures of the ELPs-GNPs were studied by circular dichroism (CD). In the 
second system, we aimed to functionalize GNPs with elastin-based side chain polymer 
(ESPs) through a “graft-to” strategy. Poly(PFPA) polymers were synthesised and 
modified by attachment of short elastin-like peptides. The ESPs were attached to the 
surface of GNPs through formation of gold-thiol bonds. The conformation and 
100 
 
aggregation properties of the ELP-functionalized GNPs in aqueous solution were tested 
by transmission electron microscopy (TEM), UV-Vis spectroscopy and circular 
dichroism (CD). In the third system, we aimed to use apoptotic peptide KLA to 
functionalize GNPs and study their cell toxicity and cellular uptake abilities. In the final 
system, the aim was to functionalize GNPs with ESPs and KLA in a 1:1 ratio. 
UV/visible spectroscopy, transmission electron microscopy (TEM) and dynamic light 
scattering (DLS) were used to observe the morphologies and size distributions of the 
aforementioned peptide functionalised GNPs. 
3.2 Synthesis of GNPs 
GNPs were synthesised using the Turkevich and Frens method.
8,9
 Sodium citrate was 
used to reduce Au
3+
 to Au. For GNPs A to E, the same gold chloride solution was used 
but different amounts of sodium citrate solution were added to obtain different particle 
diameters. Changing the relative amounts of reactants changes the relative rates of the 
processes of nucleation and growth of the metal particles and the more Na3-citrate used, 
the smaller the nanoparticles obtained. A standard procedure for obtaining gold colloids 
was used and the colour change of each solution was observed. At first, the colour of 
the gold chloride solution was light yellow. Then the solution started to turn dark blue 
when sodium citrate solution was added. After approximately 1 minute the dark blue 
colour suddenly changed into light red-purple which indicates the formation of gold 
nanoparticles (Table 3.1).  
Table 3.1: Synthesis of GNPs.  
Entry GNPs Solution II 
(1 wt% Na-citrate) (mL) 
Abs Peak 
wavelength 
(nm)  
Diameter based on 
TEM (nm) 
1 A 2.5  520  15 
2 B 2.0  524  19 
3 C 1.5  526  22 
4 D 1.0  532  28 
5 E 0.8  538  32 
* Solution I concentration: 0.01 wt% HauCl4, 50 mL 
As shown in Figure 3.9 a), the diluted solution of A to E showed a gradual colour 
change from bright red to red-purple to purple. A UV/Vis spectrophotometer was also 
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employed to study the optical properties of the gold nanoparticles. The bright colour of 
GNPs is attributed to the surface plasmon absorption band, which is very sensitive to 
the size and shape of the particles. Therefore, GNPs A to GNPs E have different surface 
geometries which lead to different electrical densities on the particle surfaces and cause 
them to oscillate with different frequencies. This is due to the fact that an intrinsic 
function of metal nanoparticles’ morphological features determines their optical 
properties. Based on this, the absorption spectrum of GNPs can be varied from 520 nm 
to 1000 nm by changing the geometry of the particle. Also, the size analysis of the 
GNPs could be performed by visually analysing the colour of the nanoparticle solution. 
The colour transition from brilliant red to deep purple indicates the formation of larger 
particles due to surface plasmon resonance (SPR) properties of GNPs. The UV-Vis 
spectrum of the colloidal solutions A to E exhibited a red shift of surface plasmon 
absorption peak from 520 nm to 538 nm, as shown in Figure 3.9 b). The colour data 
and UV-Vis data both show that the less Na3-citrate is used, the larger the nanoparticles. 
 
Figure 3.9: (a) The colour of solutions of GNPs A to E; (b) UV-Vis spectrum of GNPs A 
to E. 
The sizes of the gold colloids and their morphologies were determined by transmission 
electron microscopy (TEM), which is the primary technique for determining the particle 
size, shape and the size distribution. A drop of the GNPs solution was cast on the TEM 
grid and blotted with tissue in air before performing the TEM measurement. In the next 
experiment of peptide/polymer-coated gold nanoparticles, we chose the smallest size 
GNPs A. TEM images of sample A obtained are shown below. In Figure 3.10, the 
diameter of GNPs in sample A was 14.6 ± 2.6 nm. Dynamic light scattering (DLS) was 
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used to observe the size distribution of GNPs A. The mean diameter is 20.7 nm and the 
polydispersity is 0.314 (Figure 3.11).  
 
 
Figure 3.10: TEM images of GNPs A: average size is 14.6 ± 2.6 nm. 
 
Figure 3.11: DLS traces of GNPs A. The average mean diameter is 20.7 nm and the 
polydispersity is 0.314. 
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3.3 Preparation and Characterization of Short ELP-GNPs  
3.3.1 Synthesis of ELP-GNPs 
The preparation of short elastin-like peptide-gold nanoparticle (ELP-GNPs) conjugates 
employed the covalent bonding interactions between the peptide thiol and the GNPs. 
First, the GNP solution was stirred in a small round-bottom flask under nitrogen. After 
one hour, the thiol-peptide (11) solution was added into the GNP solution to give a 
homogeneous mixture (Figure 3.12). The reaction was performed under a nitrogen 
atmosphere to prevent the formation of disulfide bonds.  
Figure 3.12: The preparation of short elastin-like peptide functionalized gold 
nanoparticles. 
After the reaction, the solution was transferred to a dialysis bag and dialysed against 
deionised water for 24 hours to remove salts. If this step is omitted, the freeze-dried 
solution product is a greyish/white powder, which means that the extra salts have not 
been removed. However, the GNP-peptide obtained after dialysis and freeze drying 
gave a dark purple solid. This dark purple colour confirms that there are no extra salts 
present. This solid can be dissolved in water immediately and forms a homogeneous 
purple solution without precipitation.  
3.3.2 Properties of ELP-GNPs  
As the ELP-GNPs (30) have an amide group at their C-termini, the LCST behaviours 
were monitored at pH 7.4. Van Hest et al.
47
 reported short elastin-based 
stimuli-responsive gold nanoparticles, which have a different end. In their work, Wang 
resin was used to synthesise the peptide giving a free carboxylic acid at the C-terminus. 
Only at low pH (pH< 3.6), the free carboxylic acid was protonated and the peptide 
showed hydrophobic character. The elastin-based gold nanoparticles showed no 
thermo-sensitive behaviour when the pH was above 3.6 which is the limitation of its 
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application. In our system, the ELP-GNPs respond to the temperature change rather 
than the pH change of the solution.  
The phase transition behaviour of the ELP-GNPs (30) was studied by UV-Visible 
spectroscopy at a range of temperatures from 10
o
C to 70
 o
C as shown in Figure 3.13 a). 
At 10
o
C, the spectrum of ELP-GNPs exhibited an absorption peak at 527 nm and this 
did not change significantly when the temperature was increased from 10
o
C to 40
o
C. 
Upon raising the temperature above 40
o
C, the maximum absorption peak showed a red 
shift from 528 nm to 532 nm at 70
o
C. This indicated the aggregation of the GNPs and 
this was supported by an accompanying colour change from red to purple as shown in 
Figure 3.13 b). As a control, solutions of peptide-free GNPs were measured as well 
when the temperature was increased, and no changes were observed in the UV-Vis 
spectra. This suggested that the spectral changes of ELP-GNPs are because of the 
thermo-responsive property of the short elastin-like peptide layer on the surface of 
GNPs. Raising the temperature of the ELP-GNPs solution, the VPGVG layer underwent 
an intramolecular hydrophilic-hydrophobic transition which increased the aggregation 
of the gold colloids. The scheme of ELP-GNPs’ reversible aggregation caused by the 
thermo-triggered phase transition of the VPGVG peptide is shown in Figure 3.14 a).  
Dynamic light scattering (DLS) also offers a good means to monitor the particle 
aggregation through the increase of scattered light. Figure 3.14 b) shows the size 
distribution corresponding to the signal intensity at different temperatures. At 10
o
C, the 
main signal of ELP-GNPs gave a diameter of ca.20 nm. When the temperature was 
increased to 60
o
C, the main signal peak shifted to a diameter around 100 nm, which 
indicated aggregation and precipitation events.  
 
 
105 
 
Figure 3.13: (a) Temperature-dependent absorption spectra changes for ELP-GNPs (30) 
(0.5 mg mL
-1
) in PBS buffer at pH 7.4 from 10
o
C to 70
o
C; (b) the colour changes of 
ELP-GNPs (30) caused by the thermally-triggered phase transition of elastin-like peptide: 
at 10
o
C the colour is red which shows dispersed gold colloids, at 70
o
C the aggregation 
gives a purple colour. 
 
Figure 3.14: (a) Schematic diagram of ELP-GNPs (30) aggregation when temperature 
changes; (b) DLS results of ELP-GNPs (30) solutions (0.5 mg mL
-1
, pH 7.4) showing the 
changes in hydrodynamic diameters of the particles/aggregates at 10
o
C and 60
o
C.  
Aggregation was also observed using TEM as shown in Figure 3.15. The samples were 
prepared at 20
o
C and 60
o
C separately and then TEM images were recorded. The TEM 
images of GNPs below and above the phase transition temperature gave more direct 
evidence of ELP-GNPs (30) aggregation.  
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Figure 3.15: Transmission electron microscopy images of the ELP-GNPs at (a) 20
o
C and 
(b) 60
o
C.  
The temperature dependencies of the secondary structure of the peptides in ELP-GNPs 
conjugates in dilute solution (0.2 mg mL
-1
) were evaluated using CD spectroscopy. The 
spectra obtained in a PBS buffer (pH 7.4) from 10
o
C to 70
o
C and are shown in Figure 
3.16. ELP-GNPs (30) have the same changing trend as peptide 11 shown in Figure 2.41 
(Chapter 2). This indicates that the conformation changes when the temperature 
increases were led by the property of the peptide conjugated to the GNPs.  
At the lowest temperature (10 
o
C), the mean residual ellipticity (MRE) was about -7500 
deg cm
2
dmol
-1
 at 195 nm which represents a random coil. The CD peaks at 195 to 200 
nm decreased with increasing temperature, with a smaller decrease in amplitude at 206 
to 212 nm. With increasing temperature, the molar ellipticity [θ] value at 195 to 200 nm 
and 206 to 212 nm decreased which supports increasing β-turn content. When the 
temperature is increased, there also exists a smaller increase in CD amplitudes at 222 
nm. This peak is associated with a type I/III β-turn. The data studied here exhibited an 
increase in MRE at 198 nm and 206 nm with increasing temperature, supporting the 
folding of the peptide and leading to a β-turn formation. The conformational transition 
from random coil to β-turn occurred gradually over a wide temperature range from 10oC 
to 70
o
C.  
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The [θ] value which changes at 198 nm was plotted with temperature in Figure 3.17. 
From 10
o
C to 20
o
C, no obvious change is observed. From 20
o
C to 60
o
C, the value 
increased gradually and uniformly. Then the value decreased a little when the 
temperature increased to 70
o
C. From these data we can conclude that the transition 
temperature is around 40
o
C.   
In order to test the reversibility of the ELP-GNPs (30), a cyclic thermal response 
experiment was performed by changing temperature between 50
o
C and 10
o
C. Figure 
3.18 a) and b) shows the cyclic thermal response of ELP-GNPs (30) solutions. CD 
spectra were acquired at 10
o
C and 50
o
C for 5 cycles. After each temperature change, the 
sample was allowed to equilibrate for 5 min. These data show that the structural 
changes of the ELP-GNPs (30) are reversible and can be induced several times without 
apparent degradation. They also show that the temperature-induced formation of the 
β-turn is due to intramolecular interactions rather than intermolecular associations.  
 
Figure 3.16: Temperature dependence circular dichroism (CD) spectra of ELP-GNPs (30) 
(0.2 mg mL
-1
) in PBS buffer at pH 7.4 between 10
o
C and 70
o
C.  
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Figure 3.17: Temperature profile of [θ]198 values for ELP-GNPs (30) (0.2 mg mL
-1
) in 
PBS buffer at pH 7.4 between 10
o
C and 70
o
C. 
 
 
Figure 3.18: (a) The CD signal and (b) the CD spectra at 198 nm of ELP-GNPs (30) (0.2 
mg mL
-1
) in PBS buffer at pH 7.4 when alternating the temperature 5 times between 10
o
C 
and 50
o
C. 
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3.4 Preparation and Characterization of Elastin based side chain 
polymer-GNPs (ESP-GNPs) 
3.4.1 Synthesis of ESP-GNPs 
The preparation of elastin-like peptide functionalized polymer-coated GNPs 
demonstrated the reaction between macromolecular thiols and gold nanoparticles. Two 
elastin based polymers PF75-GABA(VPGVG) (26) and PF100-GABA(VPGVG) (29) 
were used to functionalise GNPs to obtain ESP75-GNPs (31) and ESP100-GNPs (32). 
Here, we describe the preparation of 32 as an example.  
PF100-GABA(VPGVG) (29) was dissolved in 1mL deionized water and then added 
into 10 mL of the citrate-stablized GNPs solution and left for overnight reaction under a 
nitrogen atmosphere. The reaction scheme is shown in Figure 3.19. Then the 
ESP100-conjugated GNPs were dialyzed (MWCO=50,000 Da) against distilled water for 
3 days to remove any unreacted polymers. The ESP100-GNPs (32) were then 
freeze-dried to obtain a purple fluffy powder. The freeze-dried GNPs/polymer hybrid 
nanoparticles were easily re-dispersed in water. 
 
Figure 3.19: The scheme of polymer functionalized GNPs (ESP-GNPs) preparation. 
TEM images of ESP100-GNPs (32) obtained are shown below. In Figure 3.20, the 
diameter of 32 is 32.74 ± 6.7 nm on average. Dynamic light scattering (DLS) was used 
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to observe the size distribution of 32, which is shown in Figure 3.21. The average mean 
diameter is 36.8 nm and the polydispersity is 0.367.  
 
Figure 3.20: TEM image and UV-Vis data of ESP100-GNPs (32).  
 
Figure 3.21: DLS traces of ESP100-GNPs (32). 
3.4.2 Properties of ESP-GNPs 
We studied the thermo-responsiveness of ESP-GNPs (31, 32) by turbidity 
measurements. The concentration of ESP75-GNPs (31) solution was 0.5 mg mL
-1
 in PBS 
buffer (pH 7.4). UV-Visible spectroscopy gives good evidence of aggregation 
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phenomena. As shown in Figure 3.22, when the temperature increased the GNPs 
aqueous solution changed colour from red to purple accompanied by a red shift from 
532 nm to 535 nm. This observation suggests that the nanoparticles aggregated and the 
transition temperature was around 65
o
C. As discussed in Section 2.4.2.1, the transition 
temperature of polymer 26 was 68
o
C as shown in Table 2.6. Here, the ESP75-GNPs (31) 
showed a thermo-responsiveness very slowly from 15
o
C to 70
o
C which means that 
polymer 26 endowed GNPs with the same character by anchoring to the GNPs surface.  
 
Figure 3.22: UV-Vis spectra of ESP75-GNPs (31) versus temperature. Each spectrum 
was taken after an increase of 5
o
C (from 15
o
C to 70
o
C). Picture of ESP75-GNPs (31) 
dispersed in PBS buffer at 25
o
C and 65
o
C, respectively.  
The same LCST experiment was performed with ESP100-GNPs (32) to test the 
sensitivity of the functionalized GNPs. Elastin-based side chain polymers in aqueous 
solution were mixed with the GNPs, and the strong affinity of the thiol functionality for 
the gold surface resulted in the assembly of polymers onto the gold surface. After 
polymer attachment, the solution had a slight colour change and the plasmon resonance 
absorption peak underwent a shift from 532 nm to 540 nm as shown in Figure 3.23. As 
ESP100-GNPs (32) have a longer chain and a lower transition temperature than 
ESP75-GNPs (31), when attached to GNPs they gave the gold solution a lower transition 
temperature. The colour of the solution changed from red to purple when the 
temperature increased from 20
o
C to 45
o
C, confirming the assembly process.  
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Figure 3.23: The LCST behaviour of ESP100-GNPs (32) (0.5 mg mL
-1
) in PBS buffer at 
pH 7.4 between 20
o
C and 45
o
C. 
The temperature dependencies of the secondary structure of the polymer ESP100-GNPs 
(32) conjugates in dilute solution (0.2 mg mL
-1
) were evaluated using CD spectroscopy. 
The spectra obtained in a PBS buffer (pH 7.4) from 10
o
C to 65
o
C are shown in Figure 
3.24. The ESP100-GNPs have the same trend as polymer 29 which indicates that the 
polymer covered the gold nanoparticles, leading to a conformation change when the 
temperature increased.  
At the lowest temperature (10
o
C), the MRE was about -12,000 deg cm
2 
dmol
-1
 at 195 
nm which represents a random coil. The CD amplitudes at 195 to 200 nm decreased 
with increasing temperature, with a smaller decrease in amplitude at 206 to 212 nm. 
With increasing temperature, the molar ellipticity [θ] value at 195 to 200 nm and 206 to 
212 nm increased, which supports increasing β-turn content. With increasing 
temperature, there exists a smaller increase in CD amplitudes at 222 nm. This peak is 
associated with a type I/III β-turn. The data studied here exhibited an increase in MRE 
at 198 nm and 206 nm with increasing temperature, supporting the folding of the 
peptide and leading to a β-turn formation. The conformational transition from random 
coil to β-turn occurred gradually over a wide temperature range from 10oC to 65oC.  
The change in [θ] value at 198 nm was plotted against temperature in Figure 3.25. 
From 10
o
C to 60
o
C, the value increased gradually and uniformly. Then the value 
decreased a little when the temperature increased to 65
o
C. From these data we can 
conclude that the transition temperature is around 35
o
C.   
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In order to test the reversibility of ESP100-GNPs (32), a cyclic thermal response 
experiment was performed by changing the temperature between 50
o
C and 20
o
C. 
Figure 3.26 shows the cyclic thermal response of the ESP100-GNPs (32) solution. CD 
spectra were acquired at 20
 o
C and 50 
o
C for 3 cycles. After each temperature change, 
the sample was allowed to equilibrate for 5 min. These data show that the structural 
changes of the ESP100-GNPs are reversible and can be induced many times without 
apparent degradation. The CD data obtained also show that the temperature-induced 
formation of the β-turn structure is due to intramolecular and not intermolecular 
interactions.  
 
 
Figure 3.24: Temperature dependence CD spectra of ESP100-GNPs (32) (0.2 mg mL
-1
) in 
PBS buffer at pH 7.4 between 10
o
C and 65
o
C. 
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Figure 3.25: Temperature profile of [θ]198 values for ESP100-GNPs (32) (0.2 mg mL
-1
) in 
PBS buffer at pH 7.4 between 10
o
C and 65
o
C. 
 
 
Figure 3.26: The CD spectra (left) and the CD signal at 198 nm (right) of ESP100-GNPs 
(32) (0.2 mg mL
-1
) in PBS buffer at pH 7.4 when alternating the temperature 3 times 
between 20
o
C and 50
o
C. 
To obtain more direct proof of the aggregation of ESP100-GNPs (32), the aggregates 
were observed using TEM as shown in Figure 3.27. The samples were prepared at 20
o
C 
and 50
o
C separately and TEM images were taken. The TEM images taken below and 
above the phase transition temperature gave more direct evidence of ESP100-GNPs (32) 
aggregation. At low temperature, they are generally well dispersed, although a few 
aggregates may not be completely excluded. When temperature increased to 50
o
C, 
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aggregation was dominant and accompanied with the colour change of the sample 
solution.  
  
Figure 3.27: TEM data obtained of ESP100-GNPs (32) prepared at 20
o
C and 50
o
C 
separately.  
3.5 Preparation and Characterization of Synthesis KLA-GNPs 
3.5.1 Synthesis of thiol-TTDS-KLA peptide (38) 
Fmoc solid phase peptide synthesis was used to obtain the pro-apoptotic D-KLA peptide 
(33), which has a sequence of D-(KLAKLAK)2. In order to prevent its inactivation by 
enzymatic hydrolysis in vivo, all the amino acids in its sequence were D-amino acids.  
In order to conjugate D-KLA (33) with GNPs to form KLA-GNPs hybrid nanomaterials 
through the thiol-Au interaction, a linker and a thiol end are needed. The linker we 
finally chose was Fmoc-TTDS-OH (34) and 3-tritylsulfanyl-propionic acid. However 
prior to this we tried two other linkers for comparison. As shown in Figure 3.28, 
C(Ahx)KLA (36) was first synthesised with Fmoc-Ahx-OH (35) as a spacer coupled 
with cysteine as the terminal amino acid which gave a free thiol end. However, the gold 
solution aggregated immediately when a solution of C(Ahx)KLA (36) was added. This 
may because the linker is quite short, the D-KLA (33) is positively charged and the gold 
surface is negatively charged. We then lengthened spacer by using four Fmoc-Ahx-OH 
(35) and two glycine residues to obtain C(Ahx)4GGKLA (37). However, when this was 
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reacted with the gold solution, the aggregation still occurred. These results led us to 
finally choose a short PEG linker Fmoc-TTDS-OH (34). We also changed cysteine to 
3-tritylsulfanyl-propionic acid as it is the same thiol end for peptide SH-VPGVG (11). 
The short PEG linker provides a more hydrophilic environment which produces a stable 
spacer between GNPs and D-KLA peptide (33).  
 
Figure 3.28: The structure of synthesised thiol-KLAs with different linkers. 
The D-(KLAKLAK)2 (33) was synthesised manually as shown in Figure 3.29. Rink 
Amide resin was chosen to give an amide at the C-terminus meaning the overall charge 
of the peptide would not be affected by a pH change. Fmoc-D-Lys(Boc)-OH, 
Fmoc-D-Leu-OH and Fmoc-D-Ala-OH were used. The coupling of each amino acid was 
repeated twice to make sure there were fewer deletion fragments of the final targeted 
peptide. In addition, a test cleavage was carried out in the middle of the sequence to 
check the coupling efficiency and to prove the method could be used continually. At the 
end of the D-KLA peptide synthesis, the linker Fmoc-TTDS-OH (34) was chosen to 
conjugate to the peptide sequence. The coupling process is the same as coupling each 
amino acid. Finally, 3-tritylsulfanyl-propionic acid was added to the sequence to 
provide a free thiol end group. After completion of the synthesis, the resin was finally 
washed with DMF, DCM and diethyl ether three times separately. The cleavage of the 
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peptide on resin was performed by adding a cleavage cocktail, which contained TFA 
(95%), TIPS (2.5 %) and H2O (2.5 %), for 3 h. TIPS acts as a scavenger preventing any 
side reactions. The filtrate was concentrated to a viscous solution by rotary evaporation 
followed by precipitation in cold ether solvent. The ether was slowly decanted and the 
crude thiol-TTDS-KLA (38) was collected. Then the crude peptide was dissolved in 
distilled water and freeze-dried (Figure 3.29).  
 
Figure 3.29: Overview showing the synthesis of D-KLA (33) and thiol-TTDS-KLA (38). 
Semi-preparative HPLC was used to purify the crude peptide as described in Section 
6.1.2.5. A sample of crude peptide 38 (7~10 mg mL
-1
) was dissolved in water and 
analysed using a gradient of 0-20% solvent B in 10 min, 20%-55% solvent B in 40 min 
and 55%-100% solvent B in 10 min. The flow rate was set to 2.0 mL/min and the 
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detector monitored absorbance at 220 nm. The peptide was the main peak at RT= 29.5 
min, denoted by an asterisk. The chromatogram is illustrated in Figure 3.30. The yield 
of purified peptide 38 after RP-HPLC was 13%. 
After purification, a small sample of the peptide was dissolved in water and analyzed by 
analytical HPLC, MALDI, LC-MS and accurate mass. Analytical HPLC analysis is 
shown as Figure 3.31. The retention time of the peak is 14.7 min and a tiny impurity 
shoulder is apparent. The molecular weight of thiol-TTDS-KLA (C89H169O20N23S) 
peptide (38) was examined by MALDI and found to be 1935.2 which is [M+ Na]
+
 as 
shown in Figure 3.32. The LC-MS data was shown in Appendix 3.3: [M+5H]
5+
 383.0, 
[M+4H]
4+
 480.4, [M+3H]
3+
 639.3, [M+2H]
2+
 957.6. In Appendix 3.4, HRMS m/z (ESI) 
957.6361, consistent with empirical formula C89H169O20N23S with an accuracy of 5 ppm 
(accepted as (M + 2H)
2+
).  
 
Figure 3.30: Semi-preparative HPLC chromatogram of crude peptide 38. The peak with 
an asterisk on it represents the target peptide peak. 
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Figure 3.31: Analytical HPLC trace of purified thiol-TTDS-KLA (38). Retention time = 
14.7 min. 
 
Figure 3.32: MALDI spectrum of thiol-TTDS-KLA (38) after RP-HPLC purification, 
indicationg the peaks found to confirm the presence of thiol-TTDS-KLA peptide: m/z 
1935.2 [M+Na]
+
. 
3.5.2 Synthesis of KLA-GNPs (39) 
The GNPs were synthesised via the same method as described in Section 6.4. However, 
the concentration of the mother solution of Au
3+
 was tripled to prepare more 
concentrated GNPs (1mM). Due to the same ratio of trisodium citrate to gold was used, 
the size of GNPs (1mM) is the same as GNPs A (0.3mM). 
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The preparation of thiol-TTDS-KLA peptide (38) functionalized gold nanoparticles 
(KLA-GNPs) was achieved through thiol-gold covalent bonding. The weight/weight 
ratio of peptide to gold was 2:1 to ensure an excess of peptide. A colour change from 
red to purple was observed when a solution of 38 was slowly added into GNPs. The 
mixture was stirred overnight at room temperature under a nitrogen atmosphere to 
prevent disulphide bond formation. Then the purple solution obtained was transferred to 
a dialysis bag (MWCO: 3500 Da) and dialysed against deionised water for 2 days. The 
KLA-GNPs (39) collected were then freeze-dried to obtain a dark purple solid. The 
structure of the KLA-GNPs (39) is shown in Figure 3.33.  
TEM images of KLA-GNPs obtained are shown in Figure 3.34. The mean diameter of 
KLA-GNPs from TEM was found to be 17.7 ± 4.6 nm. Dynamic light scattering (DLS) 
was also used to observe the size distribution of KLA-GNPs (Figure 3.35). The average 
mean diameter is 26.5 nm and the polydispersity is 0.097. The CD spectrum of 
KLA-GNPs (0.2 mg mL
-1
) obtained in a PBS buffer (pH 7.4) is shown in Figure 3.36. 
The positive bands aroud 208 nm and 225 nm were indicative of α-helical conformation 
of KLA-GNPs (39).  
 
Figure 3.33: Overview of the synthesis of KLA-GNPs (39). 
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Figure 3.34: TEM image and UV-Vis analysis of KLA-GNPs (39).  
 
 
Figure 3.35: DLS traces for KLA-GNPs (39). 
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Figure 3.36: The CD spectrum of KLA-GNPs (39) (0.2 mg mL
-1
) in PBS buffer at pH 
7.4.  
3.5.3 Cytotoxicity of KLA-GNPs (39) 
(The MTT data were obtained by Lijun Jiang at Hong Kong Baptist University) 
The cytotoxicity of D-KLA peptide (33) and KLA-GNPs (39) were evaluated using 
HeLa cells. As Figure 3.37 shows, a D-KLA (33) exhibits lower anti-cancer activity 
than 39. For 33, the HeLa cell viability is still 56 ± 3% even at a concentration of 500 
µM.  
As we can see from Figure 3.38, KLA-GNPs (39) showed better anti-cancer activity 
than D-KLA (33). At the highest concentration of 39 tested (100 µM), HeLa cell 
survival is only around 30 ± 3.3%. When the concentration of 39 was diluted to 50 µM, 
the cell viability was 73.4 ± 4.9%, which means the half maximal inhibitory 
concentration (IC50) of KLA-GNPs (39) is between 50 µM and 100 µM.   
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Figure 3.37: MTT assay determined cell viability of HeLa cell line after incubation 
with D-KLA (33) for 24 h at 37
o
C. The data represent the mean ± standard deviation of 
three independent experiments. 
 
Figure 3.38: HeLa cell viability after incubation with KLA-GNPs (39) for 24 h at 37
o
C. 
The data represent the mean ± standard deviation of three independent experiments. 
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From the cytotoxicity experiment, it has been found that KLA-GNPs 39 have a lower 
IC50 value than free D-KLA peptide (33), which suggests that 39 may have been 
internalized into cells. Confocal microscopy was used to confirm the cellular 
internalization of 39. KLA-GNPs (39) incubated with HeLa cells for 24 h were 
examined by laser confocal microscopy. As shown in Figure 3.39, the localization of 
39 is exactly the same as the mitochondrial tracker dye. The merged picture of Figure 
3.39 a) and b) strongly confirms that GNPs can deliver the KLA peptide (33) into the 
mitochondria of cells, leading to an improvement of anti-cancer activity.  
 
Figure 3.39: Confocal microscope images of KLA-GNPs (39) in HeLa cells. (Conc.: 
10µM, Incubation time: 24 h). For costaining of the mitochondria the cells were treated 
with Mitochondria Green
TM
 (a). The images (c) show the merges of the respective 
emission channels of each line: 499–552 nm for the detection of the mitochondria 
(green, a), and 593–696 nm for the detection of the KLA-GNPs (red, b). Bar 15µm. 
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3.6 Preparation and Characterization of KLA-ESP100-GNPs  
3.6.1 Synthesis of KLA-ESP100-GNPs (40) 
The preparations of both thiol-TTDS-KLA (38) and PF100-GABA(VPGVG) (29) 
functionalized GNPs KLA-ESP100-GNPs (40) were achieved using thiol-gold covalent 
bonding as well. The weight/weight ratio of peptide 38, polymer 29 and GNPs was 
1:1:1 to produce equal functionalization of the gold nanoparticles. In the process, 
thiol-KLA peptide (38) and polymer (29) were separately dissolved in deionized water. 
Through the use of two syringes, both peptides were simultaneously slowly added 
dropwise into filtered GNPs (1 mM). The mixture was stirred overnight at room 
temperature under a nitrogen atmosphere. The purple solution was then transferred to a 
dialysis bag (MWCO: 50,000 Da) and dialysed against deionised water for 24 h, after 
which the KLA-ESP100-GNPs (40) were freeze-dried to obtain a dark purple solid. The 
scheme of the synthesis is shown in Figure 3.40.  
 
Figure 3.40: Synthesis of KLA-ESP100-GNPs (40). 
The TEM images of the KLA-ESP100-GNPs (40) obtained are shown in Figure 3.41. 
The diameter of KLA-ESP100-GNPs (40) by TEM was 22.8 ± 3.5 nm on average. The 
plasmon resonance band of the KLA-ESP100-GNPs (40) solution was centred at 530 nm. 
Dynamic light scattering (DLS) was used to observe the size distribution of 
KLA-ESP100-GNPs (40), which is shown in Figure 3.42. The average mean diameter 
was found to be 30.3 nm, and the polydispersity is 0.213.  
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Figure 3.41: TEM image and UV-Vis data of KLA-ESP100-GNPs (40).  
 
Figure 3.42: The DLS trace of KLA-ESP100-GNPs (40). 
3.6.2 Properties of KLA-ESP100-GNPs (40) 
The phase transition behaviour of KLA-ESP100-GNPs (40) was studied by UV-Visible 
spectroscopy as the solution temperature was increased from 20
o
C to 80
o
C, as shown in 
Figure 3.43. At 20
o
C, the spectrum of KLA-ESP100-GNPs (40) exhibited an absorption 
peak at 530 nm and did not change significantly from 10
o
C to 35
o
C. Upon raising the 
temperature to 40
o
C, the maximum absorption peak showed a red shift from 530 nm to 
532 nm at 80
o
C. This indicated the aggregation of nanoparticles and was accompanied 
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by a colour change from purple to darker purple. This suggested that the changes of 
KLA-ESP100-GNPs (40) were because of the thermo-responsive property of the 
elastin-based polymer (29) layer on the GNPs’ surface. However, the changes observed 
are less than for ESP-GNPs (32). When the temperature of the KLA-GNP-ESP100-GNP 
(40) solution was raised from 20
o
C to 80
o
C, only the ESP layer underwent an 
intramolecular hydrophilic-hydrophobic transition, not thiol-TTDS-KLA (38) layer. 
Due to 38 having no thermo-responsive property, the UV-Vis changes are not that 
significant. 
 
Figure 3.43: The LCST behaviour of KLA-ESP100-GNPs (40) (0.2 mg mL
-1
) in PBS 
buffer at pH 7.4 between 20
o
C and 80
o
C. 
The temperature dependencies of the secondary structure of the KLA-ESP100-GNP (40) 
conjugates in dilute solution (0.2 mg mL
-1
) was evaluated using CD spectroscopy. The 
spectra obtained in PBS buffer (pH 7.4) from 20
o
C to 90
o
C are shown in Figure 3.44. 
The CD amplitudes at 200 to 210 nm had a positive band and the MRE at 222 nm was 
negative which implies a typical β-turn structure. The MRE between 190 nm and 200 
nm were indistinguishable from background signals and so cannot be used to determine 
secondary structures. This may due to the strong β-turn structure of the 
KLA-ESP100-GNPs (40) leading to a higher concentration of particles. The CD 
amplitudes at 200 to 210 nm increased with increasing temperature, with a similar scale 
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decrease in amplitude at 220 to 230 nm. With increasing temperature, the molar 
ellipticity [θ] value at 206 nm and 222 nm increased in value which supports increasing 
β-turn content. These peaks are known to be associated with type I/III β-turn. The 
conformational transition from random coil to β-turn occurred gradually over a wide 
temperature range from 20
o
C to 90
o
C. KLA-ESP100-GNPs (40) still have the same trend 
as P(PFPA)100-GABA(VPGVG) (29) and ESP100-GNPs (32) which indicates that ESP 
layers were covered on the GNP surfaces which led to a conformation change when the 
temperature increases.  
 
Figure 3.44: Temperature dependence circular dichroism (CD) spectra of 
KLA-ESP100-GNPs (40) (0.2 mg mL
-1
) in PBS buffer at pH 7.4 between 20
o
C and 90
o
C. 
3.6.3 Evaluation of the anti-cancer properties of KLA-ESP100-GNPs (40) 
(The MTT data was collected by Lijun Jiang at Hong Kong Baptist University) 
The anti-cancer and cytotoxic effects of KLA-ESP100-GNPs (40) were evaluated against 
the HeLa cancer cell line and normal MRC-5 lung cell lines. HeLa and MRC-5 cells 
were treated with 40 for 1 h at 37
o
C or 42
o
C, then cell viability was determined by a 
MTT reduction assay.  
Figure 3.45 shows the cytotoxic effect of KLA-ESP100-GNPs (40) against HeLa cells. 
The concentration of 40 was started at 300 µg mL
-1
 and diluted to 1 µg mL
-1
. At the 
highest concentration tested (300 µg mL
-1
), 40 was toxic to approximately 80% of HeLa 
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cells at 37C or 42C. Within the concentration range of 300 to 100 µg mL-1, the cell 
viability was very similar between 42C and 37C. These results indicate that the heat- 
triggered phase transition behavior of 40 had little impact on enhancing the cytotoxic 
effect. From concentrations 50 to 1 µg mL
-1
, the cell viability at 42C was a little lower 
than the viability at 37C. These results may demonstrate the impact of heat-triggered 
phase transition on cytotoxicity. However, the difference of the two was not significant. 
The explanation of these results maybe that the temperature response of 40 is not sharp 
enough when the temperature is raised to 42C for 1 h.  
In Figure 3.46, the cytotoxic effect of KLA-ESP100-GNPs (40) was evaluated in the 
normal lung cell line MRC-5. The data were very similar to those obtained from HeLa 
cells. At the highest concentration of 300 µg mL
-1
, 40 killed approximately 80% of 
MRC-5 cells at 37C or 42C. This indicated that multi-functionalized GNPs show no 
selectivity between normal cells and cancer cells.  
Confocal microscopy images of KLA-ESP100-GNPs (40) incubated for 1 h at 42C are 
shown in Figure 3.47, the GNPs have the ability to penetrate into cells this should have 
been seen in the images. However, there were very few red spots inside the cells. This 
may due to the size of KLA-ESP100-GNPs (40) which is bigger than KLA-GNPs (39). 
From the TEM data, the size of 39 was 17.7 nm while the size of 40 was 22.7 nm. In 
order to further confirm this hypothesis, a confocal microscopy experiment on 
ESP100-GNPs (32) will be needed. The size of ESP100-GNPs (32) was 32.7 nm which is 
bigger than 40. If 32 could not penetrate into the cells which may suggest that size is a 
key control point in the system. Then we can modulate the size of KLA-ESP-GNPs by 
changing the polymer length or the size of GNPs. In addition, the temperature 
responsiveness of elastin-like polymer should be more sensitive at 42C.  
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Figure 3.45: Cytotoxic effect of KLA-ESP100-GNPs (40) against HeLa cancer cells. 
Figure 3.46: Cytotoxic effect of KLA-ESP100-GNPs (40) against MRC-5 (normal lung 
cells). 
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Figure 3.47: The confocal images of KLA-ESP100-GNPs (40) in HeLa cells. (Conc.: 10 
µM, Incubation time: 24 h). Bar 15 µm. 
3.7 Conclusions  
In this chapter, we have demonstrated the formation of several peptide functionalized 
GNPs. The first system was ELP-GNPs (30) which used short elastin-like peptides to 
functionalize GNPs. The conformation and aggregation properties of the ELP-GNPs (30) 
in aqueous solution were observed by transmission electron microscopy (TEM), circular 
dichroism (CD) and UV-Vis spectroscopy. Under normal physiological conditions, 
ELP-GNPs (30) had a red colour in aqueous solution, but as the temperature of the 
solution was raised to 70
o
C, the colour changed to a red-purple colour. In addition, the 
secondary structure of ELP-GNPs (30) was found to change from random coil to a 
mixture of α-helix and β-turn structures when the temperature was gradually increased. 
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The TEM images and DLS also indicated the aggregation of ELP-GNPs (30) at higher 
temperatures.  
The second system used elastin-based side chain polymers to functionalize GNPs. The 
thermo-responsive polymer PF100-GABA(VPGVG) (29) was attached to GNPs through 
the formation of gold-thiol bonds. The conformation and aggregation properties of 
ESP100-GNPs (32) in aqueous solution were investigated by UV-Vis spectroscopy. The 
results showed that the hybrid ESP100-GNPs (32) have similar thermo-responsive 
character to the ‘free’ elastin-based side chain polymers. When the temperature was 
increased, the GNPs aqueous solution changed colour from red to purple, and this was 
accompanied by a red shift from 532 nm to 540 nm. CD spectra of ESP100-GNPs (32) 
also supported aggregate formation when the temperature was increased from 10 to 
65
o
C. The transition temperature of ESP100-GNPs was found to be around 45
o
C. 
In the third system, the anti-cancer peptide D(KLAKLAK)2 (33), was synthesised and 
characterized. The pro-apoptotic peptide D(KLAKLAK)2 was conjugated to the surface 
of GNPs via a gold-thiol linker. The MTT results show that KLA-GNPs (39) have 
enhanced anti-cancer properties over free KLA. It was hypothesised that the enhanced 
activity was due to the ability of 39 to enter cancer cells. Confocal microscopy images 
of KLA-GNPs (39) confirmed their ability to localize into cells by endocytosis, even 
specifically into mitochondria.  
In the final system, the KLA peptide and ESP100 were used to functionalize GNPs in a 
1:1 weight ratio. The KLA-ESP100-GNPs (40) were characterized by UV-Vis and CD 
experiments. These results indicated that ESP100 was linked to the surface of GNPs and 
endowed GNPs thermo-responsibility. Cytotoxicity of KLA-ESP100-GNPs was tested in 
HeLa cells and MRC-5 cells at 37C or 42C. However, the cells’ viability was not 
much different between 42C and 37C and showed no selectivity between cancer cells 
and normal cells. In addition, confocal imaging showed no penetration inside the cells 
probably due to the big size of KLA-ESP100-GNPs (40). In the future, more experiments 
will be designed and performed to investigate this hypothesis.  
In summary, the different peptides endowed the GNPs with different properties. The 
elastin-like peptide, elastin-based side chain polymers and anti-cancer peptide may be 
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applied as capping ligands to make hybrid systems with GNPs which could be used in 
cancer therapy. 
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Chapter 4: Cell-penetrating peptoids as a delivery method for 
apoptotic peptide KLA  
4.1 Introduction 
4.1.1 Antimicrobial peptides as a new class of anti-cancer agents  
Recently, peptides have attracted increasing attention in cancer chemotherapy due to 
their ease of synthesis, low immunogenicity and target specificity.
1-3
 In particular 
research has been focused on cationic antimicrobial peptide (AMPs), also termed host 
defense peptides (HDPs).
4-6
 AMPs have been found in almost every living organism 
including fungi, plants, bacteria and animals and they have been shown to have a  
broad spectrum of anti-infective activity against bacteria, fungi and viruses.
4
 The cell 
selectivity of most AMPs arises due to the electrostatic interactions between the 
positively charged AMPs and the negatively charged membranes of bacteria.
6
 As the 
exterior membranes of bacteria are negatively charged, the positively charged 
antimicrobial peptides preferentially bind to them over mammalian cells, which have 
neutral membranes. Research has also shown that a significant number of AMPs exhibit 
anti-cancer activities (Table 4.1).
6, 7
 The molecular mechanism behind the anti-cancer 
properties of many AMPs is still not fully understood.  
AMPs are typically short, ranging from 5 to 40 amino acids in length. They tend to 
contain a high number of positively charged residues (Arg or Lys) giving the peptide an 
overall net charge of between +2 to +9 at neutral pH.
8
 AMPs can have a great degree of 
variation in their secondary structures. Most linear AMPs, for example the magainins, 
are unstructured in diluted aqueous solution, only become alpha-helical in amphipathic 
media, such as membranes or micelles.
9
 LL37, also a linear peptide, but an exception, 
shows helical structure in aqueous solution. Tachyplesin 1, a cyclic peptide, forms a 
β-sheet due to the presence of disulphide bonds.  
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Table 4.1: Summary of select naturally occurring cationic antimicrobial peptides (AMPs) 
with anti-cancer activities.
6
 
Peptide  Origin 
Source  
Primary amino acid 
sequence 
a
 
Class Anti-cancer 
Activities 
BMAP-28 Cow GGLRSLGRKILRAWK
KYGPIIVPIIRI 
α-Helix Membranolytic 
HNP-1 
(β-defensin) 
Human AC1YC2RIPAC3IAGERR
YGTC2IYQGRLWAFC3
C1 
β-sheet Membranolytic 
Lactoferricin 
B 
Cow FKC1RRWQWRMKKL
GAPSITC1VRRAF 
β-sheet Membranolytic, 
Apoptosis inducer, 
Antiangiogentic 
LL-37 Human LLGDFFRKSKEKIGKE
FKRIVQRIKDFLRNLV
PRTES 
α-Helix Membranolytic 
Magainin 2 Frog GIGKFLHSAKKFGKAF
VGEIMNS 
α-Helix Membranolytic 
Melittin Honeybee GIGAVLKVLTTGLPAL
ISWIKRKRQQ 
α-Helix Membranolytic, 
Phospholipase A2 
activator, 
Phospholipase D 
activator 
Tachyplesin 1 Horseshoe 
Crab 
KWC1FRVC2YRGIC2Y
RRC1R 
β-sheet Binds hyaluronan 
and activates 
complement (C1q) 
Induces cancer cell 
differentiation 
a 
Subscripts indicate pairings of Cys residues that form disulphide bonds. Boldface indicates 
cationic amino acid residues.  
The secondary structures of AMPs enhance their amphipathicity, which plays a very 
important role in their mechanism of antimicrobial action. It is known that membrane 
surfaces give an amphiphilic environment, the external part is hydrophilic and the 
internal part is hydrophobic. When AMPs bind to membranes, apart from their 
structural folding features (net charge, amphipathicity, hydrophobicity, secondary 
structure), the membrane composition also has an impact on the mechanism of how an 
AMP executes its function.
10
 For bacterial membranes, the surface toward the exterior 
aqueous phase generally consists of negatively charged phospholipid head groups. For 
plant and animal membranes, the outer leaflet is populated by neutral lipids and 
cholesterol.
11
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The mechanism behind the AMP membrane-disruption process has attracted 
considerable attention and several models have been proposed. An appealing model 
which explains most AMPs’ activities is the Shai-Matsuzaki-Huang (SMH) model.11-13  
The SMH model suggests that the peptide causes cell death by inserting into the 
bacterial membrane and creating a pore through which cellular contents leak out.
14
 In 
this process the first step involves the peptide binding to the cell surface, and this is then 
followed by displacement of lipids resulting in thinning of the membrane. Finally, the 
increasing surface tension of the thinned lipid bilayers leads to cell lysis.   
Four models are commonly used to describe the activity of AMPs and their insertion 
into membranes, these are the carpet model, the barrel-stave model, the toroidal-pore 
model and the detergent-like model.
15
 As shown in Figure 4.1, in the carpet model, the 
most commonly found model, the AMP binds to the surface of membrane in a 
carpet-like manner. The penetration of the peptide occurs if the concentration of peptide 
covering the membrane is high.
12
 In the barrel-stave model, specific peptide-peptide 
interaction between the AMPs occurs leading to the formation of a ion-channel pore.
12
 
In the toroidal-pore model, AMPs insert into the membrane and affect the surface 
bilayer in a cooperative way which increases curvature strain on the membrane surface 
and leads to the formation of toroid-pores.
15
 These pores form at a threshold 
concentration of AMPs, an early step before the collapse of the membrane. In the 
detergent-like model, when the peptide carpet is at high concentration, the aggregation 
peptides behave like detergents resulting in catastrophic collapse of lipid membranes 
into small fragments.
16
  
It has been found that certain AMPs have the ability to selectively target and kill cancer 
cells while sparing healthy cells. The fundamental difference in charge between the cell 
membranes of normal cells and malignant tumour cells is suggested as the reason 
behind this selective lytic activity.
17
 Cancer cell membranes, typically present overall 
net negative charge due to a high percentage of anionic molecules such as 
phosphatidylserine (PS) and O-glycosylated mucines.
18, 19
 In addition, the number of 
microvilli on cancer cells is higher than on normal healthy cells which enlarge the 
surface binding area for AMPs.
20
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Figure 4.1: Models of AMP-induced membrane permeabilization. Reprinted from 
15
 with 
permission from American Chemical Society, copyright © 2010.  
4.1.2 Anti-cancer activity of KLA peptide 
It is known that the amphipathic α-helix is a common structural feature of many AMPs 
isolated from nature. Therefore, novel peptides with a amphipathic α-helix structure 
have been designed and investigated for their biological activities (antimicrobial and 
anti-cancer) 
21, 22
  Of these newly designed peptides, one of the most widely studied is 
D-(klaklak)2 (KLA peptide), which has been shown to have both significant 
antimicrobial and anti-cancer activities.
23, 24
 
In 1996, McLaughlin et al.
25
 designed a series of L-configured amphipathic α-helical 
peptides with the common sequences [(PNN)P(PNN)]n and [(PNN)(PNN)K)]n with P 
equal to a polar residue, N equal to Leu, Ala or Gly. The repetitive heptad approach was 
used to design sequences that place i and i +7 residues next to each other on helical 
wheels.
25, 26
 Lys was chosen as the polar residue due to its high helical propensity, as 
were Leu and Ala. Antibacterial activities of all designed peptides against Escherichia 
coli, Pseudomonas aeruginosa and Staphylococcus aureus were tested. They found that 
(KLAKLAK)n (n=2 or 3) had the greatest antibacterial activities and relatively low 
cytotoxicities towards human erythrocytes. However, it should also be noted that 
(KLAKLAK)3 does display strong cytotoxicity against mouse embryo fibroblast (3T3 
cells) with MIC (minimum inhibitory concentration) value 9 μM.25  
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Subsequently, Ellerby and colleagues
23
 demonstrated that shorter 14-mers such as 
D-(KLAKLAK)2 also have the ability to induce mitochondrial-dependent apoptosis 
which was proven by a swelling assay performed on rat liver mitochondria. Due to the 
difference of membrane potentials and charge of phospholipids, KLA peptide targeted 
the mitochondrial membrane (high potentials, negative charge) rather than the 
eukaryotic plasma membrane (low potentials, neutral charge).
23
 The KLA peptide can 
induce mild mitochondrial swelling at 3 μM which is only 1% of the concentration 
required to kill eukaryotic cells. The pro-apoptotic activity of KLA comes from its 
cationic α-helical amphipathic structure, enabling the compound to induce permeation 
and swelling of mitochondria, resulting in the release of cytochrome c and cell 
apoptosis. 
27, 28
  
Despite promising apoptotic activity, KLA displays very poor permeability to the 
eukaryotic plasma cell membrane. Two tumour targeting peptides, cyclic peptide 
CNGRC and the bi-cyclic peptide ACDCRGDCFC (RGD-4C), have been conjugated to 
KLA to promote cellular uptake via receptor-mediated internalization.
23
 A 
computer-generated model of CNGRC-GG-D(KLAKLAK)2 is shown in Figure 4.2.
23
 
Both conjugates were used to treat nude mice with human tumour xenografts. In both 
treatments, the volumes of the tumour were on average 10% less that of controlled 
groups and mice lived several months longer. This positive result indicated that the 
apoptotic KLA peptide has the potential to be a novel anti-cancer agent if it can be 
delivered across the plasma cell membrane.  
 
Figure 4.2: A computer generated structure of CNGRC-GG-D(KLAKLAK)2. Reprinted 
from 
23
 with permission from Nature Publishing Group, copyright © 1999. 
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Recently, an increasing area of research has been developing in relation to the design of 
different tumour-targeting domains combined with KLA. Fusing KLA with the cationic 
peptide transduction domain (PTD-5) has been tested in a variety of cell lines in vitro, 
such as MCA205 murine fibrosarcomas and human brain tumour cells (22B). The 
results suggest that KLA-PTD-5 conjugate was able to induce cell apoptosis.
27
 Due to 
the poor cell penetrating ability of KLA, another approach was to fuse a cell penetrating 
peptide (D-hepta-arginine or R7) to KLA. The D-forms of both KLA and the cell 
penetrating peptide afforded better properties, such as cell permeability, resistance to 
protease degradation and efficient apoptosis both in vitro and in vivo.
29
 This 
combination R7-KLA was not designed for a specific tumour type, but had an average 
high cell toxicity (IC50 values in the range of 3-25 µM) against several different tumour 
cell lines (such as HeLa, fibrosarcoma and Lewis lung carcinoma). In comparison with 
other clinically-used anti-cancer agents, R7-KLA showed faster kinetics of cell killing. 
The KLA was also conjugated to a prostate-specific membrane antigen (PSMA) peptide. 
This peptide conjugate (PSMA-KLA) was found to induce apoptosis in a human 
prostate cancer cell line with an LC50 19 µM.
30
 The PSMA-KLA fusion peptide 
selectively induced cell death in PSMA-expressing cells, thereby offering a potential 
therapeutic for prostate cancer.   
The examples discussed above demonstrate the potential approach of combining a 
targeting peptide with KLA to produce a highly efficacious anti-cancer agent. Research 
has also been done to improve the efficacy and selectivity of KLA via conjugation to 
short cyclic peptides
31
, nanoparticles
32-34
, self-assembling peptide amphiphilic 
nanofibers
35
 and cell penetrating peptides.
27, 29, 36-38
 All these methods have improved 
the cellular delivery of KLA to a certain extent, however, new and efficient ways to 
deliver KLA into cancer cells are still needed.  
4.1.3 Cell penetrating peptoids (CPPos) 
Compared to antibodies, peptides, due to their smaller size, have the potential advantage 
of penetrating further into tissues, organs and tumours.
39, 40
 During the last decade, cell 
penetrating peptides (CPPs) have been developed extensively and applied to CPP-based 
drug delivery strategies. However, despite success in the laboratory, CPPs are still 
generally considered to be poor candidates for the development of therapeutics due to 
their low stabilities in plasma, sensitivity to proteases and a short half-life.
2
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Cell penetrating peptoids (CPPos) offer a promising alternative to CPPs, as they 
preserve the key chemical and physical properties of CPPs. The increasing interest of 
newly designed peptoids is due to the most advantageous feature of a peptoids’ structure, 
which is the stability of the repeating N-alkyl amide backbone unit, which renders it 
highly resistant towards degradation by proteases.
41
 
Peptoids are comprised of repeating oligo-N-substituted glycine units.
42
 The backbone 
sequence of peptoids is identical to that of peptides, with the difference in the structure 
arising to the position of the side chain appendage. The side chains in peptoids are 
attached to the nitrogen atoms of the backbone, rather than the carbon atoms (Figure 
4.3).
43
 Peptoid backbones contain no chiral centres (chiral alpha-carbon atom) and they 
lack a hydrogen bond donor capacity (NH group). Thus, controlling a peptoid’s 
secondary structure e.g. helix or β-sheet is more challenging. However, chirality can be 
introduced into the peptoid monomer side chains, enabling a stable secondary structure 
to be obtained.
44-46
  
 
Figure 4.3: Comparison of the primary structure of peptide and peptoid oligmers.
43
  
Peptoid synthesis is easy, cost-effective and efficient. The most common approach used 
is known as the solid phase sub-momoner strategy and this is shown in Figure 4.4. In 
the ‘sub-monomer’ approach, the N-subsitituted glycine monomer is generated from a 
two step process: bromacetic acid and a primary amine.  
In the first step, bromoacetic acid in the presence of N,N-diisopropylcarbodiimide (DIC) 
is reacted with resin-bound secondary amine; this reaction is termed bromoacetylation. 
In the second step, an excess of primary amine replaces the resin-bound bromide via 
nucleopholic displacement. Bromoacetylation and amine displacement steps are 
repeated to obtain each monomer until the full peptoid sequence is achieved. Compared 
with solid-phase peptide synthesis (SPPS), the acylation of sercondary amines is more 
efficiently achieved by using bromoacetic acid than N-substituted glycine. In addition, 
due to the vast number of commercially availabe primary amines, this sub-monomer 
142 
 
appraoch has been greatly advanced to prepare novel designed peptoids. The high yields 
of each step allow the growth of peptoid chains, which can be up to 48 residues.
47
  
 
Figure 4.4: Solid-phase sub-monomer peptoid synthesis. 
Generally, cell penetrating peptides (CPPs) include many polycationic amino acids in 
the sequence, such as Lys (lysine), Arg (arginine) and Orn (ornithine) which facilitate 
cell membrane uptake. By introducing cationic side chains into peptoids, similar 
physical and chemical properties to CPPs are retained in the corresponding CPPos. For 
example, a peptidomimetic form of Tat49-57 has been synthesised and achieves a similar 
function of preventing HIV replication and improving membrane translocation 
activity.
48, 49
  
More research has been carried out to demonstrate that short peptoids have great 
advantages in drug delivery system.
50
 Recently, Kӧlmel et al.51 demonstrated that short 
CPPos can enter cells and even have organelle specificity. A range of side chains can be 
chosen to form novel CPPos, giving rise to different organelle targeting specificity such 
as the nucleus or mitochondria. As shown in Figure 4.5, four different sequences of 
rhodamine-labelled CPPos (I-IV) were listed on the left and their fluorescence confocal 
images of incubated HeLa cells after 24 h are shown on the right. Co-localization 
experiments were performed by co-staining the nuclei and mitochondria with Hoechst 
33342 (blue: A, E, I, M) and Mitochondria Green
TM 
(green: B, F, J, N) separately. 
Rhodamine B labelled peptoids (I-IV) were detected at 593-696 nm emission channels 
(red: C, G, K, O). Images D, H, L, P show the merges of these three different emission 
channels of each line. These four CPPos have all shown ability to be taken up by the 
cells and the locations of I to IV gradually change from nucleus to mitochondria.  
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Figure 4.5: Cellular uptake of Rhodamine labelled CPPos I-IV in HeLa cells. 1 x 10
4
 
HeLa cells were treated with 1 µM of peptoid I (A-D), II (E-H), III (I-L), and IV (M-P) 
for 24 h at 37
o
C. Reproduced from 
51
 with permission from Pharmaceuticals.  
4.1.4 Chapter aims  
Our aim is to conjugate the anti-cancer peptide KLA to a series of cell penetrating 
peptoids (CPPos) to prepare a series of peptoid-peptide hybrids (CPPos-KLA). The 
investigation of anti-cancer, antimicrobial and cell penetrating properties of the hybrids 
will then be carried out. The anti-cancer properties of the CPPos-KLA conjugates will 
be analysed against HeLa cells. Differences in the side chains of CPPos makes a 
difference to the location of KLA peptide in cells.
51
 Confocal experiments will be 
performed to confirm the specificity into the mitochondria area of Rhodamine B 
labelled KLA-CPPo6. For the antimicrobial behaviour, D-/L-KLA and two CPPos-KLA 
will be evaluated against Staphylococcus aureus, Escherichia coli, Serratia marcescens 
and Pseudomonas aeruginosa.  
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4.2 Synthesis of KLA peptide  
In order to compare the effects of stereochemistry of their biological properties, both 
D-KLA (33) and L-KLA (41) were synthesised (Figure 4.6). 
            
Figure 4.6: The structures of D-/L-KLA peptides. 
The synthesis of D-KLA (33) was achieved using Fmoc-protected D-amino acids and 
solid phase peptide synthesis. The coupling of each residue was undertaken twice (i.e. 
double coupling) in order to make sure each step had gone to completion.  
Semi-preparative reverse phase HPLC was used to purify the crude peptide (as 
described in Section 6.1.2.5. A sample of crude peptide 33 (7~10 mg mL
-1
) was 
dissolved in water and analysed using a gradient of 0%-55% solvent B in 40 min and 
55%-100% solvent B in 10 min. The flow rate was set to 2.0 mL/min and the detector 
monitored absorbance at 220 nm. The peptide was the main peak at RT= 18.1 min 
(Figure 4.7). The yield of purified peptide 33 after RP-HPLC was 15%. After 
purification, a small sample of the peptide was dissolved in water and analyzed by 
analytical HPLC, MALDI, LC-MS and HRMS (accurate mass). The analytical HPLC 
trace is shown in Figure 4.8. The molecular weight of D-KLA peptide was analysed by 
MALDI and found to be 1544.9, which is [M+ Na]
+
 as shown in Appendix 4.1. The 
LC-MS data was [M+3H]
3+
 508.5, [M+4H]
4+
 381.7. HRMS m/z (ESI) 1523.0907, 
consistent with empirical formula C72H138N21O14 with an accuracy of 1.18 ppm 
(accepted as (M + H)
+
).  
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Figure 4.7: Semi-preparative HPLC chromatograph of D-KLA peptide. HPLC 
purification was carried out on a semi-preparative column (C18, 250 x 10 mm, 5µm 
particle size). The peptide was eluted in H2O/MeCN +0.1% trifluoroacetic acid. Peptide 
33 had a retention time = 18.1 min*.  
 
Figure 4.8: Analytical HPLC trace of purified D-KLA peptide (33) using a linear gradient 
of 0-100% of solvent B ((v/v) 5% H2O/95% CH3CN with 0.1 TFA) over 30 min. 
Retention time = 11.4 min.  
L-KLA (41) was synthesised using the same method as D-KLA (33) but with Fmoc 
protected L-amino acids. Semi-preparative reverse phase HPLC was used to purify 
crude 41 and the yield was 16%. After purification, a small sample of freeze-dried 41 (1 
mg/mL) was dissolved in water and analyzed by analytical HPLC, MALDI, LC-MS and 
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HRMS (accurate mass). The analytical HPLC trace is shown in Figure 4.9. The 
retention time of the peak is 11.4 min and a very little impurity peak can be seen. The 
molecular weight of L-KLA peptide was analysed by MALDI and found to be 1546.1 
which is [M+ Na]
+
. The LC-MS data was [M+3H]
3+
 508.3, [M+4H]
4+
 381.6. HRMS 
m/z (ESI) 1523.0878, consistent with empirical formula C72H138N21O14 with an 
accuracy of 0.72 ppm (accepted as (M + H)
+
). The characterization of L-KLA (41) has 
been attached in Appendix 4.2.  
 
Figure 4.9: Analytical HPLC trace of L-KLA peptide (41) using a linear gradient of 0-100% 
of solvent B ((v/v) 5% H2O/95% CH3CN with 0.1 TFA) over 30 min. Retention time = 
11.4 min.  
To investigate the secondary structure of D-KLA (33) and L-KLA (41), circular 
dichroism (CD) spectroscopy was used. As shown in Figure 4.10, as expected the 
peptides D-KLA (33) and L-KLA (41) have mirror image CD spectra. For D-KLA (33), 
the positive bands near 208 nm and 230 nm are indicative of a random coil 
conformation. It is apparent that L-KLA displays the same conformation as D-KLA in 
aqueous buffer. For most linear cationic peptides, they are unstructured in diluted 
aqueous solution and turn to alpha-helical in membranes.  
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Figure 4.10: CD spectra of D-/L-KLA peptide in PBS buffer. 
4.3 Synthesis of peptoid hybrids  
4.3.1 CPPos 
The peptoids were synthesised manually on resin using the sub-monomer method
22 
on a 
shaker. The synthetic approach used to prepare all peptoids is detailed in Figure 4.4 and 
discussed in Section 4.1.3.   
The CPPos library used was designed by Kӧlmel et al.51 have combinations of 
hydrophobic and hydrophilic submonomers and the total length is four. All the peptoids 
have at least one positive charge which gives them the ability to act as CPPos. Also, the 
third position of all the sequences was fixed to have a cationic and hydrophilic side 
chain. The other three positions were variable and modulated by replacing more 
hydrophobic submonomers for hydrophilic ones. Four different submonomers were 
used and their structures are shown in Figure 4.11. The peptoid syntheses were 
processed via applying the Boc protected diamine (42), benzylamine (43), 
p-chlorobenzylamine (44) and p-methoxybenzylamine (45). The Boc group of 42 was 
removed after the acid cleavage from the resin. In aqueous solution, the side chain of 
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submonomer 42 will provide a positive charge due to its protonation. The other three 
submonomers 43-45 can provide variable hydrophobicity into the sequence. Based on 
the different name of submonomers, the peptoid monomer can be name as Nlys, Nphe, 
Npcb and Npmb as shown in Figure 4.11.  
 
Figure 4.11: The structures of submonomers 42-45, the annotation of peptoid monomers 
(Nlys, Nphe, Npcb, Npbm). 
The original peptoid synthesis method, describing as oligomers of N-substituted glycine 
residues, was first discovered by Zuckermann et al. in 1992. Subsequently, increasing 
research has been done due to the highly efficient sub-monomer solid phase synthesis 
strategy. The peptoid oligomers were manually synthesised by the solid-phase 
sub-monomer method. Rink amide resin was swelled in DMF overnight at room 
temperature. The resin was treated with 20% piperidine in DMF to remove the Fmoc 
group. Solutions of bromoacetic acid and DIC were added into the resin. The reaction 
tube was placed on the shaker for 20 min at room temperature. The resin was washed 
with DMF before the desired amine monomer was added for 60 min on the shaker. 
Bromoacetylation and amine displacement (Figure 4.4) steps were repeated until the 
final monomer had been added. This procedure was repeated four times to obtain each 
peptoid. With the synthesis of the peptoid complete two Gly residue were coupled to the 
N-terminus to provide a spacer between the peptoid and peptide.  
To test cleavage of the peptoid from the resin, a solution of 1 mL TFA, TIPS and H2O 
(95:2.5:2.5) was added to the resin and this was left for 120 min at room temperature on 
the shaker. The resin was rinsed once with 0.5 mL TFA. Then the resin was removed by 
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filtration and the obtained peptoid was precipitated in diethyl ether. The product was 
then dissolved in water and freeze dried. The crude peptoids were analysed by LC-MS. 
The structures of all CPPos are shown in Figure 4.12. All the LC-MS data were shown 
in Table 4.2.  
  
Figure 4.12: The structures of cell penetrating peptoids 46-51. 
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Table 4.2: Summary of all peptoids prepared. 
Name Sequence 
Molecular 
weight  
Observed mass 
Fmoc-CPPo 1 (46) Fmoc-GGNlysNlysNpcbNlys 910.52 460.1 (M+2H
+
) 
Fmoc-CPPo 2 (47) Fmoc-GGNlysNlysNlysNphe 885.08 443.2 (M+2H
+
) 
CPPo 3 (48) GGNpmbNlysNlysNphe 711.40 356.8(M+2H
+
) 
CPPo 4 (49) GGNpmbNlysNpcbNlys 745.36 746.3 (M+H
+
) 
CPPo 5 (50) GGNlysNlysNpcbNphe 715.35 358.7(M+2H
+
) 
CPPo 6 (51) GGNpmbNlysNpcbNphe 764.34 764.8(M+H
+
) 
 
4.3.2 KLA-CPPos 
The KLA peptide was added to each of the peptoids after the Gly-Gly spacer using 
Fmoc SPPS (Figure 4.13). Table 4.3 shows all the sequences of the peptide D-KLA (33) 
and peptide-peptoid hybrids 52-57. The synthesis and purification process were the 
same as described for D-KLA (33). Semi-preparative HPLC was used to purify as a 
standard method, which was described in Section 6.1.2.5. After purification, a small 
sample of each peptide-peptoid hybrid was dissolved in water and analyzed by 
analytical HPLC, MALDI, LC-MS and accurate mass analysis. Detailed characteristic 
data is given in Appendices 4.3 to 4.8. Here, we summarize hybrids characterization as 
shown in Table 4.4 and 4.5.   
Table 4.3: Sequences of peptide-peptoid hybrids prepared  
Compound Peptide-Peptoid Hybrid Sequence 
KLA-CPPo1 (52) H-(klaklak)2-GG-NlysNlysNpcbNlys-NH2 
KLA-CPPo2 (53) H-(klaklak)2-GG-NlysNlysNlysNphe-NH2 
KLA-CPPo3 (54) H-(klaklak)2-GG-NpmbNlysNlysNphe-NH2 
KLA-CPPo4 (55) H-(klaklak)2-GG-NpmbNlysNpcbNlys-NH2 
KLA-CPPo5 (56) H-(klaklak)2-GG-NlysNlysNpcbNphe-NH2 
KLA-CPPo6 (57) H-(klaklak)2-GG-NpmbNlysNpcbNphe-NH2 
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Figure 4.13: Solid phase approach to build up peptide-peptoid hybrids. 
Table 4.4: Low resolution ESI-MS data for peptide-peptoid hybrids prepared. 
Compounds Calculated Mass              Observed mass
a
 
KLA-CPPo1 (52) 2200.5 441.3 (5H
+
) 
KLA-CPPo2 (53) 2167.4 723.6 (3H
+
), 434.5 (5H
+
) 
KLA-CPPo3 (54) 2216.4 1108.8 (2H
+
), 555.2 (4H
+
), 444.6 (5H
+
) 
KLA-CPPo4 (55) 2250.4 1126.3 (2H
+
), 563.7 (4H
+
), 451.3 (5H
+
) 
KLA-CPPo5 (56) 2220.4 1112.2 (2H
+
), 741.4 (3H
+
), 445.0 (5H
+
) 
KLA-CPPo6 (57) 2269.3 1135.6 (2H
+
), 568.6 (4H
+
), 455.1 (5H
+
) 
a
 Observed in ESI-MS. Parent peaks were not observed due to the mass range of the instrument 
(up to m/z 2000). The observed masses are doubly charged (2H
+
) and triply charged (3H
+
) peaks, 
not fragments. 
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Table 4.5: MALDI-ToF data for the peptide-peptoid hybrids prepared. 
Compounds Calculated mass        Observed mass
b
 
KLA-CPPo1 (52) 2200.5        [M+H]
+
 = 2203.5 
KLA-CPPo2 (53) 2167.4 [M+Na]
+
 = 2191.5 
KLA-CPPo3 (54) 2216.4 [M+Na]
+
 = 2240.5 
KLA-CPPo4 (55) 2250.4 [M+H]
+
 = 2252.9 
KLA-CPPo5 (56) 2220.4  [M+Na]
+
 = 2244.4 
KLA-CPPo6 (57) 2269.3  [M+Na]
+
 = 2293.2 
b
 Observed in MALDI-ToF. 
4.3.3 Rhod-KLA-CPPo6 (59) 
In order to evaluate the drug delivery capability of KLA-CPPo6 within cell-based 
assays, KLA-CPPo6 (57) was fluorescently tagged with rhodamine B (58).  
Rhodamine B has been commonly used as a dye in microscopy for biological 
applications as it is cheap and has a high extinction coefficient. The fluorophore 
Rhodamine B was coupled to the N-terminus of hybrid 57 via DIC and HOBt in DMF 
and incubated for 1 hour at room temperature. This process was repeated again to make 
sure reaction was completed. The final product was cleaved by adding trifluoroacetic 
acid (TFA, 95%) in DCM and shaking at room temperature for 2.5 h. The cleavage 
solution was filtered and the resin was thoroughly washed with MeOH until colourless. 
Due to the intensive colour of the Rhodamine-conjugated hybrid 57, the process can be 
monitored visually. Water was added, frozen and lyophilised to give the crude product. 
Then, semi-preparative HPLC was used to purify 59 as a standard method. After 
purification, LC-MS analysis and MALDI-TOF MS of Rhod-KLA-CPPo6 (59) were 
taken. The molecular weight of 59 was analysed by MALDI and found to be 2694.6 
which is [M+ H]
+
. The LC-MS data was [M+2H]
2+
 1347.8, [M+5H]
5+
 539.7, [M+6H]
6+
 
449.9. HRMS m/z (ESI) 540.321, consistent with empirical formula C72H138N21O14 with 
an accuracy of -3.8 ppm (accepted as (M + 5H)
5+
). The characterization of 
Rhod-KLA-CPPo6 (59) is given in Appendix 4.9.  
It is known that rhodamine B exists in ‘nonfluorescent’ (58a) and ‘fluorescent’ (58b) 
forms in the equilibrium shown in Figure 4.14. The non-fluorescent structure exists as a 
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closed spirolactam while the fluorescent form has an open structure. The equilibrium is 
controlled by the number of proton ions in the aqueous media.  
 
Figure 4.14: Structure change of rhodamine B (58) molecule in the presence or absence 
of H
+
. 
Analytical HPLC analysis of 59 showed two peaks with retention times at 17.6 min and 
19.6 min (Figure 4.15). As Birtalan et al.
52
 have discussed in a similar HPLC 
separation of a peptoid linked with Rhodamine, they showed that non-fluorescent has a 
lower retention time than fluorescent structure. Based on this, we assumed that the first 
peak represented the closed form of 59 and the second peak represented the fluorescent 
structure of 59. We also confirmed this by adding few drops of 1% TFA into the sample 
tube. At the lower pH, the second peak became larger suggesting that it represents the 
fluorescent Rhod-KLA-CPPo6 (59). 
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Figure 4.15: Analytical HPLC trace of purified Rhod-KLA-CPPo6 (59) at 220 nm and 
the structures that represented the two peaks. 
The absorption bands of Rhod-KLA-CPPo6 (59) are 563 nm in PBS buffer. We 
measured the absorption spectra of 59 at PBS with different concentrations at pH 3, 4 
and 5. At pH 3, the spectra of concentrations from 1.25 μM to 10μM are shown in 
Figure 4.16. The maximum absorbance peak was at 563 nm and the peak increased in 
intensity when the concentration increased. In Figure 4.17, the linear constant of the 
peak value at 563 nm of concentration 1.25 μM to 10μM was obtained and was used as 
the extinction coefficient of 59 at pH 3. 
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Figure 4.16: The absorbance spectra of 59 measured at PBS (pH=3) with different 
concentration.  
 
Figure 4.17: The absorbance value of 59 measured at PBS (pH=3) at 563 nm with 
different concentration. The extinction coefficient was calculated by the linear constant.  
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Table 4.6: Comparison of the absorption maxima and extinction coefficients of 59 at 
different pH values. (Spectra measured in PBS) 
pH value λabs(nm) Extinction Coefficient ε[M
-1
 cm
-1
] 
3 563 23300 
4 563 11400 
5 563 800 
 
4.4 Biological evaluation of peptide-peptoid hybrids 
4.4.1 Cytotoxicity of KLA and KLA-CPPos 
(MTT data was carried out by Lijun Jiang at Hong Kong Baptist University) 
In the cytotoxicity experiment, D-KLA (33) and the hybrids 52-57 were evaluated using 
HeLa cells. As we can see from Figure 4.18, D-KLA (33) exhibits low anti-cancer 
activity, and even at a concentration of 500 µM HeLa cell viability is 56 ± 3%.  
It has been reported that cell penetrating peptoids (CPPos) can be designed by varying 
the backbone scaffolds and side-chain appendages
51
. The combination of lipophilic and 
cationic residues in different peptoids have been synthesised and showed the ability to 
enter human cells efficiently. Here, we chose six different CPPos in the library and used 
them as delivery vectors to improve the cell penetrating ability and cytotoxicity of the 
KLA peptide.  
KLA-peptoid hybrids 52-57 were incubated with HeLa cells (concentration 100 µM to 
1µM), and all showed improved anti-cancer activity compared to KLA itself (Figure 
4.19). Hybrids 52-54 have similar properties at the highest concentration of 100 µM, 
with HeLa cell survive around 70%. This shows that hybrids 52-54 can deliver D-KLA 
(33) into the HeLa cells but the location may not be the mitochondria. However, hybrids 
55-57 have increased cytotoxicity compared to hybrids 52-54. At the highest 
concentration of 100 µM, the HeLa cell viability was only 14 ± 3%, 7 ± 2%, 0.2 % for 
hybrid 55, 56 and 57 respectively. At 20µM, hybrids 55 and 56 lost activity but hybrid 
57 still showed a good level of activity with HeLa cell viability 17 ± 2%. 
An extra cytotoxicity experiment of peptide-peptoid 57 was under taken to more 
accurately define the IC50 value. The concentration range was controlled from 20 μM to 
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5 μM. At 8 µM, the viability of HeLa cells was 38 % ± 1%, which proves the IC50 is 
lower than 10 µM. While at the lowest concentration 5 µM, cell viability is over 100%. 
From the data as shown in Figure 4.20, the more accurate IC50 of 57 is ca. 8 µM.   
 
Figure 4.18: MTT assay determined cell viability of HeLa cell line after incubation with 
D-KLA (33) for 24 h at 37
o
C. The data represent the mean ± standard deviation of three 
independent experiments. 
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Figure 4.19: MTT assay determined cell viability of HeLa cell line after incubation with 
six KLA-peptoid hybrids (52-57) for 24 h at 37
o
C. The data represent the mean ± standard 
deviation of three independent experiments. 
 
Figure 4.20: MTT assay determined cell viability of HeLa cell line after incubation with 
peptide-peptoid hybrid 57 for 24 h at 37
o
C. The data represent the mean ± standard 
deviation of three independent experiments. 
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4.4.2 Cellular uptake and in vitro imaging  
From the cytotoxicity experiments, it was found that KLA-CPPo6 (57) had the best 
activity. We hypothesised that this was due to the fact that CPPo6 has the ability of 
internalizing KLA into cells and localizing it specifically in the mitochondria. In order 
to prove this hypothesis, a Rhodamine dye was coupled to KLA-CPPo6 (57) in order to 
produce a conjugate that could be used in fluorescence microscopy experiments. The 
synthesis of Rhod-KLA-CPPo6 (59) has been previously described.  
The cellular uptake of Rhod-KLA-CPPo6 (59) (10 μM) into HeLa cells could be 
observed very clearly (Figure 4.21). In addition, confocal images of Rhod-KLA-CPPo6 
(59) within the HeLa cells after incubation for 24 h were examined by laser confocal 
microscopy. As shown in Figure 4.22, Rhod-KLA-CPPo6 (59) co-localsises in exactly 
the same location as the mitochondrial tracker dye. This result confirms that CPPo6 (51) 
can deliver KLA (33) into mitochondria, leading to significant improvement in its 
anti-cancer activity.  
 
Figure 4.21: The cellular uptake of Rhod-KLA-CPPo6 (59) by flow cytometry in human 
cervical carcinoma HeLa cells.  
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Figure 4.22: The confocal images of Rhod-KLA-CPPo6 (59) in HeLa cells. (Conc.: 
10µM, Incubation time: 24 h). Bar 15µm.  
4.4.3 Antibacterial screening  
(Antibacterial screening data was carried out by Mark Laws at Durham University) 
KLA-mediated mitochondrial membrane disruption has been demonstrated to occur in 
preference to disruption of the eukaryotic plasma membrane.
23
 The similarity in the 
membrane compositions of mitochondria and gram-negative bacteria suggests that gram 
negative-active cationic AMPs may have potential applications in oncotherapy. This 
also indicates that α-helical mitochondria-targeting peptides such as KLA may possess 
antimicrobial activity.
53
 
McGrath et al. have studied the antimicrobial spectrum of the KLA peptide in depth and 
report minor activity against Pseudomonas aeruginosa PAO1 and Escherichia coli 
ATCC 25922 strains (MIC of 150 μg mL-1 against both).24 In an attempt to increase the 
stability of KLA peptide towards proteolysis, the same group also reported the 
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biological screening of an all-D amino acid enantiomer (D-KLA). Identical MICs to 
those of the L-KLA enantiomer were reported for all gram-negative strains tested, but 
D-KLA was observed to have greatly enhanced stability towards proteolytic degradation 
(25% of D-KLA vs. 100% of L-KLA degraded on treatment with human liver-derived 
microsomes for 24 h).
24
   
As discussed in Section 4.2, we have produced both L-KLA (41) and D-KLA (33) 
peptides; to expand upon the work of McGrath et al., screening against different 
bacterial strains was conducted, i.e. Staphylococcus aureus, Serratia marcescens and 
Pseudomonas aeruginosa. As Table 4.7 and Figure 4.23 show, L-KLA (41) was found 
to possess no antimicrobial activity against any of the organisms screened. However, 
antibacterial activity was noted for D-KLA (33) against both gram-positive S. aureus 
(MIC 256 μg mL-1; IC50 ~192 μg mL
-1
) and gram-negative E. coli (MIC 64 μg mL-1; 
IC50 ~48 μg mL
-1
). In particular it is worth noting that the activity of D-KLA (33) 
against E. coli is comparable to that of the antibiotic control, ampicillin (MIC 32 μg 
mL
-1
;
 
IC50 ~16 μg mL
-1
). 
The data recorded may be reconciled on the basis of relative biological stabilities of the 
two peptides. L-KLA (41) inactivity may be due to, amongst other factors, degradation 
via proteases either secreted by the bacteria or released upon lysis of the first bacterial 
cells. In comparison, D-KLA (33) will possess enhanced stability towards proteolytic 
degradation, potentially giving rise to the discrepancy between the antimicrobial 
activities of the two peptides. Alternatively, the superior antimicrobial activity of 
D-KLA (33) may be due to a different, specific method of action involving binding of an 
unidentified membrane/intracellular component for which it possesses the requisite 
spatial orientation of residues to bind and elicit the antimicrobial effect. Further 
investigation is required to provide a definitive explanation for this observation. 
When D-KLA is combined with cell penetrating peptoids (CPPos), the data for 52 and 
53 are similar to those of D-KLA, except for the activity of the conjugates against P. 
aeruginosa which was greater, as shown in Figure 4.24. This may due to the peptoid 
section enhancing the cell penetrating ability of D-KLA to interact with the cell 
membrane of P. aeruginosa. Further investigation to elucidate the mode of action of 
these conjugates is thus required. 
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When comparing the data obtained for D-KLA, activities against S. aureus and S. 
marcescens remained the same, activities against E. coli have decreased (MIC 128 and 
256 mgL
-1
;
 
IC50 64 and ~96 mgL
-1
 for 52 and 53, respectively). However, the activities 
against P. aeruginosa have increased as observed by lower MIC and IC50 (MIC 32 and 
64 mgL
-1
;
 
IC50 ~24 and ~48 mgL
-1
 for 52 and 53, respectively).  
Table 4.7: Summary of MIC and IC50 values attained from biological testing (µg mL
-1
). 
IC50 is the half maximal inhibitory concentration, defined as the concentration of 
antibiotic required for 50% inhibition of bacterial growth (achieve 50% cell viability). 
Compound 
Bacteria 
S. aureus E. coli S. marcescens P. aeruginosa 
MIC IC50 MIC IC50 MIC IC50 MIC IC50 
L-KLA (33) >256 >256 >256 256 >256 ~192 >256 >256 
D-KLA (41) 256 ~192 64 ~48 >256 128 >256 ~96 
KLA-CPPo1 (52) 256 ~192 128 64 >256 ~192 32 ~24 
KLA-CPPo2 (53) 256 ~192 256 ~96 >256 ~192 64 ~48 
Ampicillin 4 <2 32 ~12 64 ~12 256 ~192 
 
Figure 4.23: Antibacterial screening results of L-KLA (41) and D-KLA (33).  
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Figure 4.24: Antibacterial screening results of KLA-CPPo1 (52) and KLA-CPPo2 (53). 
4.5 Conclusions 
In this chapter, the known anti-cancer peptide D-KLA was conjugated to a series of cell 
penetrating peptoids (CPPos) in an effort to improve its cell penetrating properties and 
its cytotoxicity. The advantage of using CPPos as delivery agents is that they have the 
same membrane-crossing ability as cell penetrating peptides, but they are stable to 
protease digestion. We prepared a series of CPPos-KLA hybrids (52-57). Each hybrid is 
a fusion of a short sequence peptoid and the D-form of KLA, as well as two glycine 
residues in the middle as a spacer. All peptide-peptoid hybrids were obtained by 
solid-phase synthesis. Six different cell penetrating peptoids (CPPos) were selected and 
conjugated with KLA and their anti-cancer properties evaluated against Hela cells. The 
results show that the CPPos-KLA hybrids have an increasing trend in killing ability due 
to the increasing of mitochondria-targeting ability. The IC50 of KLA-CPPo6 (57) (ca.8 
μM) was more than 62.5 fold lower than that of D-KLA peptide alone.  
By altering the side chains of the CPPos, different organelle localization can be 
achieved.
51
 KLA-CPPo6 labelled with Rhodamine B (59) was monitored by fluorescent 
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confocal microscopy of its cellular uptake efficiency. The Rhodamine B labelled 
KLA-CPPo6 (59) was shown to have the ability to enter cells by endocytosis and to 
specifically localize in the mitochondria. This system proves that CPPos have the 
potential to be used to deliver anti-cancer drugs with a specificity at the subcellular 
level.  
For antibacterial experiments, both L-KLA and D-KLA peptides were screened against 
different bacterial strains. We found that L-KLA possessed no antimicrobial activity, 
while D-KLA peptide had activity against both gram-positive S. aureus (MIC 256 μg 
mL
-1
;
 
IC50 ~192 μg mL
-1
) and gram-negative E. coli (MIC 64 μg mL-1; IC50 ~48 μg 
mL
-1
). The activity of D-KLA against E. coli was almost as good as the antibiotic 
control, ampicillin (MIC 32 μg mL-1; IC50 ~16 μg mL
-1
). 
In addition, we screened KLA-CPPo1 (52) and KLA-CPPo2 (53) against four bacterial 
strains as well. The data obtained were similar to D-KLA, except for the increased 
activity of 52 and 53 against P. aeruginosa. Activities against P. aeruginosa have 
increased compared to both L-KLA and D-KLA, even better than Ampicillin (MIC 32 
and 64 mgL
-1
;
 
IC50 ~24 and ~48 mgL
-1
 for 52 and 53, respectively). This may be due to 
the novel intracellular peptoid section of the conjugates specific to P. aeruginosa.   
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Chapter 5: Conclusions and Future Work 
As outlined in the original aim of this thesis, three different delivery vehicles that have 
the potential to be applied in the development of new anti-cancer drug delivery systems 
have been studied. The research involved biomaterial design, functionalization of GNPs 
and the application of novel cell penetrating peptoids (CPPos).  
In Chapter 2, we synthesised and studied a series of short elastin-like peptides (ELPs) 
with different N-terminal end groups. A solid phase peptide synthesis approach was 
applied and Rink Amide resin was used in all cases. Neutral solutions (pH=7) of peptide 
9 (VPGVG) showed no lower critical solution temperature (LCST) behavior, but at pH 
9, the free amine end was not protonated providing peptide 9 a more hydrophobic 
character with a transition temperature of 44
o
C. The turbidimetry data obtained from the 
study of all the ELPs prepared showed that only peptide 10 (N-acetylated VPGVG) had 
a transition temperature (45
o
C) close to the target range (38-42
o
C) at pH 7. In order to 
use this short ELP in further applications (Chapter 3), an equivalent thiol-functionalized 
peptide 11 was synthesised. The secondary structures of peptide 10 and peptide 11 in 
aqueous buffer were examined using circular dichroism (CD). The results showed that 
they both display similar trends to previously studied long chain elastin-like peptides. 
The mean residue ellipticity (MRE) at 198 nm became shallower and the [θ] value at 
222 nm increased when the temperature was increased, which indicated changes in 
structure from random coil to a more organised conformation (mixture of α-helix and 
β-turn structures).  
As we were able to confirm that the shortest sequence studied (VPGVG) has similar 
LCST behaviour to that displayed by long elastin-like polypeptides, we used it to 
prepare elastin-based side chain polymers (ESPs). To prepare the ESPs we utilised the 
RAFT technique to polymerize pentafluorophenyl acrylate (PFPA). Different molecular 
weights of poly(PFPA) (16-19) were synthesised and characterized by both NMR and 
gel permeation chromatography (GPC). The poly(PFPA)s prepared were subsequently 
modified by attachment of the short ELPs in the presence of triethylamine (TEA), to 
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give a series of elastin-based side chain polymers (ESPs) (22-29). We have investigated 
the influence of the chain length, molecular weight and NaCl concentration on the 
LCST behaviour of a series of ESPs. By increasing the polymer concentration or its 
molecular weight, the transition temperature was lowered. These results proved that it 
was possible to incorporate a short ELP into a polymer to prepare a peptide-polymer 
grafts that displays the same properties as the free peptide. Amongst all the ESP 
prepared and studied, polymer 29 had the lowest transition temperature (47
o
C at pH 7). 
This is because PF100-GABA(VPGVG) (29) had the longest polymer chain length and 
the longer linker between polymer backbone and side chain peptides. In future, the 
transition temperature of the ESP could be modulated by introducing an amphiphilic 
copolymers structure. The polymerized pentafluorophenyl acrylate P(PFPA) chain 
could be extended by adding a more hydrophobic monomer, such as butyl acrylate, via 
RAFT polymerization again. Then P(PFPA) part of copolymers can be subsequently 
modified by attachment of short ELPs which become the hydrophilic part. Through 
varying the chain ratio of hydrophobic and hydrophilic domains, different transition 
temperatures and different formulations such as micelles or vesicles can be obtained. 
These newly designed amphiphilic copolymers prepared via RAFT polymerization 
could have potential as stimuli-responsive drug delivery systems.  
In Chapter 3, gold nanoparticles (GNPs) were synthesised with controlled sizes using 
the Frens and Turkevich method. GNPs A were formed and they had an average size of 
15 nm as determined by transmission electron microscopy (TEM). The UV-Vis spectra 
of colloidal solutions of GNPs A exhibited a surface plasmon absorption peak at 520 
nm. In the next step, GNPs A were functionalised with short ELP 11 to provide 
ELP-GNPs (30) hybrids. The conformation and aggregation properties of ELP-GNPs 
(30) in aqueous solution were proved by UV-Vis spectroscopy, dynamic light scattering 
(DLS) and transmission electron microscopy (TEM). In addition, the temperature 
dependencies of the secondary structure of the peptides in ELP-GNPs (30) hybrid were 
evaluated using CD spectroscopy. Compared to the trends discussed above for the free 
ELPs, the ELP-GNPs (30) were found to have the same trend as peptide 11 and peptide 
10. These data indicated that short ELPs successfully covered the GNPs and endowed 
the LCST behavior to the ELP-GNPs hybrids, resulting in a conformation change when 
the temperature was increased to around 40°C.  
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We were also able to prepare ESP hybrid GNPs; ESP75-GNPs (31) and ESP100-GNPs 
(32). ESP 26 and 29 both had thiol ends which were converted from the trithiocarbonate 
moiety of RAFT agent (benzyl 2-hydroxyethyl carbonotrithioate). This showed the 
advantageous properties of RAFT agents and the polymers made from them to be able 
to bond to and incorporate GNPs via thiol-gold linkages. The conformation and 
aggregation properties of the ESP-GNPs 31 and 32 in aqueous solution were analysed 
by UV-Vis spectroscopy. The results showed that both the functionalised nanoparticles 
31 and 32 have similar thermo-responsive characteristics to the original ESPs. When the 
temperature was increased above 40
o
C, the aqueous solution of 32 changed colour from 
red to purple and this was accompanied by a red shift from 532 nm to 540 nm in the 
UV-Vis spectra. This observation suggests that the nanoparticles were aggregated. The 
LCST behaviour of 32 was also confirmed by CD spectroscopy when measured across a 
temperature range from 10
o
C to 65
o
C. The ESP100-GNPs 32 had the same trends as 
polymer 29 which indicates that the polymer was successfully conjugated to the GNPs 
and demonstrated a conformational change when the temperature was increased to 45
o
C. 
In addition, TEM analysis of samples of 32 prepared at both 20
o
C and 50
o
C gave direct 
evidence of ESP-GNPs temperature dependant aggregation.   
We also synthesised a modified version of the pro-apoptotic KLA. With a thiol end and 
a PEG-like linker coupled to the KLA sequence, thiol-TTDS-KLA (38) was prepared 
via SPPS and it was conjugated to GNPs via a gold-thiol bond. The KLA-GNPs (39) 
prepared were characterized by UV-Vis, DLS and TEM. In order to compare the drug 
delivery ability of GNPs, we evaluated the cytotoxicity of D-KLA peptide (33) and 
KLA-GNPs (39) against HeLa cells. Free un-conjugated D-KLA peptide (33) was found 
to have low cytotoxicity (IC50 > 500 μM) on HeLa cells. In comparison, KLA-GNPs 
(39) showed much better anti-cancer activity (100 μM > IC50> 50 μM). The increased 
activity was believed to be due to the ability of 39 to enter into the HeLa cells and thus 
deliver KLA to its intracellular target, the mitochondria. Confocal imaging was used to 
prove the internalization of KLA-GNPs (39) and its specificity for the HeLa cells 
mitochondria. Taking all of the data together it was confirmed that GNPs can be used to 
deliver the apoptotic peptide KLA into mitochondrial of cancer cells, leading to 
improvement anti-cancer activity.  
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In the final system studied, we conjugated both the pro-apoptotic peptide D-KLA 
peptide (33) and the polymer ESP100 (29) to GNPs in a weight/weight ratio of 1:1. The 
KLA-ESP100-GNPs (40) prepared were fully characterized by UV-Vis, DLS and TEM. 
The LCST behaviour of 40 was studied using UV-Visible spectroscopy, increasing the 
temperature from 20
o
C to 80
o
C. Upon raising the temperature, the maximum absorption 
peak showed a red shift from 530 nm (40
o
C) to 532 nm (80
o
C). The results obtained 
suggested that there is a red shift but not as much as ESP-GNPs (32). The temperature 
dependencies of the secondary structure of the KLA-ESP100-GNPs (40) were also 
evaluated via CD spectroscopy. At 20
o
C the CD amplitudes at 200 to 210 nm had a 
positive band and the mean residue ellipticity (MRE) at 222 nm was negative implying 
a typical β-turn structure. When the temperature was increased, the MRE at 206 nm and 
222 nm increased in value, which was the same trend as 29. Compared with polymer 29, 
40 had a much more ordered β-turn structure at room temperature. The cytotoxic effects 
of 40 were evaluated against both HeLa and MRC-5 cell lines. The anti-cancer activity 
at 37C and at 42C was found to be relatively similar which indicated triggered phase 
transition behaviour of 40 showed no impact on enhancing the cytotoxicity. Confocal 
imaging of 40 showed very few red spots inside the cells which means 40 was not 
efficiently taken up by HeLa cells. This result may due to the size of 
KLA-ESP100-GNPs (40) which is bigger than KLA-GNPs (39). In future work, this 
hypothesis will be tested and the size of KLA-ESP-GNPs will be modulated by 
changing the polymer length.  
In Chapter 4, the known anti-cancer peptide D(KLAKLAK)2 was synthesised and 
characterized. D-KLA (33) was then conjugated to a series of cell penetrating peptoids 
(CPPos) in an attempt to improve its membrane permeating ability and cytotoxicity. The 
advantage of using CPPos as delivery agents is that they have the same 
membrane-crossing ability as cell penetrating peptides, but are stable towards protease 
digestion. These results show that, overall, the CPPos-KLA hybrids had increased 
anti-cancer activities (against HeLa cells) compared to free KLA. The IC50 of the best 
hybrid, KLA-CPPo6 (57) (ca.8 μM) was found to be more than 62.5 fold lower than that 
of D-KLA (33) alone. KLA-CPPo6 labelled with Rhodamine B was monitored by 
fluorescence confocal microscopy in order to investigate its cellular uptake efficiency. 
The Rhod-KLA-CPPo6 (59) was shown to have the ability to enter HeLa cells by 
endocytosis, and even specifically localize in the mitochondria. Our initial work in this 
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area on peptide-peptoid systems proves that CPPos have great potential to be used as 
vehicles to deliver anti-cancer drugs to specific subcellular locations within cancer cells. 
In the next step for research in this area, a targeting domain binding to specific cancer 
cells could be conjugated to the peptide-peptoid hybrid, which will enhance specific 
antitumor effects.  
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Chapter 6: Experimental Procedures  
6.1 General experimental 
6.1.1 Materials  
All solvents and reagents were used as supplied unless otherwise stated. Coupling agent 
PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) was 
purchased from Novabiochem. Rink Amide resin was purchased from Bachem. 
9-Fluorenylmethoxy carbamate protected valine (Fmoc Val-OH, >99%), glycine (Fmoc 
Gly-OH, >99%), proline (Fmoc Pro-OH, >99%), Fmoc-D-Lys(Boc)-OH, 
Fmoc-D-Ala-OH and Fmoc-D-Leu-OH were purchased from Bachem and were used as 
received.  
NMM (N-Methylmorpholine), N,N'-diisopropylcarbodiimide (DIC), 
N,N-diisopropyl-N-ethylamine (DIPEA), 1-hydroxybenzotriazole (HOBt),  
bromoacetic acid (BrAA), piperidine, 4-methoxybenzylamine, benzylamine, 
4-chlorobenzylamine and Rhodamine B were purchased from Sigma-Aldrich. 
N-(tert-butoxycarbonyl)-1,4-diaminobutane was purchased from TCI.  
Anhydrous dimethylformamide (DMF), diethyl ether and benzene were obtained from 
Sigma Aldrich. The polymerization initiator 2,2’-azobisisobutyronitrile (AIBN) was 
supplied by Acros Organics and recrystallized from methanol before use. 
Pentafluorophenol and triethylamine (TEA) were purchased from Sigma Aldrich.  
HPLC grade DMF was used for coupling reactions and was purchased from 
Sigma-Aldrich. Trifluoroacetic acid (TFA, 99%) and triisopropylsilane (TIPS, 99%) 
were purchased from Sigma-Aldrich and used as received. Acetic anhydride (>99%) 
was purchased from Sigma-Aldrich. 3-Tritylsulfanyl-propionic acid (Mpr(Trt)-OH) was 
purchased from Bachem and used as received. 4-Aminobutanoic acid (GABA) and 
6-(Fmoc-amino) caproic acid (Fmoc-Ahx-OH) were purchased from Sigma Aldrich. 
N1-(9-fluorenylmethoxycarbonoyl)-1,13-diamino-4,7,10-trioxatridecan-succinamic acid 
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(Fmoc-TTDS-OH) was purchased from Iris Biotech GMBH. Trisodium citrate 
dihydrate (C6H5O7Na3•2H2O), gold (III) chloride trihydrate (HAuCl4•3H2O) were both 
obtained from Sigma-Aldrich. All solvents and other reagents were purchased from 
commercial sources and used without purification. 
6.1.2 Instruments  
6.1.2.1 UV-Vis measurement  
UV-Vis absorption spectroscopy measurements were performed using a Varian 
CaryBio-100 spectrophotometer equipped with a thermoelectric temperature controller. 
The samples were measured using a quartz cell with 1 cm path length at different 
temperatures and different buffer pH values. Samples of peptides were prepared in 
cuvettes sealed with a Teflon stopper and heated at a rate of 1 
o
C/min. The 
measurements were carried out at a fixed wavelength of 300 nm. In this study, in order 
to calculate the phase transition temperature, all the experimental data were normalized 
to 1, and lower critical solution temperature (LCST) was defined as the temperature at 
which 50% of the normalized turbidity was obtained. 
6.1.2.2 DLS measurement  
Dynamic light-scattering (DLS) measurements were conducted using a Brookhaven 
Instruments 90 Zeta-Plus particle size analyser. Briefly, sample solution (500μM) in 
phosphate buffer (10mM, pH 7.4) was prepared. Before analysis all samples were 
filtered through a 0.2µm-pore-size syringe filter to minimise contamination with dust. 
The diameter of ELP-GNPs was measured between 10 °C and 60 °C. At each 
temperature, the sample was incubated for 10 min. 
6.1.2.3 TEM measurement  
Transmission electron microscopy (TEM) was conducted on a Hitachi 7600 instrument 
at an acceleration voltage of 100 kV. A small drop of the colloidal gold solution was 
placed on a carbon-coated copper grid (200 mesh), and excess solution was removed by 
wicking using filter paper. The grid was dried after allowing the solvent to evaporate for 
several minutes and turned into a thin film of particles. TEM images were captured 
from different parts of the grid and with different magnifications. Approximately ten 
particles were measured for determining average particle diameter. 
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6.1.2.4 CD measurement  
Circular dichroism (CD) spectra were recorded on a Jasco J-810 spectropolarimeter 
equipped with a Jasco PFD-425S temperature control unit. Experiments were performed 
in a quartz cell with a 0.1 cm path length over the range of 198-250 nm at various 
temperatures. The sample solution (200μM, 10mM phosphate buffer) was injected into 
the quartz cell. The scan speed used was 50 nm/min. 
6.1.2.5 HPLC purification  
Semi-preparative RP-HPLC was performed with a Perkin Elmer Series 200 LC pump 
fitted with a 785A UV/Vis detector using a SB-Analytical ODH-S optimal column (250 
× 10 mm, 5 µm); flow rate 2 ml min
−1
; generally linear gradient elution 0-65% of 
solvent B over 30 min (A = 0.1% TFA in 95% H2O and 5% MeCN, B = 0.1% TFA in 5% 
H2O and 95% MeCN). For some longer peptides, the gradient was modulated in order 
to detect the compound peaks in the best separation.  
Purified peptides were characterised by a PerkinElmer series 200 Autosampler onto a 
Waters XBridge
TM 
BEH C18 column (4.6 x 100 mm, 3.5 m particle size) which 
attached to a PekinElmer Series 200 LC Pump and Series 200 UV/Vis detector. The 
temperature of the column was 40
o
C controlled by PerkinElmer Series 200 Peltier 
column oven. Peptides were eluted in H2O/MeCN + 0.05% TFA and the gradient 
elution was set at 0-100% B in 30 min with flow rate 1 ml min
−1. 
 
The LCT Premier XE mass spectrometry using a Acquity UPLC BEH analytical 
column (C18, 2.1 x 50 mm, 1.7 m particle size) was carried out on a TQD mass 
spectrometer (Waters Ltd, UK) with a flow rate of 0.6 ml min
-1
 and a linear gradient of 
5-95% of solvent B over 3.8 min (A = 0.1% formic acid in H2O, B = 0.1% formic acid 
in MeCN). For accurate mass detection, QToF Premier mass spectrometry was used 
applied with same column and same solvent condition.  
Pepetides, peptoids and peptide-peptoid hybrids identities were also confirmed by 
MALDI-TOF mass spectra analysis (Autoflex II ToF/ToF mass spectrometer Bruker 
Daltonik GmBH) operating in positive ion mode using an α-cyano-4-hydroxycinnamic 
acid (CHCA) matrix. The samples were prepared at concentrations of no more than 1 
mg/mL.   
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6.1.2.6 NMR spectroscopy 
1
H, and 
19
F NMR spectra were recorded using Varian Mercury-400 (
1
H, 
13
C, 
19
F), 
Bruker Avance-400 (
1
H, 
13
C, 
19
F) spectrometers. CDCl3, CD2Cl2 or DMSO-D6 were 
used as solvents. All chemical shifts are quoted in parts per million relative to 
tetramethylsilane (H = 0.00 ppm) and coupling constants are given in Hertz (Hz) to the 
nearest 0.5 Hz.  
6.1.2.7 IR spectroscopy 
Infrared spectra (IR) were recorded using a Diamond ATR (attenuated total reflection) 
accessory (Golden Gate).  
6.1.2.8 Mass spectrometry 
Electrospray mass spectra (ES) were obtained on a Micromass LCT Mass Spectrometer. 
High resolution mass spectra were obtained using a Thermo-Finnigan LTQFT mass 
spectrometer or XevoQToF mass spectrometer (Waters UK, Ltd) by Durham 
University Mass Spectrometry service. The samples were prepared at concentrations of 
no more than 1 mg/mL.  
6.1.3 General experimental procedures  
6.1.3.1 Manual Fmoc-SPPS 
Manual SPPS was carried out at room temperature for 1.5 h with amino acid (3.0 eq.), 
PyBoP (3.0 eq.) and DIPEA (3.0 eq.) in a fritted polypropylene vessel. For successive 
couplings the vessel was drained after the each coupling cycle and the coupling cycle 
was repeated with fresh reagents. The Fmoc deprotection step was carried out for 15 
min with a solution of 20% piperidine in DMF, followed by a further treatment for 15 
min with a fresh solution of 20% piperidine in DMF. In all steps agitation was provided 
by shaking machine.  
6.1.3.2 Peptide cleavage  
Peptide-resins were washed with DCM and diethyl ether three times respectively, then 
left to air dry for 5 min. Subsequently the peptide-resins were treated with a (3 mL per 
0.1 mmol of resin) solution of 2.5% TIPS and 2.5% H2O in TFA for 4 h at room 
temperature. The cleavage cocktail was reduced to around one-fourth of its original 
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volume by rotary evaporator under vacuum at 40
o
C. Then the condensed solution was 
added to cold diethyl ether whereas the peptide precipitated as a white powder. The 
supernatant was decanted off carefully and the precipitate was washed with cold diethyl 
ether. Then precipitate was dissolved with distilled water and freeze-dried.  
6.1.3.3 Synthesis of peptoids  
Fmoc-protected Rink Amide resin (normally 100-300 mg, 0.1-0.3 mmol) was swollen 
in DMF (minimum 1 hour, room temperature, overnight preferred) and deprotected with 
piperidine (20% in DMF v/v, 2 x 20 mins). After DMF washing, the resin was treated 
with bromoacetic acid (8 eq. wrt. resin, 2M in DMF) and DIC (8 eq. wrt. resin, 2M in 
DMF) for 15 min at 50 ˚C on a heated shaker with a metal block (400 rpm). The resin 
was washed three times with DMF, before the desired amine submonomer was added (4 
eq. wrt. resin, 1M in DMF) and allowed to react for 15 min at 50 ˚C. The resin was 
washed three times with DMF again. The bromoacetylation and amine displacement 
steps were repeated until the final submonomer had been added and the desired peptoid 
sequence had been obtained. Cleavage was performed with TFA (95%), TIPS (2.5%) 
and H2O (2.5%) for 90 min at room temperature. The cleavage cocktail was collected in 
a 50 ml falcon tube and precipitated with 50 mL diethyl ether. The solution was 
centrifuged for 15 min at 5,000 rpm. Afterwards, the ether phase was decanted. The 
crude was dissolved in acidified H2O (with 0.1% TFA) or a mixture of acidified H2O 
and MeCN, and lyophilized. The crude products were redissolved in acidified H2O 
(with 0.1% TFA) or a mixture of acidified H2O and MeCN, and purified by RP-HPLC. 
A typical method used for the purification was 0–50% B over 60 min then 50-100% B 
over 15 min (A = 0.1% TFA in 95% H2O and 5% MeCN, B = 0.1% TFA in 5% H2O 
and 95% MeCN) at 250 nm wavelength. Relevant fractions were collected, lyophilised 
and analysed by LC-MS and MALDI-TOF. 
6.1.4 Anti-cancer screening and anti-bacterial screening by collaborators 
(The cell culture, MTT, celluar uptake and confocal experiments were carried out by 
Lijun Jiang at Hong Kong Baptist University) 
6.1.4.1 Cell culture 
Human cervical carcinoma HeLa cells were purchased from the American type Culture 
Collection (ATCC) (#CCL-185, ATCC, Manassas, VA, USA). The HeLa cells were 
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grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin and streptomycin at 37C and 5% CO2. 
6.1.4.2 MTT assay 
Cells (10
5
 per sample) were incubated in a 96 well-plate overnight. Afterwards, HeLa or 
MRC-5 cells treated with the peptide or peptoid for 24 h were further incubated in dark 
for 24h. Cell viability was determined by the 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) reduction 
assay. The cell monolayers were rinsed with PBS and then incubated with 0.5 mg/ml 
MTT solution for 3 h (5% CO2, 37C). The formazan crystal formed was dissolved in 
DMSO and the absorbance of dissolved formazan crystal at 540 and 690 nm was 
measured using a 96-well plate reader (ELx800 Absorbance Microplate Reader). 
6.1.4.3 Flow cytometry analysis on cellular uptake 
Cells (10
5
 per sample) were seeded to 35 mm Petri dish for overnight and then the cells 
were incubated with Rhod-KLA-CPPo6. Afterwards cells were trypsinized and washed 
twice with phosphate-buffered saline (PBS). The Rhod-KLA-CPP06’s uptake by cells 
was analysed by flow cytometry. The cells were excited with 488 nm argon laser and 
emission was collected with FL-3 (equipped with 650 nm long pass filter) and 10000 
events were analysed. 
6.1.4.4 Confocal microscopic imaging 
Cells were seeded onto coverslip in 35 mm culture dishes overnight. The cells were 
initially incubated with Rhod-KLA-CPPo6 for 30 min in the dark. The emitted 
fluorescent signals were examined using a Leica SP5 (upright configuration) confocal 
microscope equipped with argon laser, HeCd laser and a femtosecond-pulsed Ti: 
Sapphire laser (Libra II, Coherent) inside the tissue culture chamber (5% CO2, 37C). A 
40*oil immersion objective and a pinhole size of 110 µm was used for image capture. 
6.1.4.5 Bacterial MIC determination  
(The anti-bacterial screening experiments were carried out by Mark Laws at Durham 
University) 
Species used in MIC assays included gram-negative Escherichia coli K12 W3110, 
Pseudomonas aeruginosa laboratory strain PAO2 and Serratia marcescens laboratory 
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strain and gram-positive Staphylococcus aureus NCTC 6571 and Micrococcus luteus 
laboratory strain. 
Bacterial cultures were prepared by streaking the bacterial strains on to agar plates with 
an inoculation loop and incubating overnight at 37°C. A single colony was then selected 
and placed in 5 mL of Iso-Sensitest broth using an inoculation loop and incubated at 
37°C with shaking overnight. 
MIC values were attained according to the protocol described by J. M. Andrews et al.
1
  
and were conducted in 96-well microtitre plates in triplicate. 10-50 µL of each 
overnight culture was inoculated into 1.2 mL of Iso-Sensitest broth and grown at 37°C 
with shaking. An inoculum density of ~10
4
 cfu/spot was determined by comparison 
with 0.5 MacFarland standard (240 µM BaCl2 in 0.18 M H2SO4 aq.) and was found to 
relate to an A650nm of 0.07 after calibration with regular Iso-Sensitest broth. The 
inoculum was diluted ten-fold with Iso-Sensitest broth before use (to ~10
3 
cfu/spot). 
Peptide solutions were initially dissolved in DMSO (5 mg mL
-1
) and then diluted further 
with Iso-Sensitest broth to achieve a concentration range of 4 mgL
-1
 to 512 mgL
-1
 using 
2-fold serial dilutions. Samples were vortexed between dilutions where necessary to aid 
dissolution. 50 µL of inoculum and 50 µL of peptide solution were added to each test 
well to achieve a final concentration range of 2 mgL
-1
 to 256 mgL
-1
. Separate dilutions 
of ampicillin and DMSO were made up in a similar manner to act as a positive 
antibacterial control and a +DMSO control, respectively. 50 µL of inoculum and 50 µL 
of Iso-Sensitest broth were used as a positive control and 100 µL of inoculum was used 
as a negative control. Positive and negatives controls were conducted multiple times in 
parallel per plate. MIC was defined as the lowest concentration which completely 
inhibited bacterial growth after incubation at 37°C for 16 h with shaking. IC50 was 
defined as the concentration of antibiotic which achieved a 50% inhibition of bacterial 
growth after incubation at 37°C for 16 h with shaking. Quantitative data were attained 
as A650nm values using a BioTek® Synergy™ H4 Hybrid Multi-Mode Microplate 
Reader. 
179 
 
6.2 Synthesis of short Elastin-like peptides  
6.2.1 Synthesis of peptide H-VPGVG-NH2 (9) 
Solid-phase peptide synthesis with an Fmoc-protecting group strategy and Rink Amide 
resin was employed to synthesise the peptide H-VPGVG-NH2 (9). A suspension of Rink 
Amide resin (0.25 g, 0.19 mmol, 1 eq) was pre-swollen in DCM for 30 min and washed 
by DMF three times. Then, 20% (v/v) piperidine in DMF was added for 5 min to 
remove the Fmoc group and this was repeated three times. After each time the resin was 
washed with DMF (3 × 5 mL). Fmoc-Gly-OH (0.11 g, 0.37 mmol, 2 eq) was 
pre-activated with PyBOP (0.19 g, 0.36 mmol, 2 eq) and NMM (40μL, 0.37 mmol, 2 eq) 
in DMF for 10 min and then was added into the pre-swollen resin, the reaction mixture 
was constantly agitated for 2 h. This procedure was then repeated with the following 
four amino acids: Fmoc-Val-OH (0.13g, 0.37 mmol, 2 eq), Fmoc-Gly-OH (0.11 g, 0.37 
mmol, 2 eq), Fmoc-Pro-OH (0.13 g, 0.37 mmol, 2 eq), and Fmoc-Val-OH (0.13 g, 0.37 
mmol, 2 eq). Piperidine (20% v/v) in DMF was added to the resin to remove the Fmoc 
group. The resin was washed repeatedly with DMF, DCM and diethyl ether. Peptide 9 
was then cleaved from the resin using 3 mL of 95% TFA containing 2.5% of water and 
2.5% of TIPS. After cleavage for 3 h, the resin was removed by filtration and the 
obtained peptide was precipitated in diethyl ether. The product was then dissolved in 
water and freeze dried. 45 mg of peptide 9 was obtained, yield was 56%. 
LC-MS for peptide 9 (VPGVG-NH2): 427.2 (M+H
+
), MW: 426 Da.  
HRMS m/z (ESI) 427.2663, consistent with empirical formula C19H35N6O5 with an 
accuracy of 1.4 ppm (accepted as (M + H)
+
). 
Analytical RP-HPLC using a linear gradient of 0-100% of solvent B – this being (v/v) 5% 
H2O/95% CH3CN with 0.1% TFA as explained in Section 6.1.2.5 – over 30 min 
showed a retention time of 9 at 7.8 min. 
6.2.2 Synthesis of acetylated peptide Ac-VPGVG-NH2 (10) 
Acetylated peptides were synthesised using 20% v/v acetic anhydride in DMF to cap the 
end groups of the peptides and the same coupling procedure for peptide 9 was applied. 
The resin (0.1 g, 0.74 mmol g
-1
) was swelled and washed three times in 9 mL of DCM 
for 15 min. Then 10 mL DMF containing 20% v/v piperidine was added to remove the 
Fmoc group. After that 10 mL DMF solution containing 20% v/v acetic anhydride was 
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added and reacted for 30 min, twice. When the reaction had finished, the resin was first 
rinsed with DMF and Et2O twice each, and then the peptide was cleaved from the resin 
using 95% TFA, 2.5% water and 2.5% TIPS for 3 h to remove any reactive side chain 
of the amino acids. The peptide was precipitated in cold Et2O in a round-bottom flask 
for 5 min and then the solution was evaporated. The peptide was dissolved in water and 
freeze dried to obtain the product. 17 mg of peptide 10 was obtained, yield was 50%. 
LC-MS for peptide 10: 469.2 (M+H
+
), 938.1 (2M+H
+
), MW: 468 Da. 
HRMS m/z (ESI) 469.2769, consistent with empirical formula C21H37N6O6 with an 
accuracy of 1.3 ppm (accepted as (M + H)
+
).  
Analytical RP-HPLC using a linear gradient of 0-100% of solvent B – this being (v/v) 5% 
H2O/95% CH3CN with 0.1% TFA as explained in Section 6.1.2.5 – over 30 min 
showed a retention time of 10 at 10.3 min. 
6.2.3 Synthesis of thiol-functionalised peptide SH-VPGVG-NH2 (11) 
3-Tritylsulfanyl-propionic acid was used to synthesise the thiol-functionalized peptide 
SH-VPGVG. First, 0.1 g Rink Amide resin (0.77 mmol g
-1
) loaded with Fmoc-peptide 
VPGVG (0.077 mmol, 1 eq) was pre-swollen in DCM for 30 min and washed with 
DMF three times. Then, 20% v/v piperidine in DMF was added for 5 min to remove the 
Fmoc group and the procedure was repeated three times. After each time the resin was 
washed with 9 mL DMF three times. The exposed amino acid was coupled by adding a 
mixture of 3-tritylsulfanyl-propionic acid (0.134 g, 0.385 mmol, 5 eq) with PyBOP 
(0.197 g, 0.385 mmol, 5 eq) and NMM (50 μL, 0.385 mmol, 5 eq) in 10 mL DMF. The 
mixture was shaken for 2 h, after which the resin was washed thoroughly with DMF. 
When the reaction was complete, the resin was rinsed repeatedly with DCM and diethyl 
ether three times each. The thiol-functionalized peptide was cleaved from the resin 
using 3 mL of 95% TFA containing 2.5% water and 2.5% TIPS to remove any reactive 
side chain of the amino acids. After 3 h, the resin was removed by filtration and the 
obtained peptide was precipitated in cold diethyl ether. The product was then dissolved 
in water and then freeze dried. From 0.1 g of rink amide resin, 10 mg of thiol-peptide 
(11) was obtained and yield was 25 %.   
LC-MS for peptide 11: 515.1 (M+H
+
), MW: 514 Da. 
HRMS m/z (ESI) 515.2652, consistent with empirical formula C22H39N6O6S with an 
accuracy of 0.4 ppm (accepted as (M + H)
+
). 
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Analytical RP-HPLC using a linear gradient of 0-100% of solvent B (solvent A = 0.1% 
TFA in 95% H2O and 5% MeCN, solvent B = 0.1% TFA in 5% H2O and 95% MeCN), 
over 30 min showed a retention time of 11 at 11.7 min. 
6.3 Synthesis of Elastin-based side chain polymers  
6.3.1 Synthesis of pentafluorophenyl acrylate (14) 
Pentafluorophenyl acrylate (PFPA) was synthesised as described in the literature.
2
 In a 
two neck round bottomed flask connected to a N2 supply, pentafluorophenol (PFP) (10g, 
54.3 mmol, 1 eq) and triethylamine (TEA) (6.6g, 65.2 mmol, 1.2 eq) were dissolved in 
100 mL of dry diethyl ether and the mixture was cooled in an ice bath. Acryloyl 
chloride (6.0 g, 66.3 mmol, 1.2 eq) was added drop-wise through a needle under cooling 
with an ice bath. The clear solution of PFP and TEA turned into a white suspension 
immediately. Then remove the ice bath and the suspension was stirred overnight at 
ambient temperature with N2 protection.
3
  
The precipitated triethylamine hydrochloride salt was removed by filtration, and the 
solid was washed with diethyl ether. After evaporation of the solvent, the residue was 
filtered again to obtain a clear yellow liquid. The reaction mixture containing the 
unreacted PFP (12), acryloyl chloride (13) and crude product (14) were analysed by 
TLC (petroleum ether 40-60
o
C as eluent). The TLC showed two spots with Rf values of 
0.48 and 0.68 which are due to PFP and crude product respectively. The yellow crude 
product was purified by using an auto column chromatography. The column material 
was silica gel and the solvent we used was petroleum ether (40-60
o
C). The collected 
fraction was putted on the rotary evaporator to remove the petroleum ether. After 
evaporation, the final product was obtained (6.7 g, 27.5 mmol) and the yield was 52%. 
Pure PFPA was stored in the refrigerator. 
1
H-NMR (400 MHz, 298K, CDCl3) δH / ppm: 6.65 (1H, dd, Hc), 6.28 (1H, dd, Ha), 6.13 
(1H, dd, Hb). 
13
C-NMR (400 MHz, 298K, CDCl3) δC / ppm: 161.7 (1C, s, CO), 141.2 
(2C, m, C2), 139.5 (1C, m, C4), 137.9 (2C, m, C3), 135.4 (1C, s, CH2), 125.3 (1C, s, 
CH), 125.0 (1C, m, C1). 
6.3.2 Synthesis of RAFT agent (15) 
(The synthesis was carried out by Ali Abdulkarim at Durham University) 
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In a one neck round bottom flask, potassium phosphate (27.2g, 128 mmol) was stirring 
in 350 mL of acetone. After 10 min, mercaptoethanol (10g, 128 mmol, 1 eq) was added 
into the suspension. The solution was stirred for 10 min and followed by the dropwise 
addition of carbon disulfide (21.9 g, 128 mmol, 1 eq) in ice bath and the solution was 
turned to yellow. After another 10 min, benzyl bromide (29.2g, 384.5mmol, 3eq) was 
added slowly through a funnel and the reaction was continuously stirred at ambient 
temperature for 30 min. The reaction scheme is described as in Figure 6.1. 
 
Figure 6.1: Synthesis of RAFT agent benzyl 2-hydroxyethyl carbonotrithioate (15). 
 
After reaction, the precipitated potassium bromide salt was removed by filtration, and 
the solid was washed with acetone. After evaporation of the solvent, the residue was 
filtered again to obtain a clear liquid. The yellow crude product was purified by using an 
auto column chromatography. The eluent ratio was 3:1 of petroleum ether (40-60 
o
C) 
and ethyl acetate. The final product was putted under high vacuum to remove all 
solvents. The product was obtained as light yellow oil in a yield of 72% (22.3g). The 
synthesised RAFT agent was characterised by 
1
H NMR spectroscopy (Appendix 6.1) in 
solvent CDCl3. Pure benzyl 2-hydroxyethyl carbonotrithioate was stored in the freezer.  
The product was characterized by 
1
H-NMR (CDCl3): 7.31-7.11 (5H, m, Ph), 4.52 (2H, s, 
benzyl-CH2), 3.74 (2H, q, -CH2-OH), 3.48 (2H, t, -S-CH2).  
6.3.3 Synthesis of poly(pentafluorophenyl acrylate) polymers 
Here we give one example of polymerisation of poly (pentafluorophenyl acrylate) 
poly(PFPA)-100 (19). Pentafluorophenyl acrylate (PFPA) (0.5g, 2.1 mmol, 100 eq), 
benzyl 2-hydroxyethyl trithiocarbonate (5.1mg, 2.1x10
-5
 mol, 1 eq), AIBN solution (2.0 
mg, 1.05x10
-5 
mol, 0.5 eq) and benzene (5.0 mL) were added to a schlenk tube with 
stirring. The solution was cooled down in an ice bath and purged with nitrogen for 30 
min. After that, the ice bath was removed and the solution was heated to 70
o
C for 6 h. 
Conversion was determined by 
1
H NMR.  
+ + 
+ K
3
PO
4
 
+ Acetone 
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After 6 h, the schlenk tube was cooled at ambient temperature with N2 protection. Then 
the reaction was quenched by putting the whole tube into a box of dry ice for 10 min. 
Afterwards the product could be left under atmospheric oxygen. Then solution was 
partially removed under vacuum and the rest was precipitated in methanol which was 
cooled to 0
o
C beforehand. After centrifuging and decanting the methanol, the polymer 
was dissolved in THF and re-precipitated again. The operation was repeated three times 
to remove any unreacted RAFT agent and any trace monomers. The polymer was dried 
under vacuum oven over night to yield a yellow powder. The sample was characterized 
by THF GPC, 
1
H-NMR and 
19
F NMR (CD2Cl2) and FT-IR spectroscopy. The 
experiments of all the polymers (16-19) synthesised are summarized in Table 2.2.  
Taking P(PFPA)-100 (19) as an example. The coversion rate is calculated based on the 
equation shown as below.  
The equation is given below (eq.1).  
                         (1) 
So for 19, the integral of polymer peak (c) is 4.69, while the monomer peak is 1.00. 
(Figure 2.33)  
                        (2)    
Theoretical Mn was calculated using the following equation:  
Mn,theor = [M]/[RAFT] x MWmonomer + MWRAFT agent 
[M]/[RAFT] represents the ratio of monomer and RAFT agent concentration, 
MWmonomer is the molar mass of PFPA (14) (238 g.mol
-1
) and MWRAFT agent is the molar 
mass of RAFT agent 15 (244 g.mol
-1
).  
Experimental Mn was measured by 
1
H NMR spectroscopy and calculated by the 
following equation: 
Mn,NMR  =[ I 
CH at 3.0 ppm
/ (I 
phenyl group at 7.2 ppm
 /5)]x MWmonomer + MWRAFT agent 
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I 
CH at 3.0 ppm
 and I 
phenyl group at 7.2 ppm 
are corresponding to the intensity of signals at 3.0 
ppm and 7.2 ppm respectively. 
1
H-NMR and 
19
F NMR spectra of P(PFPA)-25,50,75 (16-18) can be found in 
Appendices 2.1-2.3. 
1
H-NMR and 
19
F NMR spectra of P(PFPA)-100 (19) are shown in 
Figure 2.34. 
6.3.4 Synthesis of short elastin-like peptides for coupling to P(PFPA) 
Solid-phase peptide synthesis with an Fmoc-protecting group strategy and rink amide 
resin was employed to synthesise the peptide 9, 20 and 21 as described in Table 2.3. 
The synthesis approach was the same as peptide 9 discussed in Section 6.2.1.  
Rink Amide resin (0.25 g, 0.19 mmol, 1 eq) was pre-swollen in DCM for 30 min and 
washed by DMF three times. Then, 20% v/v piperidine in DMF was added for 5 min to 
remove the Fmoc group and this was repeated three times. After each time the resin was 
washed with DMF (3 × 5 mL). Fmoc-Gly-OH (0.11 g, 0.37 mmol, 2eq) was 
pre-activated with PyBOP (0.19 g, 0.36 mmol, 2 eq) and NMM (40 μL, 0.37 mmol, 2eq) 
in DMF for 10 min. Finally, the pre-activated solution was added to the pre-swollen 
resin, and the reaction mixture was constantly agitated for 2 h. After this, the resin was 
washed with DMF (3 × 5 mL). The reaction sequence was repeated to ensure complete 
functionalization. At the last coupling process, amino acids Fmoc-Gly-OH (0.11 g, 0.37 
mmol, 2 eq) and 4-(Fmoc-amino) butyric acid (Fmoc-GABA-OH) (0.12 g, 0.37 mmol, 
2 eq) was added respectively for 20 and 21. The peptide was then cleaved from the resin 
using 3 mL of 95% TFA containing 2.5% of water and 2.5% TIPS. After cleavage for 3 
h, the resin was removed by filtration and the obtained peptide was precipitated in 
diethyl ether.  
From 0.25 g of Rink Amide resin, 45 mg of purified peptide 9 was obtained (yield: 
56%); 48 mg of purified peptide 20 was obtained (yield: 53%); 53 mg of purified 
peptide 21 was obtained (yield: 55%).  
LC-MS for 9 (VPGVG-NH2): 427.2 (M+H
+
), MW: 426 Da. Analytical retention time 
was 7.8 min. LC-MS for 20 (GVPGVG-NH2): 484.0 (M+H
+
), MW: 483 Da. Analytical 
retention time was 8.3 min. LC-MS for 21 (GABA-VPGVG-NH2): 511.9 (M+H
+
), MW: 
511 Da. Analytical retention time was 9.1 min. 
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All the retention time was measured by analytical RP-HPLC using a linear gradient of 
0-100% of solvent B (solvent A = 0.1% TFA in 95% H2O and 5% MeCN, solvent B = 
0.1% TFA in 5% H2O and 95% MeCN) over 30 min.  
6.3.5 Synthesis of elastin-based side chain polymers (22-29) 
An example is given for the peptide modification of Poly(PFPA) as follows: Poly(PFPA) 
(20 mg, 8.2 × 10
-5
 mol of pentafluorophenyl groups) was dissolved in 2.5 mL of DMF 
in a glass vial. The solution was purged with nitrogen. Peptide solution was prepared by 
dissolution of peptide 9 (50 mg, 1.2 × 10
-4
 mol) in dimethyl sulfoxide (DMSO) (0.7 
mL). Triethylamine (18 µL, 1.3 × 10
-4 
mol) was then added to the peptide solution. The 
peptide solution was subsequently added slowly to the poly(PFPA) solution by using a 
syringe. The solution was stirred for 5 h or overnight at 30
o
C and the colour of the 
solution changed from orange to very light yellow.  
After reaction, the polymer was dialyzed (MWCO=3500 Da) against water for 3 d to 
remove any unreacted peptide. The elastin-based side chain polymer was freeze dried 
and analysed by 
1
H NMR, 
19
F NMR in d6-DMSO, GPC and FT-IR spectroscopies 
(Appendices 2.6-2.13).  
6.4 Synthesis of Gold nanoparticles (GNPs) 
Gold nanoparticles (GNPs) were synthesised by using Frens and Turkevich method.
4
 
All glassware used for synthesis of colloidal gold was cleaned using aqua regia (3:1 
HCl: HNO3), rinsed extensively with water, and dried in the oven at 60°C. A 
HAuCl4•3H2O solution (0.01 wt %, 0.3 mM, 50 mL) was brought to boiling with rapid 
stirring in a 100 mL round-bottom flask fitted with a reflux condenser. Once the 
solution resumed boiling, trisodium citrate (1 wt%, 1.5 mL) solution in water was added 
quickly with continued stirring, after that the solution started to turn to dark blue and 
finally red. The reaction was refluxed for 5 min and stirring continued for another 30 
min. The colloidal gold suspension was cooled to room temperature and filtered through 
a 0.2 µm filter. The diameter of the colloids was determined by transmission electron 
microscopy (TEM) and dynamic light scattering (DLS). 
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6.5 Synthesis of short elastin-like peptide functionalised GNPs 
(ELP-GNPs) 
The synthesis of short elastin-like peptide functionalized gold nanoparticles (ELP-GNPs) 
used the reaction between thiol and gold nanoparticles. Thiol-peptide (7 mg, 0.01 mmol) 
was dissolved in 1mL deionized water and then added into a 20 mL filtered GNP 
solution (0.3 mM, 0.006 mmol of Au). The mixture of the thiol-peptide and GNPs was 
stirred overnight at room temperature in a small round-bottom flask under nitrogen. 
After that the solution was transferred to a dialysis bag (MWCO: 3500 Da) and dialysed 
against deionised water for 24 h. The ELP-GNPs (30) were then freeze-dried to obtain a 
dark purple solid.                                                              
6.6 Synthesis of polymer functionalised GNPs (ESP-GNPs) 
The fabrication of elastin-like peptide functionalized polymer coated gold nanoparticles 
used the reaction between thiol and gold nanoparticles. P(PFPA)100-GABA(VPGVG) 
(10mg, 0.0007 mmol) was dissolved in 1mL deionized water and then added into a 10 
mL of the citrate-stablized gold nanoparticle solution (0.3 mM, 0.003 mmol of Au). The 
reaction was taken overnight and under N2 protection. Then the polymer coated GNPs 
were dialyzed (MWCO=50,000 Da) against water for 3 d to remove any unreacted 
polymers. The GNP-polymer was then freeze-dried to obtain a purple fluffy powder.  
6.7 Synthesis of KLA peptide functionalized GNPs (KLA-GNPs) 
6.7.1 Synthesis of GNPs 
The gold nanoparticles were synthesised via the same method as described in Section 
6.4. However, the concentration of the mother solution of Au
3+
 is tripled. Briefly, 50 
mL of 1 mM the HAuCl4•3H2O was dissolved in a 150 mL round bottomed flask and 
refluxed for 5 mins. Then, 8.5 mL of trisodium citrate solution (1 wt%, 38.8 mM) was 
added quickly into the boiling solution and a colour change from light yellow to dark 
blue was observed immediately. And 1 min later, the colour changed again from dark 
blue to red and the solution was refluxed for another 10 mins. Cool the solution to room 
temperature naturally and subsequently filtered through 0.45 µm aqueous phase 
membrane filter and the gold nanoparticle were used for the next functionalization.  
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6.7.2 Synthesis of thiol-TTDS-KLA (38) 
The D-(KLAKLAK)2 peptide was synthesised manually using a standard Fmoc chemistry 
through the solid phase peptide synthesis. Briefly, Rink Amide resin (0.77 mmol g
-1
 
loading, 0.13 g, 0.1 mmol) was weighed out and swollen in a fritted PTFE reaction 
vessel for 1 hour in DMF. Then using 20% piperidine in DMF for 5 min and 10 min to 
deprotect the resin and washed by DMF three times after the deprotection. The coupling 
of the first residue used 3 equiv (relative to the substitution degree of resin) 
Fmoc-protected amino acid, PyBOP (0.3 mmol, 158 mg) and DIPEA (0.6 mmol, 115 
μL) in a DMF solution for 1 hour at room temperature. The reacton vessel was placed 
on a shaker for the duration of the coupling steps and each residue was coupled twice. 
During the synthesis, Fmoc protection groups were removed by 20% piperidine/DMF. 
At the end of the KLA synthesis, the linker of Fmoc-TTDS-OH (0.3 mmol, 162 mg) 
was conjugated to the peptide sequence. The coupling process is the same as coupling 
each amino acid. Finally, 3-tritylsulfanyl-propionic acid (0.3 mmol, 104 mg) was added 
to the sequence to provide a free thiol end. 
After the completion of the synthesis, the resin was finally washed with DMF, DCM 
and diethyl ether three times separately. The cleavage of the peptide on resin was 
performed by adding a cleavage cocktail in to the vessel, which containing TFA (95%), 
TIPS (2.5 %) and H2O (2.5 %) for 3 h. The filtration was concentrated to a viscous 
solution by rotary evaporation and followed by precipitation in cold ether solvent. 
Decant the ether slowly and the crude product was collected. Then the crude peptide 
was dissolved in distilled water and freeze dried.  
The molecular weight of thiol-TTDS-KLA (C89H169O20N23S) peptide was analysed by 
MALDI and found in 1935.2 which is [M+ Na]
+
. HRMS m/z (ESI) 957.6361, consistent 
with empirical formula C89H169O20N23S with an accuracy of 5 ppm (accepted as (M + 
2H)
2+
).  
Analytical RP-HPLC using a linear gradient of 0-100% of solvent B – this being solvent 
A = 0.1% TFA in 95% H2O and 5% MeCN, solvent B = 0.1% TFA in 5% H2O and 95% 
MeCN – over 30 min showed a retention time of 38 at 14.7 min. 
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6.7.3 Synthesis of KLA-GNPs (39) 
The synthesis of SH-TTDS-KLA peptide functionalized gold nanoparticles 
(KLA-GNPs) was achieved through thiol-gold covalent bonding. The weight ratio of 
peptide to gold is 2:1 to make the peptide excess to gold nanoparticles. In the process, 
3.5 mg of peptide was dissolved in 1 mL deionized water and slowly dropped into 10 
mL (0.01 mmol, 1.9 mg) of filtered gold nanoparticles (1 mM) and the colour changed 
from red to purple. The mixture was stirred overnight at room temperature with nitrogen 
protection. Then the purple solution was transferred to a dialysis bag (MWCO: 3500 Da) 
and dialysed against deionised water for 2 d. The KLA-GNPs were then freeze-dried to 
obtain 4 mg of dark purple solid.  
6.8 Synthesis of KLA-ESP100-GNPs (40) 
The preparation of thiol-TTDS-KLA and PF100-GABA(VPGVG) peptides 
functionalized gold nanoparticles (KLA-ELP100-GNPs) was achieved via thiol-gold 
covalent bonding. The weight ratio of peptides used was 1:1. In the process, 2 mg of 
thiol-TTDS-KLA (38) and 2 mg of PF100-GABA(VPGVG) (29) were dissolved in 0.5 
mL deionization water separately. Through two separate syringes, both peptides were 
dropped slowly into 10 mL of filtered GNPs (0.01 mmol, 1.96 mg) and the colour 
changed from red to purple. The mixture was stirred overnight at room temperature 
under nitrogen. Then the purple solution was transferred to a dialysis bag (MWCO: 
50,000 Da) and dialysed against deionised water for 24 h. The KLA-ELP100-GNPs were 
then freeze-dried to obtain 5 mg of dark purple solid.  
6.9 Synthesis of D-/L-KLA peptides 
The D-(KLAKLAK)2 peptide (33) was synthesised manually using a standard Fmoc 
chemistry through solid phase peptide synthesis. Briefly, the Rink Amide resin (0.77 
mol/g loading, 0.1 mmol) was weighed out and swollen in a fritted PTFE reaction 
vessel for 1 hour in DMF. Then using 20% piperidine in DMF for 5 mins and 10 mins 
to deprotect the resin and washed by DMF three times after the deprotection. The 
coupling of the first residue used 3 equiv (relative to the substitution degree of resin) 
Fmoc-protected amino acid, 3 equiv of PyBOP and 6 equiv of DIPEA in a DMF 
solution for 1 hour at room temperature. The reacton vessel was placed on a shaker for 
the duration of the coupling steps and each residue was coupled twice. During the 
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synthesis, Fmoc protected groups was deprotected with 20% piperidine/DMF. The 
coupling steps were repeated for the rest amino acids. A test cleavage was carried out at 
7
th
 amino acid using 1 mL cleavage cocktail (95% TFA, 5% TIPS and 5% water) with 
shaking at room temperature for 2 h. Final cleavage from resin was taken by 3 mL of 
same cleavage cocktail for 3 h. The filtrate was concentrated to a viscous solution by 
rotary evaporation and followed by precipitation in cold ether solvent. Decant the ether 
slowly and the crude product was collected. Then the crude peptide was dissolved in 
distilled water and freeze dried. Semi-preparative HPLC was used to purify 33 as 
described in Section 6.1.2.5. After HPLC purification, 23 mg D-KLA was obtained and 
the yield was 15%. For L-KLA, 25 mg was obtained with a yield 16%.  
The molecular weight of D-KLA (33) was analysed by MALDI and found in 1544.9 
which is [M+ Na]
+
. LC-MS for D-KLA: 508.5 (3H
+
), 381.7 (4H
+
), MW: 1523.1 Da. 
(Appendix 4.1) 
The molecular weight of L-KLA (41) was analysed by MALDI and found in 1946.1 
which is [M+ Na]
+
. LC-MS for L-KLA: 508.3 (3H
+
), 381.6 (4H
+
), MW: 1523.1 Da. 
(Appendix 4.2) 
Analytical RP-HPLC using a linear gradient of 0-100% of solvent B – this being solvent 
A = 0.1% TFA in 95% H2O and 5% MeCN, solvent B = 0.1% TFA in 5% H2O and 95% 
MeCN – over 30 min showed a retention time of 33 and 41 both at 11.4 min. 
6.10 Synthesis of peptoid hybrids  
6.10.1 Synthesis of peptoids 
The peptoid oligomers were synthesised using the solid-phase sub-monomer method 
5, 6
. 
The Rink Amide resin (135 mg, 100 µmol, 1.00 equiv) was covered with 5 mL DMF 
and swollen overnight at room temperature. The solvent was filtered and the resin was 
thoroughly washed with DMF. The resin was treated with 20% piperidine in DMF 
(5 min and 15 min with 3 mL each), and thoroughly washed with DMF. A solution of 
bromoacetic acid (1 mL, 0.6M in dry DMF, 3.00 equiv) and DIC (0.2 mL, 50% v/v in 
DMF, 3.00 equiv) was added to the resin. The reaction tube was placed on the shaker 
for 20 min at room temperature. The resin was washed with DMF (3 × 2 mL) before the 
required amine sub-monomer (1mL, 1.0 M in DMF, 3.00 equiv) was added for 60 min 
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on the shaker. Bromoacetylation and amine displacement steps were repeated until the 
final submonomer had been added. This procedure was repeated four times to obtain 
each peptoid. The resin was washed with DMF (3 × 2 mL each). To a solution of 
Fmoc-Gly-OH (78 mg, 3.00 equiv) in DMF (2 mL) were added PyBOP (156 mg, 3.00 
equiv) and DIPEA (115 μL, 6.00 equiv) before adding to the resin. The reaction was 
taken 60 min on the shaker at room temperature. The reaction conditions were used a 
second time as described above (double coupling). The resin was washed with DMF (3 
× 5 mL each). The resin was treated with 20% piperidine in DMF (3 × 5 min with 3 mL 
each), and thoroughly washed with DMF. The solution of Fmoc-Gly-OH (78 mg, 3.00 
equiv), PyBOP (156 mg, 3.00 equiv) and DIPEA (115 μL, 6.00 equiv) in DMF (2 mL) 
were added again to the resin. Each amino acid coupling was carried out twice on the 
shaker. The reaction time was 60 min for each coupling. Two glycines were coupled to 
the peptoid at the N-terminus.  
To test cleave the peptoid from the resin, a solution of 1 mL TFA, TIPS and H2O 
(95:2.5:2.5) was added to a small amount of the resin and allowed to incubate for 120 
min at room temperature on the shaker. The resin was rinsed once with 0.5 mL TFA. 
Then the resin was removed by filtration and the obtained peptoid was precipitated in 
diethyl ether. The product was then dissolved in water and freeze dried. The crude 
peptoids were analysed by LC-MS. Summary of the data is shown in Table 4.2 
(Chapter 4).  
6.10.2 Synthesis of KLA-CPPos 
Peptide-peptoid hybrids were synthesised according to the above peptoid synthesis 
protocol, followed by standard peptide Fmoc/tBu-methodology and PyBOP/DIPEA 
coupling. Here we give one example of KLA-CPPo1 (52) coupling procedure. The Rink 
Amide resin (135 mg, 100 µmol, 1.00 equiv) containing the CPPos was covered in 5 
mL DMF for at least 30 min to be pre-swollen. The resin was treated with 20% 
piperidine in DMF (3 × 5 min with 3 mL each), and thoroughly washed with DMF. The 
solution of Fmoc-D-Lys(Boc)-OH (154mg, 3.00 equiv), PyBOP (156mg, 3.00 equiv) 
and DIPEA (115 μL, 6.00 equiv) in DMF (2 mL) were added to the resin. The reaction 
was shaken at room temperature for 60 min. The reaction conditions were repeated a 
second time as described above (double coupling). The same method was applied when 
adding Fmoc-D-Leu-OH and Fmoc-D-Ala-OH to the resin. The cleavage of the 
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peptide-peptoid hybrid was using a solution of 1 mL TFA, TIPS and H2O (95:2.5:2.5), 
and the resin was shaking for 4 h at room temperature. After HPLC-purification 24 mg 
of CPPo1 (52) was obtained with a yield of 11%. Analytical HPLC, accurate mass and 
MALDO-ToF data of all the peptide-peptoid hybrids (52-57) are shown in Appendix 
4.3-4.8.  
6.10.3 Rhodamine-KLA-CPPo6 (59) 
The Rink Amide resin (34 mg, 25 µmol, 1.00 equiv) was covered in 5 mL DMF for at 
least 30 min to be pre-swollen. Afterwards the resin was washed with 3 × DMF (3 mL). 
The Fmoc deprotection was treated with 20% piperidine in DMF (5 min and 15 min 
with 3 mL each), and thoroughly washed with DMF. Rhodamine B (59.6 mg, 0.125 
mmol, 5.0 equiv) was coupled using DIC (31.9μL, 0.125 mmol, 5.0 equiv) and HOBt 
(16.9 mg, 0.125 mmol, 5.0 equiv) in DMF for 1 hour at room temperature. This process 
was repeated again to make sure the full completion of the reaction. Finally, the crude 
product was cleaved by adding trifluoroacetic acid (95% in CH2Cl2) and shaking at 
room temperature for 2.5 h. The cleavage solution was filtered and the resin was 
thoroughly washed with MeOH. This procedure of adding cleavage solution and rinsing 
with methanol was repeated until the cleavage solution was colourless. Water was 
added, frozen and lyophilised to give crude product. After purification by 
semi-preparative HPLC, 5 mg pure product was obtained with a yield of 15%. The 
LC-MS analysis and MALDI-TOF MS of Rhod-KLA-CPPo6 were shown in following 
data (Appendix 4.9):  
LC-MS of Rhod-KLA-CPPo6:  1347.8 (2H
+
), 539.7 (5H
+
), 449.9 (6H
+
). MALDI of 
Rhod-KLA-CPPo6: [M+H]
+
=2696.4. HRMS m/z (ESI) 540.321, consistent with 
empirical formula C72H138N21O14 with an accuracy of -3.8 ppm (accepted as (M + 
5H)
5+
). Analytical RP-HPLC using a linear gradient of 0-100% of solvent B – this being 
(v/v) 5% H2O/95% CH3CN with 0.1% TFA as explained in Section 6.1.2.5 – over 30 
min showed a retention time of 59 at 19.6 min. 
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Appendices 
 
Appendix 2.1: 
1
H NMR and 
19
F NMR spectra of P(PFPA)-25 (16) in solvent CD2Cl2. 
 
Appendix 2.2: 
1
H NMR and 
19
F NMR spectra of P(PFPA)-50 (17) in solvent CD2Cl2. 
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Appendix 2.3: 
1
H NMR and 
19
F NMR spectra of P(PFPA)-75 (18) in solvent CD2Cl2. 
 
Appendix 2.4: Semi-preparative HPLC chromatogram of crude peptide 20 (GVPGVG). 
The peak with an asterisk on it represents the target peptide peak. 0-100% solvent B in 45 
min. Retention time = 18.0-22.5 min.  
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Appendix 2.5: Semi-preparative HPLC chromatogram of crude peptide 21 
(GABAVPGVG). The peak with an asterisk on it represents the target peptide peak. 
Retention time = 18.6-20.5 min.  
 
Appendix 2.6: 
1
H NMR and 
19
F NMR spectra of PF25-VPGVG (22) in d6-DMSO. 
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Appendix 2.7: 
1
H NMR and 
19
F NMR spectra of PF50-VPGVG (23) in d6-DMSO. 
 
Appendix 2.8: 
1
H NMR and 
19
F NMR spectra of PF75-VPGVG (24) in d6-DMSO. 
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Appendix 2.9: 
1
H NMR and 
19
F NMR spectra of PF100-VPGVG (27) in d6-DMSO. 
 
Appendix 2.10: ATR-FTIR spectra of P(PFPA) and PF(25,50,75,100)-VPGVG. 
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Appendix 2.11: 
1
H NMR and 
19
F NMR spectra of PF75-GABAVPGVG (26) in 
d6-DMSO. 
 
Appendix 2.12: 
1
H NMR and 
19
F NMR spectra of PF100-GVPGVG (28) in d6-DMSO. 
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Appendix 2.13: 
1
H NMR and 
19
F NMR spectra of PF100-GABAVPGVG (29) in 
d6-DMSO. 
 
Appendix 3.1: TGA for ELP-GNPs (30) nanoparticles revealed 42% mass decrease 
between 200
o
C and 500
o
C. 
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Appendix 3.2: TGA for ESP100-GNPs (32) nanoparticles revealed 56% mass decrease 
between 200
o
C and 500
o
C. 
 
Appendix 3.3: LC-MS spectrum of thiol-TTDS-KLA (38).  
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Appendix 3.4: HRMS m/z (ESI) 957.6361, consistent with empirical formula 
C89H169O20N23S with an accuracy of 5 ppm (accepted as (M + 2H)
2+
). 
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Appendix 3.5: TGA for KLA-GNPs (39) nanoparticles revealed 47% mass decrease 
between 200
o
C and 500
o
C. 
 
 
Appendix 3.6: TGA for KLA-ESP100-GNPs (40) nanoparticles revealed 48% mass 
decrease between 200
o
C and 500
o
C 
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Appendix 4.1: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
D-KLA (33). 
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HRMS m/z (ESI) 1523.0907, consistent with empirical formula C72H138N21O14 with an 
accuracy of 1.18 ppm (accepted as (M + H)
+
). 
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Appendix 4.2: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
L-KLA (41). 
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HRMS m/z (ESI) 1523.0878, consistent with empirical formula C72H138N21O14 with an 
accuracy of 0.72 ppm (accepted as (M + H)
+
). 
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Appendix 4.3: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
KLA-CPPo1 (52). 
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HRMS m/z (ESI) 735.1545, consistent with empirical formula C103H189ClN30O20 with an 
accuracy of -0.54 ppm (accepted as (M + 3H)
3+
). 
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Appendix 4.4: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
KLA-CPPo2 (53). 
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HRMS m/z (ESI) 1085.2368, consistent with empirical formula C103H190N30O20 with an 
accuracy of -10.2 ppm (accepted as (M + 2H)
2+
). 
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Appendix 4.5: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
KLA-CPPo3 (54). 
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HRMS m/z (ESI) 1109.7328, consistent with empirical formula C107H189N29O21 with an 
accuracy of 6.4 ppm (accepted as (M + 2H)
2+
). 
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Appendix 4.6: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
KLA-CPPo4 (55). 
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HRMS m/z (ESI) 1126.7159, consistent with empirical formula C107H188N29O21Cl with 
an accuracy of 4.0 ppm (accepted as (M + 2H)
2+
). 
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Appendix 4.7: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
KLA-CPPo5 (56). 
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HRMS m/z (ESI) 1111.7184, consistent with empirical formula C106H186N29O20Cl with an 
accuracy of 2.8 ppm (accepted as (M + 2H)
2+
). 
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Appendix 4.8: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
KLA-CPPo6 (57). 
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HRMS m/z (ESI) 1136.2086, consistent with empirical formula C110H185N28O21Cl with an 
accuracy of 1.2 ppm (accepted as (M + 2H)
2+
). 
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Appendix 4.9: Structure, analytical HPLC, MALDI-ToF, and accurate mass data for 
Rhod-KLA-CPPo6 (59). 
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HRMS m/z (ESI) 540.3219, consistent with empirical formula C138H214N30O23Cl with an 
accuracy of -3.8 ppm (accepted as (M + 5H)
5+
). 
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Appendix 6.1: 
1
H NMR spectra of benzyl 2-hydroxyethyl carbonotrithioate (RAFT agent) 
(15) in solvent CDCl3.  
 
 
 
 
 
 
